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For when a man excels by gifts of nature,  
It is no wonder if his life is blessed;  
In him we worship the Creator's power,  
Through feeble human clay made manifest;  
But he who overcomes himself has gained  
The greatest triumph, stood the hardest test,  
And well may he to all the world be shown:  










The purchase of medical devices involves engaging various stakeholders as well as 
balancing clinical, technical and financial requirements. Failure to consider these 
requirements can lead to wider consequences in the delivery of care. This study first builds 
a general knowledge base of current purchasing practice in a sample of NHS Trusts, which 
confirms the direction and guidance given by policy documents and literature as to the 
extent of the challenges faced by purchasing stakeholders. This then leads to an analysis to 
identify inefficiencies in the purchasing process, and how such practice can lead to risks in 
the delivery of care. These risks range from injury to individuals, impacts to the healthcare 
delivery service, and financial and litigation risks. Finally, a framework that highlights 
these potential risks in the life-cycle of medical devices in hospitals is presented.  
 
Key policy guidance has encouraged both researchers and implementers of healthcare 
services to approach patient safety from a systems perspective, acknowledging that medical 
device errors are not only directly related to device design, but to the design of the 
healthcare delivery service system in which the device operates. Little evidence exists of 
successfully applying systems approaches specifically to medical device purchasing practice. 
Medical device purchasing, because of its implications to patient safety on the one hand, 
and the uniqueness of the healthcare context, requires a unique approach. By 
demonstrating the influence of purchasing practice to service delivery and patient care, the 
thesis made is that taking a holistic systems approach is one method to improve device 
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Clinical Engineering: This refers to the department in a hospital that deals with 
maintenance and repair of medical equipment. In some cases, they include a research and 
development department where new clinical products can be developed. Other terms used 
in literature for this group are „medical engineering‟ or Electro-Biomedical Engineering 
(EBME). 
 
Clinician: This is the term used to define any healthcare professional, including doctors 
and nurses. 
 
EBME: This is the main term used to describe Clinical Engineering department, as above.  
 
End-user: This refers to the person using a medical device at the front-end of the 
healthcare system (e.g. clinician, doctor, nurse). End-users are distinguished from the term 
„user‟ in this thesis, which is used in a more general sense, to mean any user of a process, 
device, or the healthcare system (e.g. patients, purchasers, management staff, and end-
users).  
 
Medical Device or Equipment: This refers to any product or technology designed and 
intended for use in a healthcare setting.  
 
Medical Equipment Committee (MEC): Also termed the Medical Device Committee, this is 
a body responsible mainly for allocating funds to capital device purchases. A sub-body of 
this group, the MEC Procurement Subgroup, was a subject of study at the NHS Trusts.  
 
Medical Physics: This is a department in a hospital that oversees Clinical Engineering 
department but also encompasses other clinical technology areas such as radiology, 
imaging, and may include its own research and development.  
 
NHS Trust (or „Trust‟): The UK‟s National Health Service (NHS) includes both primary 
and secondary care. Primary care is the first point of contact for most people and is 
delivered by a wide range of independent contractors, including general practitioners 
(GPs), dentists, pharmacists and optometrists. Trusts fall into the category of secondary 
care and include services in acute healthcare and can be either elective care or emergency 
ix 
care. The Trusts referred to in this thesis usually refer to either one larger hospital or a 
collection of hospitals governed by one such Trust. 
 
Procurement: This refers to the process of managing activities associated with the purchase 
of goods and services required to operate the organisation. Procurement also refers to the 
department in an NHS Trust that deals with administering purchases (also termed 
Supplies). To avoid confusion, the holistic process of procurement in this thesis is therefore 
referred to as „purchasing‟, and usually placed within the phrase „purchasing process‟ or 
„purchasing system‟.  
 
Purchasing: This usually refers to here as the transactional placement and processing of 
purchases, i.e. buying and selling. In this study, purchasing is used as the generic term for 
procurement and purchasing activities (as above). When used in this context, the term 
„purchasing process‟ or „purchasing system‟ is used to distinguish between administrative 
purchasing and the more holistic purchasing perspective.  
 
Purchaser: A large part of this study consisted in establishing who would be considered a 
purchaser in relation to medical devices. Traditionally named „purchasing administrators‟ 
who sit in the Procurement or Supplies department as above, are included as „purchasers‟, 
but this term also extends to anyone who initiates a purchase (requisitioner), or has the 
authority to approve a requisition (budget-holder), which may included a variety of end-
users and other stakeholders. 
 
Risk: The general definition for risk is the chance of hazards or bad consequences; or 
exposure to chance of injury or loss. The level of risk is expressed in terms of hazard 
probability and consequence of failure. Risks in this study can refer to risk to the service, 
injury to any individual, and financial and litigation risks to the hospital.  
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In the 1990s, most hearing aids supplied by the UK National Health Service (NHS) were 
out of date by over a decade, compared to the newer digital ones available in private 
practice. In response to growing pressure from patients and the public, the NHS secured a 
contract to buy new digital aids in bulk, providing patients with better technology and a 
long-term cost saving for the taxpayer, despite the greater immediate costs. Patients 
received the hearing aids they wanted and Trusts achieved a cost-effective deal. Around 
this time, the Purchasing and Supply Agency1 (PASA) was formed, and the power of the 
NHS as a purchaser to influence the supply chain was highlighted (Phillips et al. 2007), 
which suggests that if the correct drivers are in place, the supply chain could be influenced 
to provide better products at lower cost. In short, purchasing policy changed practice 
through patient need.  
 
However, such an exercise has not been repeated since, perhaps largely due to the 
changing national agencies in the NHS and the fact that most purchasing is conducted 
locally. In the above example, although there was a common understanding of what the 
patient desired, there is no record of the assessments made to demonstrate the safety of the 
                                               
1 At the time of writing, PASA announced its closure for 2010. Most of the references in this thesis refer to its 
jurisdiction between 2005-9. Some of its regional and local agencies continue to exist. 




new product in the user context. Furthermore, clinicians and purchasers were initially 
hesitant to change practice, due to the initial costs involved, and the changes to clinical 
practice that would have to take place (Phillips et al. 2007). A decade later a study was 
conducted to explore the representation of user needs at the interface between the NHS 
and the wound dressing industry (Browne et al. 2004), concluding that methods are still 
needed to be able to truly communicate user needs to manufacturers.  
 
The questions remaining after such a story may include: Does such lack of incentive still 
exist for other medical devices? What are requirements of other devices and should they 
also be standardised and undergo a similar exercise? Do medical device purchases in the 
NHS take into account safety metrics? And, finally, who is the purchaser, if there is not 
one organisation such as PASA to make similar national deals? Such general questions led 
to the motivation behind this research project.  
 
In this chapter, the motivation for studying medical device purchasing is introduced, 
together with some background to “purchasing” in the context of healthcare and patient 




1.1  Research Motivation 
 
Motivation for this project consists of policy, financial, and healthcare incentives for a 
change in purchasing practice. This follows an underlying assumption that changes in 
practice are possible, and that the end-user can be part of purchasing decisions. This is 
illustrated in the previous section - a success story for the NHS - but is also alluded to in 
publications on patient safety improvement.  
 
1.1.1  Policy-driven Motivation 
At the start of this project, October 2005, purchasing in the NHS had just undergone 
changes in its structure and policy. The All-Party Parliamentary Group on Patient Safety 




had just been inaugurated (APPGPS 2005), and at one meeting focussed solely on 
purchasing, the following questions were posed:  
“How many buyers evaluate a technology before making a purchase? If patient safety is to 
be a consideration in procurement decisions alongside criteria such as clinical performance, 
maintenance and of course budget, evidence and data need to be readily available to 
support these decisions. How easy is it to make informed risk assessments when buying in 
the NHS?” (APPGPS 2005). 
 
At a steering meeting for this project held in October 2005, John Warrington from PASA 
gave more details on the topics brought forward that represented the prevalent issues at 
the time. In particular, he highlighted the need for understanding the value of new 
technology, the available access points for entry into the NHS for suppliers, and even the 
lack of clarity on who makes purchasing decisions in the NHS.  
 
Drivers for changes in purchasing led to the establishment of Collaborative Procurement 
Hubs (CPH) and Centres for Evidence-based Purchasing (CEPs), both of which are 
described in more detail in Chapter 2. Additionally, he mentioned a working party 
consisting mainly of industry, CEPs, clinicians, among others, which at that time had met 
to address the following questions: 
 
How can we (PASA) provide clarity on what happens in the NHS? 
How do we get clinicians more involved in decision-making in the NHS? 
How do we turn procurement from being a blocker of innovation to actually being 
a supporter of innovation?  
How can we change the way we measure efficiency to accomplish this? 
And, finally, what is the best level at which to coordinate this in the NHS? (i.e. 
appropriate balance between national and regional control)  
 
It was recognised therefore, that best practice purchasing is still to be identified and 
embedded into the NHS. However, given that current purchasing practice is not regulated 
through a consistent set of guidelines, it is difficult to see if any recommendations made 
either by PASA or as a result of research findings would lead to a change in practice. A 
recent publication commenting on healthcare policy adoption in the USA also echoed these 
sentiments, by highlighting that healthcare leaders cannot be expected to improve 
technology decisions without systematic changes to support their efforts (Coye & Kell 




2006). As also observed in a Institute of Medicine Committee publication on the quality of 
healthcare in the USA, “simply trying harder” will not succeed when there is a lack of a 
business case for the adoption of new policies (IOM 2001). Research is needed to assess 
how to adopt best practice, and cross the policy-practice bridge. 
 
1.1.2  Financial and Healthcare Motivation 
Modern medicine has changed dramatically since the introduction of new technologies to 
aid diagnosis and treatment (Le Fanu 2000). Whilst such innovations have improved care, 
they have also contributed to rising healthcare costs (Neumann & Weinstein 1991; Altman 
& Blendon 1977). Given the increased demand for medical services, there was also an 
indirect increased demand for medical technology (Gelijns & Halm 1991). Acting as an 
integral part of the healthcare system, the device purchasing system therefore plays an 
important role in making savings for the healthcare industry. But making the business case 
for appropriate technologies can be challenging given its variety and the complex 
combination of financial, clinical and technical expertise needed to assess true value: 
 
“Just as there was no business case for quality until networks of providers, purchasers, and 
payers changed the requirements and incentives for quality improvement, today there is no 
business case for rapid adoption of beneficial and cost-effective technologies.” (Coye 2001)  
 
Furthermore, evidence shows that not all purchasing decisions take into account the 
necessary specifications for appropriate clinical care. Certain practices in the health 
industry actually create conflicts of interest that potentially compromise on safety. For 
example, it has been suggested in previous studies that physicians are distracted by 
marketing strategies from pharmaceutical and medical device firms, which may provide 
conflicts of interest in patient care and integrity of the profession when faced with a choice 
of product (Brennan et al. 2006). Approximately 90% of the $21 billion marketing budget 
of the pharmaceutical industry in the USA continues to be directed at physicians, despite a 
dramatic increase in direct-to-consumer advertising (Kerber 2004). These interactions 
between drug companies and doctors start in medical school, continue during residency 
training and persist during physician‟s careers (Blumenthal 2004). When faced with „gifts‟ 
from pharmaceutical companies, it can be difficult for end-users to be unbiased in their 
purchasing choices (Dana & Loewenstein 2003). It could be assumed that in the UK the 
NHS has larger control of sellers‟ behaviour in hospitals, but a few early conversations 




held by the researchers together with stakeholders in preparation for this study suggest 
that this is not the case. Physicians and nurses will also develop subjective opinions about 
suppliers.  
 
Even if correct intentions are there, there is also evidence to suggest the increase of poor 
quality of care, use of ineffective and untested technology, and overuse and inappropriate 
use of technology (Banta & Luce 1993). Ineffective use of technology affects both 
healthcare practice and future purchasing decisions. It is widely acknowledged, for 
instance, that both drugs and device errors do account for increased hospital costs. The 
costs of adverse drug events (ADEs) are one of the leading categories of patient injury, 
accounting for 19% of all adverse events in the Harvard Medical Practice Study (Brennan 
et al. 2004). These estimates are considered conservative because they do not include the 
costs of injuries to patients or malpractice costs (Bates et al. 1997). In the UK, a report 
from the National Audit Office noted that an analysis of 256 (96%) NHS Trusts survey 
showed that in 2003-4 they recorded 885,832 incidents and near misses. In 2004-5 there 
were 974,000 reported incidents and near misses. The cost of settled clinical negligence 
claims in 2003-4 was £423 million and provisions for outstanding clinical negligence 
claims as at end of 2003-4 were in excess of £2 billion (NAO 2005). Studies such as these 
have led the NHS to note the savings possible if errors were to be prevented. Similarly, in 
the USA, one study involved a cost-benefit analysis showing that net benefits from lowered 
incidence and severity of injuries and decreased workers‟ compensation claims was 
$200,000 per year (Siddharthan et al. 2005).  
 
The motivations so far can therefore simply be summarised in the assumption that 
purchasing decisions can help to both a) reduce errors and b) assess value and bring overall 
benefit and hence safety. 
 
1.1.3  Background to Patient Safety 
Studies in patient safety date back to 1960s and have increased considerably in the last two 
decades (Lilford et al. 2006). Current statistics by the NPSA quote as many as 459,500 
safety incidents from October 2008 to March 2009 - the highest rate since records began 
(BBC 2009). Two key US publications formed the basis of many other studies in latest 
literature: To Err is Human (Kohn et al. 2000), and Error in Medicine (Leape 1994). In 
the UK the document An Organisation with a Memory (Department of Health 2000) was 




a pivotal publication that led to the creation of the National Patient Safety Agency (NPSA) 
and, subsequently, PASA. These publications encouraged us to approach patient safety as a 
systems error. Incident reporting culture increased as a means to highlight errors, although 
it was acknowledged that reporting errors was still not firmly established within the Trusts 
(Alberti 2001). Investigation into device errors by the Medicines and Healthcare products 
Regulatory Agency (MHRA) in 2003 reported that problems with medical devices were the 
major contributory cause in patients‟ death in around 20% of cases within a year; in the 
other cases the other contributory factors were non-device related (MDA 2003). A 
significant proportion of the remaining 80% is attributed to human error or systems error 
(Lowe 2005). In an attempt to understand systems approaches better, various sources in 
healthcare now quote Reason‟s Swiss cheese model of error - the existence of „holes‟ within 
each defence layer does not normally cause a bad outcome, but an incident occurs when 
the holes line up to permit a trajectory of accident opportunity (Reason 1990). The process 
of purchasing medical devices may well provide some of these holes in our system, which 
leads to the emergence of the term „Purchasing for Safety‟ as one layer of this system. 
 
1.1.4  Purchasing for Safety 
Responding to To Err is Human, the USA launched the Leapfrog Initiative in 2000 
(Leapfrog, web source). It was driven by organizations that buy healthcare who are 
working to initiate breakthrough improvements in the safety, quality and affordability of 
healthcare for Americans. Although their remit is to improve the power of purchasing in 
the delivery of healthcare and not specifically devices, the ultimate goal is patient safety 
and their methods of identifying good spending proportions and patterns of hospitals 
could be helpful to examine.  Since then, there have been other incentives for addressing 
purchasing and patient safety from other sources.  
 
Policy and National Initiatives for Purchasing for Safety 
The Department of Health published an influential report highlighting the importance of 
improving purchasing practice in the NHS (HITF 2004). The Cox Review also highlighted 
the potential for purchasing to shape public services (Cox 2005). Trusts themselves could 
be competing on quality of service, patient safety and level of innovation, as suggested 
further by Warrington from PASA (Sansom 2006a).  
 




While there is some published guidance on how to „purchase for safety‟ or to purchase 
efficiently for hospitals, most of this is out of date and may not be applicable in practice. 
According to a review by Coye and Kell, the lack of detailed, neutral information about 
candidate technologies leave hospital administrators poorly prepared to make appropriate 
decisions on potentially beneficial technologies (Coye & Kell 2006). Healthtec in the USA 
emerged precisely because there was a need to research emerging technologies, forecast 
their evolution and potential impact on healthcare, to facilitate planning and long-term 
strategies with respect to new innovations (Becker 2003).  
 
Empirical evidence for purchasing for safety 
On a local level, challenges to the implementation of good purchasing practice also exist, 
notably the complications associated with tendering procedures (Hughes 1996). 
Furthermore, the link between purchasing and patient safety in practice has not been 
formally established through an evidence base. 
 
There is a large body of literature available from the Centre for Research and Innovation 
in Strategic Purchasing and Supply (CRISPS), but their studies largely refer to risk to the 
organisation, not explicitly direct risk to patient, and is also centred around the whole 
supply chain. „Risks‟ in terms of risk to patients and end-users due to device design have 
also been highlighted and mitigations for these are addressed by regulatory bodies, but 
studies have shown that this is not enough to ensure safety in user context (Clarkson et al. 
1999). Only few have taken the research a step further by looking at the stakeholders 
involved in purchasing decisions and how to better identify their role in safety. For 
instance, the „disconnects‟ in the wound dressing supply chain in the UK have been 
investigated but this study is limited to one product. Other studies have been conducted as 
stakeholder analyses for infusion pump purchasing in the USA (Johnson et al. 2005; 
Keselman & Tang 2004), but these are again limited to one device, and are based in the US 
healthcare system which is different to that of the UK. In both cases the studies were 
product-specific and they did not try to generalise to the wider purchasing process.  
 
The supplier’s role in safety 
While the demand side of the supply chain may initiate safe purchasing practice, the supply 
side also has a role to play in producing patient-safe devices. However, little is provided in 




the way of practical guidance to help the device developer meet these safe device design 
requirements (Alexander & Clarkson 2000). According to Ward, interviews with medical 
device companies in the UK have shown that such advice would be helpful not only in 
achieving good design, but also to comply with the essential requirements of the medical 
device directives (Ward 2002).  
 
Regulation standards provide one way of monitoring safe design practice in the design 
process. These standards have reached far and wide but these considerations alone are not 
enough to ensure the safety of devices in the patient environment (Clarkson et al. 1999). 
Furthermore, despite differences in the manner in which regulations standards are 
practiced in the USA and the EU, these do not seem to affect the rate of incidents or 
reported percentages quoted in the UK compared to the USA (Davies & Marshall 2000). 
The direct correlation between more stringent standards and reports of incidents is still to 
be investigated. What has been shown, however, is that not all standards may imply the 
same level of safety when it comes to device use. A study on applying standards to the 
design of nuclear medical devices claims that because the directives were misleading, some 
of the radiation detectors (which ideally should be classed as Class I devices) could not 
even be considered medical devices if the standards were to be read literally (Bury 2000). 
Gamma or beta counters could also be manipulated differently since the standard to be 
applied would have to depend on where the manufacturer specifies its destination for use. 
This shows that there are still flaws in the vocabulary used in the standards, which could 
either confuse manufacturers or mislead those attempting to not cause harm with their 
design. 
 
It has also been shown that regulations and standards are not completely understood by 
designers and purchasers (Kreuzer 1998). The connection between regulation and clinical 
appropriateness may also have been lost. Despite its mandate to ensure safety and 
effectiveness, the FDA was forced by the tremendous volume of device applications to 
prioritise its resources towards ensuring the safety, rather than the effectiveness, of new 
devices in clinical practice. This has been a direct effect of taking a limited and possibly 
misunderstood „engineering approach‟ to evaluation of devices, focusing on technical 
capabilities and on failure rates, rather than clinical endpoints, such as a decreased pain, 
improved function or amelioration of disease (Ramsey et al. 1998).  
 




When addressing patient safety as part of a greater aim for healthcare improvement, the 
literature is much larger and „purchasing‟ is also mentioned in the context of culture and 
organisational behaviour. Such literature is introduced in the literature review. However, 
as elaborated above, the concept of „purchasing for safety‟ at the local decision-making 
level presents a topical and methodological gap.  
 
 
1.2  Research Approach 
 
Given the lack of studies on „purchasing as it happens‟ in the NHS as highlighted above, 
approaches to patient safety improvements through improved purchasing measures 
therefore also show a methodological gap to the research topic. The research approach is 
described in detail in Chapter 3 but an overview is provided here.  
 
1.2.1  Research Aim 
Despite the few studies mentioned here, more empirical evidence was needed at the time of 
this study to show firstly whether purchasing practice currently presents a problem in the 
NHS, and, secondly, how such practices are contributing to risks in the service. It is 
therefore not the intention to re-design purchasing practice, but rather observe current 
practice before the need and method for improvement is suggested. The second part of the 
investigation consists in assessing the effect of these practices on the healthcare delivery 
service, to then provide recommendations on possible interventions.  
 
1.2.2  Research Questions 
The detailed research questions are elaborated further in Chapter 3, following a literature 
review. Following the above aim, the main research question for this study is as follows: 
 
 
What are the characteristics of a medical device purchasing process 
that effectively focus attention on patient safety? 
 




To investigate this question, three questions were derived which are investigated 
throughout this study: 
 
1. What is current practice in medical device purchasing? 
2. (How) does current practice present risks to healthcare delivery services? 
3. Where are areas for improvement on current practice? 
 
1.2.3  Overview of Data Collection 
The challenges faced in researching in a healthcare context are introduced in Chapter 4 
together with the research methodology and general approach. Access to data in a 
healthcare context provides one of the major challenges and can even influence the 
approach taken to the research. Due to collaborations established for this study, 
opportunities for various stages in the data collection process were possible.  
 
The sources of data were a result of the following collaborations:  
 
Trust A: Collaboration with this Trust provided most of the detail in the data and 
deeper understanding of the healthcare context.  
 
Trusts B, C, and D: Collaboration with a PASA project on Purchasing for Safety2 
gave access to three further Trusts, while examining the safe purchase of infusion 
systems.  
 
Trust E: An invitation to a Scottish NHS Trust to examine the process of 
evaluation of new infusion pumps provided a third opportunity for access.  
 
 
The opportunities provided by the above Trusts allowed for the data to be collected in two 
dimensions: a general analysis and overview providing a broader scope of general 
purchasing practices across the Trusts, and a series of case examples that gave a deeper 
analysis of particular elements of purchasing practice. These in particular led to the 
                                               
2 Full details of the Purchasing for Safety project by PASA can be found in 
http://www.pasa.nhs.uk/PASAWeb/NHSprocurement/Purchasingforsafetyinjectablemedicines/ 
(Accessed 01/12/2009) 




identification of risks to healthcare delivery that arise from poor purchasing practice. A 




Figure 1: Sources of data and general approach to study 
 
The data was collected, and hence presented in this thesis, in the sets of results described 
next.  
 
Results I: Exploratory Studies (Trusts A, B, C, D) 
The aim of this stage was to establish who the main stakeholders are, the ranges of 
products involved, and an outline of the processes followed. It also elicited the main issues 
encountered by the participants. Research in this section were conducted at Trusts A, B, C, 
and D, and the focus was largely on the people and processes involved. In part, the studies 
also focussed on the products and included a literature review of the types of products 
available to hospitals and interviews with medical device sales representatives.  
Results II:  Observations of current practice (Trusts A, B, C, D, E)  
The aim of this stage was to gain a deeper understanding of the drivers and influences 
behind purchasing decisions. All sample Trusts were involved in this study to gain a broad 




understanding of the processes. The insights obtained were cross-referenced to the initial 
Exploratory Studies to obtain valid conclusions.  
 
Results III:  Risks and Challenges through Case Examples (Trusts A, E) 
Given the opportunities provided for more in-depth analysis and observations of practice 
within hospitals, Trust E and Trust A were examined in more depth and allowed for case 
studies to be developed with specific research questions following the generic study in 
Results II. Specific challenges in the process were examined and the implications of these 
challenges to the general healthcare service are discussed.  
 
Synthesis and Framework 
All results emerging from each part of the studies were analysed to provide a framework 
covering the main issues in medical device purchasing. This framework also served as a 
way of presenting the main issues back to the participants in the study, as a form of 
validation of the ideas developed.  
 
1.2.4  Research Process Framework 
On a conceptual level, this project aims to follow good design practice in its investigation 
as well as in its approach to the research matter. A design research framework is adopted, 
which advocates an understanding of current practice to then be able to prescribe the 
requirements needed for good purchasing practice.  Before best practice can be 
implemented through change, good design practices dictates that a clearer picture of the 
current context is needed, which is where most of the contribution of this research lies. 
Taking the approach suggested in Design Research Methodology (Blessing & Chakrabarti 
2009), this project covers the following:  
 
a. Sets the criteria for the research success. 
b. Describes elements of current practice of medical device purchasing in the NHS. 
c. Establishes the requirements needed to prescribe good purchasing practice.  
Each of these stages is embedded within the dissertation outline described next. 
 




1.2.5  Dissertation Outline 
The approach to the research gives an indication, firstly, of what contributions this 
research aims to achieve, and, secondly, the adopted approach taken in order to satisfy 
these aims. The aim of each section was as follows: 
 
Chapter 1: This first chapter has provided an overview of the research and 
motivation for its undertaking. 
 
Chapter 2: This chapter reviews the current available literature in this field, 
drawing from different disciplines, and concludes that there is a gap to be filled in 
current knowledge.  
 
Chapter 3: The direction and evidence gathered in the previous chapter are used to 
arrive at research questions, followed by a general research approach to then draw 
upon a suitable methodology for the research.  
 
Chapter 4: Presented as Results I, the Exploratory Studies answer the very simple 
question “What is going on in device purchasing?‟ in a very general sense, to be in 
a better position to ask further questions for the study. 
 
Chapter 5: The results presented in Results II answer general questions on current 
practice, followed by a short discussion on potential challenges in current practice.  
 
Chapter 6: The case studies in Results III provide examples where elements of poor 
practice, as concluded in Results II, are demonstrated through real life examples. 
The chapter concludes with further analysis to examine inefficiencies in current 
practice, and whether and how such practice can lead to risks in the healthcare 
service, drawing on findings from Results I, II, and III. 
 
Chapter 7: The suggested frameworks serve to then bring out the main issues in 
current practice in diagrammatic form, with the aim of serving potential 
improvements as elicited in the above stages.  
 
Chapter 8: All conclusions are re-stated, together with recommendations that 
inform future „prescriptive studies‟. 




Figure 2 summarises the structure of the dissertation in context of the design research 





Figure 2: Dissertation outline embedded into research approach 
 
 
The left part of the diagram closely resembles the design research approach suggested 
Engineering Design research (Blessing & Chakrabarti 2009), as an overall framework to 
the study. Steps a, b, and c, refer to the three steps in Section 1.2.4. Setting the criteria for 
research success (a) is established together with the description of the methodology in 
Chapter 3. The study largely constitutes a description of current device purchasing practice 
(b). The contributions made towards future design of „prescriptions‟ (c) are made 
throughout the thesis and reiterated in Chapter 8.  
 
 




1.3  Summary of Introduction 
This study aims to investigate the current situation with regards to purchasing in the NHS, 
and link these practices to patient safety. The research topic presents both a 
methodological gap and topical gap in the literature. Patient safety has been examined but 
not in context of purchasing, yet plenty of financial and ergonomical incentives exist to 
suggest this is worthy of investigation. Given the diversity and complexity of the research 
context, the NHS, a systems approach is adopted both to the methods required to conduct 
the research, and as a conceptual approach to the topic itself. Systems approaches are not 
new to patient safety, but appear to be new to purchasing in healthcare.  
 
PASA has had purchasing power in the NHS in the past, and now recently undergone 
some changes, but it is unknown if they are becoming better at purchasing medical devices, 
in response to policy drivers for such change. In particular, PASA is faced with 
understanding the „value‟ of new technologies, gathering entry points into the NHS, and 
understanding who actually makes purchasing decisions. Previous studies on patient safety 
have alluded to re-design of purchasing systems, but few recommendations have been 
found on how to implement these in practice. In purchasing literature, most of the studies 
are based on strategic purchasing, and although it is emphasised to address patient safety, 
there is little research in examining the process of purchasing medical devices from a 
hospital‟s perspective. Given the various decision-makers involved in making a purchase, a 
holistic a systems approach to purchasing a medical device is suggested to mitigate the 
risks associated with medical device errors.  This approach is also embedded into the 
approach to the study itself, by adopting a framework that focuses on understanding the 
current system first. A chapter outline that delineated the route taken in the various 


















The research subject falls under a number of different topics and research fields. This also 
constituted in the initial challenge for the research, which was to identify the core literature 
that pertains to the topics of study. The literature study was completed through the 
following strategies: 
 
Database key word search: General search through medical literature database 
PubMed, which covers not only research in front-end clinical applications, but 
covers service, management, and technological aspects of healthcare. This service 
was initially used to obtain relevant search terms using a set of controlled 
vocabulary (Medical Subject Headings or MeSH terms)3  
                                               
3 Search for terms [Search ("Equipment and Supplies"[Mesh] OR "Equipment Failure"[Mesh] OR 
"Equipment Failure Analysis"[Mesh] OR "Equipment Reuse"[Mesh] OR "Equipment Safety"[Mesh] OR 
"Equipment Design"[Mesh] OR "Equipment and Supplies, Hospital"[Mesh] OR "Disposable 
Equipment"[Mesh])] AND [Search "Materials Management, Hospital"[Mesh] OR ("Group 
Purchasing"[Mesh] OR "Practice Valuation and Purchase"[Mesh] OR "Purchasing, Hospital"[Mesh] OR 
"Financial Support"[Mesh] OR "Economics, Hospital"[Mesh]) yielded 4193 of which 984 were marked as 
relevant based on abstract/title (September 2009) 




General search engine: Using web-based search engines, general policy documents 
and media publications were found, especially on changes in the NHS 
 
Reference chasing: Further material identified in the reference lists from other key 
publications 
 
Periodic automated list services: Subscriptions to relevant journals or discussion 
forums were followed for current debates on the following topics: Electro-
Biomedical equipment engineering forum (EBME), Health Services Journal (HSJ), 
Safety-critical industries email list, and design research (PHD-DESIGN) email list 
 
 
2.1 Overview of Literature Review 
 
Theory and insights were drawn from these various fields of previously published work 
with two intents. It was first necessary to identify whether or not medical device 
purchasing had been investigated before, and by what methods, and secondly to gather 
theory on established disciplines of purchasing practice, not to analyse and apply them in 
their totality, but to understand their possible influence on current practice in a healthcare 
context.  
 
The survey of literature presented here falls under the following categories:  
 
 Purchasing and Improvement (drawing on Purchasing and Operations 
Management, and Process Improvement), which provides background to general 
purchasing practice and relevant management theory, and is compared to process 
improvements specific to healthcare and patient safety 
 
 Medical Device Purchasing, which provides background to available knowledge on 
device purchasing and identifies the challenges specific to medical device 
purchasing 
 




 Design in Healthcare, which introduces previous knowledge on general process 
improvement measures and how to approach patient safety and healthcare 
improvements with „design‟ concepts  
 
 
2.2  Purchasing and Improvement  
 
Aim: To provide background to general purchasing practice and relevant management 
theory, and compare these with literature on improvements specific to healthcare and 
patient safety 
 
Research in healthcare improvement has drawn on guidance from general purchasing 
practice as well as theories in supply chain operations management. Both subjects are 
introduced here to provide an introduction to these original sources of knowledge. 
Operations management is the activity of managing the resources that are devoted to the 
production and delivery of products and services (Slack et al. 2007). Lessons from 
operations management are important to consider for purchasing practice as they underpin 
the general context under which device purchasing occurs. The type of literature included 
is mainly core and general books on purchasing and management theory, and not analytic 
publications on these theories. The focus is on the implications and adoption of methods 
specific to healthcare.  
 
2.2.1  Purchasers and Purchasing Process 
The term procurement has been referred to in industry as the process of managing 
activities associated with an organisation‟s need to purchase goods and services, required 
to deliver their products and services or operate the organisation (ICG, web source). 
„Procurement‟ therefore usually implies a broader sense of „purchasing‟ which is the simple 
act of buying, and could involve determining which commodities or services are best, 
choosing the right suppliers, negotiating the best prices, and awarding contracts to ensure 
that the correct amount of the product or service is received at the appropriate time. In this 
study, both terms could be used interchangeably. However, to avoid confusion, the term 
purchasing is used as much as possible throughout, since it is usually placed in context of 




„the purchasing system‟ or „purchasing process‟, to emphasise the more holistic aspects of 
purchasing practice. It should be noted that the term „Procurement‟ is also used later in the 
results chapters to refer to the department that deals with administering purchases, but this 
would always be used as the phrase „Procurement Department‟.  
 
A Purchasing Cycle 
Integral to the operation of the supply chain is the purchasing cycle, as exemplified by 
Figure 3 adapted from guidance compiled by the Chartered Institute of Purchasing and 





Figure 3: The Purchasing Cycle, adapted from (CIPS 2006) 
 
 
Even a simplistic model such as the one above, if followed accurately, would enable 
appropriate articulation of end-user needs in healthcare, but this may not always the case. 
The emphasis in this cycle is on the role of the purchaser, and the articulation and 
communication of end-user needs throughout the cycle.  
 




The articulation of end-user needs resonates with guidance from other industries. Mass-
market products, such as mobile phones and computer games have their end-users at heart 
in design, and it is well understood that such devices will not sell to the general public if 
they are not ergonomically designed. Further to device usability and aesthetics, safety 
features must also be taken into consideration given the context of use of medical devices. 
A parallel can also be established between other safety-critical industries and healthcare: 
the end-user and receiver of the service is in a critical position that may have implications 
on their health and well-being. Safety-critical industries, such as aviation, rail, and defence, 
can share lessons about the standards and expectations of purchasers. One such standard 
is that of the Ministry of Defence (MoD) in the procurement of safety-critical software 
systems (MOD 1997). Several bodies are responsible at various stages of the purchasing 
process, and ultimately the software designers work hard to meet the high standards set by 
the purchasers. Checks are made by the designated Design Authority and a MoD Safety 
Assurance Authority.  
 
The purchaser’s role 
The buyer, if following the purchasing cycle adequately, and ensuring that the correct 
needs are being communicated throughout the cycle as shown in Figure 3, is a focused 
individual working in a pro-active situation. The role of the purchaser is therefore an 
important one that carries much greater responsibilities and authority. As well as 
considering the role and responsibility of the purchaser, creating a purchasing process that 
integrates into a safety-critical system is therefore also of paramount importance. As 
learned from CIPS, creating a „purchaser‟ is required that is proactive and aware of the rest 
of the cycle. Similar concepts exist in operations literature. Supply chain management has 
as its objective to satisfy the end customer, which in a healthcare scenario could be the 
end-purchaser. What the customer originally had in mind as requirements may be different 
by the time the goods are received, because of the different points in the decision making 
process that have had to take into account specific requirements common to the 
organisation (Slack et al. 2007; p. 403).  
 
Given this displacement between end-user and supplier, the purchasing manager provides a 
vital link between the operation itself and its suppliers. It is their duty to “understand the 
requirements of all the processes within the organisation and also the capabilities of the 
suppliers who could potentially provide products and services for the operation” 




(Christopher 2005). Identifying this purchaser therefore constitutes an initial part of this 
study.  
2.2.2  Operations Management 
Any changes in purchasing practice affects, or is affected by, the overall strategy and 
objectives of the organisation. In healthcare, the functions of the organisation include 
aspects of general industrial organisations such as product or service development 
function, the fulfilment of customer needs, and support functions such as accounting, 
finance, and human resources. However, ultimately, the product of this particular 
operation is intangible: a service. Some of these concepts are introduced below and 
discussed in the context of medical device purchasing.  
 
Inventory Control 
Inventory or stock can refer to the stored accumulation of material resources in a 
transformation system. In operations management literature, the term refers only to 
transformed resources, particularly materials in a company (Slack et al. 2007). However, 
there are particular aspects of inventory control that can apply to devices in a hospital. In 
particular, the setting of priorities for use of inventories, applying a degree of control to 
each item; and then investing in an information processing system that can cope with their 
particular set of inventory control circumstances (Slack et al. 2007; p. 365-399) The details 
of which method to use in inventory control are not mentioned here as it suffices to simply 
highlight its importance for managing assets, particularly when considering purchasing as 




Asset management is defined by management practitioners as the “integrated, joined-up 
management of physical infrastructure (or other items of value such as human assets, 
knowledge, reputation, etc) with the aim of raising whole life value-for-money” 
(Woodhouse, web source). According to the Woodhouse Partnership, a UK-based 
organisation working with local companies on their asset management systems, only few 
UK companies have fully succeeded in such integration (Woodhouse, web source), and 
some of the reasons they have identified from working with companies have been: 





 “Silo” thinking that prevent collaboration or shared solutions 
 Short-termism that bases success on delivering „on time‟ and „on budget‟, 
irrespective of performance and value 
 Conflicting performance measures that create competing priorities between 
departments 
 Business skills lacking for engineers/facilities managers, especially if not in line with 
finance director 
 Risk evaluations not done properly 
 Fire-fighting: firstly in not having time to think in advance, but then awarding 
competence in crisis at the expense of avoiding the fire in the first place  
 Poor data, both in quantity and accuracy 
 
To achieve integration in the armed, nuclear and airline sectors, strategies such as 
Integrated Logistics Support and Reliability Centred Maintenance have helped maintain a 
certain level of control for asset management. From the manufacturing sector, which 
highlights the importance of team working, shared responsibility and continuous 
improvement processes, has emerged the practice of Total Productive Maintenance and 
Total Quality Management (Woodhouse, web source). These will not be explained in 
detail here; it is unknown to what level such developed approaches would be applicable to 
device purchasing with no knowledge of current practice. Simply identifying some of those 
same challenges mentioned in the list above in current practice in healthcare already 
provides insights on where device purchasing stands in comparison to good practice in 
asset management.  
 
2.2.3  Process Improvement 
Key steps towards process improvement are: understanding the current process (process 
knowledge) and setting criteria for improvement on current performance.  
 
Performance Measurement 
Performance measurement can be defined as the process of quantifying action – where 
measurement means the process of quantification and the performance of the operation is 
assumed to derive from actions taken by its management (Slack et al. 2007). A comparison 




of different approaches was completed in a review (Bourne et al. 2003) that concludes that 
to demonstrate performance and measure it, the following steps must be taken: 
 
1. Identify generic or detailed factors to include as performance measures - e.g. cost, 
speed, dependability, quality, flexibility 
2. Identify which are the most important performance measures - e.g. Key 
Performance Indicators (KPIs) as used in some healthcare organisations  
3. Identify what detailed measures to use to assess performance 
 
Improvements can be of two types: breakthrough improvement, which occurs through the 
innovation of a major and dramatic change in the way the operation works, or continuous 
improvement, assuming several smaller incremental improvement steps. These two 
concepts relate closely to the ideas presented in the first chapter - whether or not this 
project aims to design a purchasing process with a „blank sheet of paper‟ and provide 
breakthrough improvement ideas, or suggest ways of re-engineering the system that 
already exists. Given the long-standing structure of the NHS as an organisation, and the 
approaches and methodological restrictions addressed in Chapter 3, the approach here 
tends towards continuous improvement. Within continuous improvement, performance is 
measured regularly and in cycles. One popular cycle used in healthcare literature is the 
Plan-Do-Study-Act (PDSA) cycle (Berwick 1996). The potential for these indicators and 
improvement performance measures are discussed in context of patient safety improvement 
in Section 2.2.4.  
 
Design Process Improvement  
Design process improvement guidelines also have contributions on generating 
improvements in an organisation:  
 
“Organisation change concerns the transition from an initial „as is‟ organisation situation, 
which is unsatisfactory in some aspect, to a desired „to be‟ situation where the problem is 
resolved. Both the future state and possible change routes that can be followed to reach 
this state have to be specified. To this end, organisational stakeholders develop hypotheses 
(termed scenarios) as to the nature of the desired solution.” (Clarkson & Eckert 2005)  
 




According to these sources, in order to create improvements, the organisation needs to take 
into account: Current-state goals; Stakeholder intentions; Contextual forces. Such 
approaches are particularly useful in this context, where the purchasing decision is made 
by stakeholders belonging to different teams, with varying knowledge of the process and of 
the product being purchased. An extra dimension specific to the healthcare context 
recognised that there are attitudes and cultures in a healthcare environment, risks 
particular to the healthcare service, and further factors that increase the complexity of 
medical device purchasing systems.  
 
These three considerations were incorporated into the design of the questionnaire used as 
the basis of the semi-structured interviews in this study, as well as taken into 
considerations in the design of the research questions, as explained in Chapter 3. The 
current-state goals as well as stakeholder intentions were elicited through discussions on 
drivers and intentions and attitudes towards purchasing for safety, and the contextual 
forces formed the basis of many of the parameters on which the findings were clustered.  
 
2.2.4  Patient Safety Improvement 
The particular challenges in firstly „measuring‟ and then „improving‟ patient safety are 
discussed in later sections, but a mention is made here on how improvement measures have 
been discussed in healthcare. Most medical publications are based on evidence-based 
medicine, although Leape, Berwick et al (Leape et al. 2002) question this formal method 
which places heavy emphasis on data from randomised control trials. However, it has been 
pointed out that in aviation practice neither empirical evidence nor controlled experiments 
were needed to suggest sound principles for safer practice, and yet the effect of Crew 
Resource Management in aviation has had a huge cultural effect and established safer 
practice. (Helmreich & Merritt 1998) 
 
With the aim of creating a process-centred tool for evaluating patient safety performance 
and guiding strategic improvement (Akins 2005), one study suggests that no system-wide 
approach or model has been agreed upon thus far for patient safety approaches, and 
suggests that this field is “in particular need of rigorous qualitative and consumer-oriented 
research to fill an existing methodological gap”. Some of the published measures for 
healthcare and patient safety improvement are introduced next.  
 





According to a review of improvement scoring systems by Nieva and Sorra, “while a 
variety of levers – clinical training and guidelines, information technology, organisational 
structures and industry regulations – are being pushed in healthcare organisations to 
improve patient safety, the belief is growing that an institution‟s ability to avoid harm will 
be realised only when it is able to create a culture of safety among its staff” (Nieva & 
Sorra 2003). This allusion to culture was already made by Reason stating that incident 
reporting requires a “flexible and learning culture”(Reason 1997). The definition of 
organisational culture, according to Helmreich and Merritt, who have spent years 
examining different safety-critical cultures, is “a complex framework of national, 
organisational, and professional attitudes and values within which groups and individuals 
function”(Helmreich & Merritt 1998). 
  
Such methods date back to 1991 with the examination of the Chernobyl disaster, with 
Pidgeon‟s paper arguing that safety culture presents “a new way of conceptualising 
processes of risk handling and management in organisational and other contexts.” 
(Pidgeon 1991) The emphasis is made not only on the norms and rules for dealing with 
risk, but the attitudes to safety and reflexivity on safety practice. In other words, safety 
practice no longer is something that needs to be controlled externally by an organisation, 
but entails a proactive participation by the individuals that are part of that organisation.  
 
Organisational Scoring Systems 
The organisational culture is defined as “a complex framework of national, organisational, 
and professional attitudes and values within which groups and individuals function” 
(Helmreich & Merritt 1998). This can differ per organisation, and implies that each one 
has its particular method of attaining its goals. The final state of a system may be reached 
from different initial conditions and in different ways. Therefore, an organisation with a 
particular set of cultural attributes may be successful in achieving patient safety, while 
another organisation with a different set of cultural attributes can also potentially achieve 
the same levels of success. 
 
Organisations with a cross-functional nature in industrial markets, such as the NHS 
environment, can provide a challenge. A conceptual model has been tested by Lonsdale 
and Watson who present a model supplemented by a real-life case showing how it can help 




managers interpret their environment. They conclude that “organisational power has been 
shown to be critical to the decision-making process” (Lonsdale & Watson 2005). 
Organisation scores are therefore one possible way of measuring patient safety maturity: 
 
“Safety climate questionnaires need to achieve as high a standard of measurement as 
possible so that healthcare managers can use the resulting data to design effective safety 
management systems and interventions” (Flin et al. 2000). 
 
Nieva and Sorra have conducted a survey of the different tools available for survey tools, 
and they conclude by recommending to look out for the following in designing 
organisational scoring systems (Nieva & Sorra 2003):  
 
1. The domains of culture that are assessed 
2. The types of staff who are expected to complete the tool  
3. The setting for which the tool was developed 
4. The availability of reliability and validity evidence about the tool 
 
A suggested approach for using an organisational scoring system for purchasing is 
suggested as follows: 
 
1. Organisation‟s own awareness of the role of purchasing in patient safety 
2. Organisation‟s own assessment on actual use of purchasing in improving patient 
safety 
3. External assessment of organisations awareness of the role of purchasing in patient 
safety 
4. External assessment of organisations actual use of purchasing in improving patient 
safety 
 
These suggested points are theoretical, but were kept in mind while exploring the potential 
for organisational scoring specific for purchasing in Results I. The particular tool tested 
out is MAPSAF, described in the next section.  
 




Maturity Assessment Frameworks 
Quantitative measurement is appropriate when the relationship between inputs and 
outputs is known or can be modelled, and parameters can be modified accordingly 
(Kaplan & Norton 1996). A balanced scorecard, introduced by Kaplan and Norton, is a 
method that balances financial objectives with operational measures of customer 
satisfaction, internal process, innovation and other improvement activities (Kaplan & 
Norton 1996). These measures need to be carefully designed to meet the overall strategic 
objectives of the organisation. A different technique is the maturity grid approach; a 
flexible technique that is used by practitioners in industry, consultants and researchers in 
academia for diagnostic, reflective and improvement purposes (Maier et al. 2009). The 
Manchester Patient Safety Assessment Framework (MAPSAF) is an example of such a 
framework for healthcare (Parker et al. 2002). In the framework, examples are given in a 
range of potential safety cultures, from worst-case (Pathological) to best (Generative). 
MAPSAF uses 9 dimensions to assess patient safety. It has not yet been validated and only 
provides a tool for hospitals to assess their own improvements and „maturity‟. However, 
the tool does claim to do the following: 
 
 Raise awareness about patient safety 
 Illustrate differences in perception between staff 
 Stimulate discussion about the strengths and weaknesses of patient safety culture 
within the organisation 
 Identify areas for improvement 
 Evaluate patient safety interventions and tracking changes over time 
 
The theoretical framework behind MAPSAF came from Westrum (Westrum 1992). This 
Manchester team then adapted it even further to be applied to community pharmacies. 
They had already created one for PCTs and their constituent general practices in the UK 
(Ashcroft et al. 2005). A copy of the tool as used in this study is available in Appendix I. 
As mentioned in their article, the main selling point about MAPSAF is that it encourages 
proactive behaviour, which they advocate, is that “increasing trust and informedness allow 
us to get on with our work without requiring extra supervision and control; audits become 
more efficient and directed, taking less time; managers can be left to manage, workers get 
on to do the work”. Anecdotal evidence from among pharmacists suggests that the tool 
does, at a minimum, raise cultural awareness (Ashcroft et al. 2005).  




In this study, the future development of a maturity framework with regards to purchasing 
is noted but not necessarily advocated. As indicated by Maier et al.‟s guide to maturity grid 
development, the planning and development phases for these grids require an 
understanding of the context, its target audience, and exact requirements (Maier et al. 
2009). This is the stage fulfilled in this study, but the MAPSAF tool is used merely to 
explore its potential future use in the initial Exploratory Studies.  
 
Overall, these safety culture approaches seem a viable route towards organisational 
change, and may be one tool used for purchasing practice improvement. Ultimately, as 
noted in these articles, behavioural change cannot be pushed onto people. The people both 
driving and facilitating the change must believe in the process; and through their 
commitment, a pull is generated among the workforce. If policy has alluded to poor 




2.3  Medical Device Purchasing 
Aim: To provide background to available knowledge on device purchasing and identify the 
challenges specific to medical devices 
 
2.3.1  Purchasing in the NHS 
Established in 1948, the NHS is the largest organisation in Europe and has actually 
enjoyed exceptional popularity. According to one Wanless report, 80% of those polled 
regarded the NHS as critical to British society (Wanless 2002). However, its approach to 
purchasing and the costs of patient safety incidents have also been subject to scrutiny:  
 
"Currently, clinicians argue the clinical case, but procurement managers and finance 
directors will typically argue cost and therefore price. The two worlds do not always come 
together.” (Dr George Findlay, previously clinical coordinator for the National 
Confidential Enquiry into Patient Outcome and Death (Sansom 2006b)) 
 
Given that the public sector spends over £150 billion a year on the goods and services 
needed to deliver public services, it is essential to achieve value for money for the taxpayer 




and effectively manage procurements (OGC 2008).  Yet devices are still contributing to 
unnecessary costs in healthcare. A recent report from the National Audit Office in the UK, 
noted that an analysis of 256 (96%) NHS Trusts survey showed that in 2003-4 they 
recorded 885,832 incidents and near misses. In 2004-5 there were 974,000 reported 
incidents and near misses. The cost of settled clinical negligence claims in 2003-4 was £423 
million and provisions for outstanding clinical negligence claims as at end of 2003-4 were 
in excess of £2 billion (NAO 2005)4. Studies such as these have led the NHS to note the 
savings possible if errors were to be prevented.  
 
Such allusions to the importance of addressing purchasing decisions must, however, stem 
from some form of evidence or proof that good purchasing practice can be implemented, 
adopted and disseminated. In terms of actual technology or ideas adoption, the UK may 
not be best placed. According to a later Wanless report, the USA is an “early” and “fast” 
adopter of technology, France, Australia and Canada are also “fast” but “late”, and the 
UK lags behind all of them by being “late” and “slow” (Wanless 2003). A recent empirical 
study of adoption of e-commerce in the health sector supply chain found that adoption is 
influenced by contextual variables, in particular „external pressure‟ and „internal readiness‟ 
which create trade-offs in adoption decisions (Harland & Knight 2008). But if no concrete 
evidence of its effectiveness is available and little recommendations on exactly how to 
implement safe purchasing practice in healthcare, what could this notion be based on?  
The hearing aid example was given at the start of Chapter 1, but another example, 
Greening the Supply Chain, also shows that procurement policy can respond to need and 
have an influence on the supply chain in the long run. In 2000, PASA became the first 
public sector purchasing organisation to achieve ISO14001 Environmental Management 
Standard (BSI 1996), making sure that suppliers are environmentally aware too. As an 
organisation, they have proven that their policies can have an influence on the behaviour 
of suppliers. An extract from the project‟s Executive Summary further emphasises this 
influence: 
 
It has been increasingly recognised in recent years that public procurement can play an 
important role in contributing to the achievement of other Government policy targets. The 
Agency is therefore not purely a "contracting" body - our remit is constantly expanding to 
                                               
4 The implications of these figures on the total cost of NHS spending was not found in the quoted reference 
but further information on financial activity for the year 2003/4 in the NHS can be found at 
http://www.pasa.doh.gov.uk/annualreport/2003_4/financial/financial-p2.htm   (Accessed 01/12/2009) 




recognise wider issues on the national agenda… On the path towards sustainability we 
have realised that our greatest contribution is through our procurement activities rather 
than estate management. However, our work goes beyond what is required by the 
framework in order to respond to our stakeholders needs and maximise our positive 
contribution to a sustainable society. (PASA 2000) 
 
The question remains whether or not this example of „purchasing for sustainability‟ can be 
replaced with „purchasing for patient safety‟ as successfully as it has been done for the 
environment.   
 
National UK Purchasing Agencies 
The NHS Purchasing and Supply Agency (PASA) had been an Executive Agency of the 
DoH since April 2000. The organisation replaced the previous NHS Supplies and has as its 
general goal to provide “best value for money” (PASA, web source). Currently, they work 
with 400 NHS Trusts, manage 3000 purchasing contracts, and influence half of the £7 
billion spent in the NHS, potentially a huge responsibility. As part of their business plan 
on inception in 2000, they had planned on: 
 
 Ensuring that the changing requirements of the NHS are identified and that they 
drive national purchasing and supply activity  
 Ensuring delivery of planned results and agreed targets through performance 
monitoring across the NHS  
 Developing and improving the provision of comparative information on the 
purchasing and supply performance of the NHS  
 Maintaining an overview of supply markets and advising the NHS on market issues  
 Providing strategic direction to NHS Logistics Authority in order to ensure support 
for national supply strategies 
 
What remains unanswered is to what extent this occurs, and what systems have been put 
in place in order to carry out the above5. The NHS is constantly undergoing reform and 
continues to have strategies for beyond 2010 (Stevens 2004). As a result of the Wanless 
                                               
5 The PASA Framework document can be downloaded from their website (2009): 
http://www.pasa.nhs.uk/PASAWeb/NHSprocurement/AboutNHSPASA/Publications/Corporatepublications.ht
m   (Accessed 01/12/2009) 




report (Wanless 2003) there followed a key publication by the Healthcare Industries Task 
Force (HITF) which was followed by innovative and key changes to procurement strategies 
followed by the DoH (HITF 2004). These plans for implementation were the main focus of 
the business plan, which looked similar to the one existing now. The previous Supply 
Chain Excellence Programme now known as NHS sourcing and Supply Chain 
Improvement Programme was targeted to deliver £1.5 billion of “efficiency gains” by 
2008/9. It was really this HITF document that brought about many of these changes. In 
theory, therefore, most of the strategy planned did call for more risk management, clinician 
and patient engagement, intelligent purchasing and considerations of „value‟ to the patient. 
The question remains whether or not these implementations all took place on a grass-root 
level, and whether or not patient benefit (and thereafter patient safety) has been increased. 
Given the recent changes in PASA structures, as well as the outsourcing of many logistical 
functions for NHS Supplies, much of the collaborative activity and decision-making 
actually occurs at a local and regional level. The main bodies that can be identified as 
being responsible for these considerations are: 
 
 Collaborative Procurement Hubs (CPHs): Intended to ensure value for money and 
implement strategic procurement plans, eventually taking over some areas of 
procurement responsibility currently managed by PASA 
 
 Centres for Evidence-based Purchasing (CEPs): Intended to help and inform 
procurement decisions, and encourage the uptake of useful, safe, innovative 
products and procedures used in health and social care. It is hoped that they will 
guide purchasing decisions throughout the NHS, but the effectiveness of this 
approach is yet to be experienced. 
 
 National Institute for Innovation and Improvement (NIII): A nationally 
coordinated institute that “supports the NHS to transform healthcare for patients 
and the public by rapidly developing and spreading new ways of working, new 
technology and world class leadership” drawing its ideas via co-production with 
the NHS and drawing from industry and international organisations.  
 
 National Innovation Centre (NIC): As part of the NHS Institute for Innovation and 
Improvement, and working together with innovations hubs, it intends to speed up 




the development and adoption of technological innovations that deliver the best 
results for the patient.   
 
 Commissioning6: The process by which the NHS decides what services are needed, 
acquires them and ensures they are provided (Davies 2008). 
 
 National Institute for Clinical Excellence: Provides technology appraisals on health 
equipment, clinical guidelines on managements of specific conditions, and clinical 
audit methods to support the other two aims. 
 
 Adoption Hubs, Innovation Hubs, and Training Hubs: Working together to help 
make better use of new technologies to increase „pull‟ of innovative products, help 
with challenges of innovators to enter the NHS, and develop training tools for the 
safe use of advanced medical technologies. 
 
 MediLink UK & Health Technologies KTN: National network of regionally-based 
independent programs working for a common goal of raising the profile of the 
medical and healthcare sectors in the UK. They have produced 
www.clinicalneed.com, which is based on a SOCN (Statements of Clinical Need) 
process; a tool for healthcare professionals to express real needs and to 
communicate those needs to industry effectively and efficiently.  
 
 Supporting organisations such as the Bath Institute of Medical Engineering (BIME), 
providing guidance on selected equipment.  
 
At face value, the framework is there, but their success is yet to be experienced. One of the 
challenges faced by these various bodies is in truly collecting evidence that can inform 
policy and good practice. A publication developed by authors from the Centre for 
Research in Strategic Purchasing and Supply (CRISPS), examines what “evidence-based 
purchasing” might mean in terms of PASA‟s strategies for purchasing improvement 
criteria. The paper first examines evidence-based management, evidence-based law, and 
                                               
6 Origins of commissioning can be traced back to the internal market in 1991 when the NHS was divided into 
purchasers and providers. It was actually referred to as „purchasing‟ then, not to be confused with the more 
specific „medical device purchasing‟ as used in this thesis. 




evidence-based medicine, evidence-based policy making, and suggests what “evidence-
based purchasing” might be (in line with the inception of centres of evidence-based 
purchasing in PASA), and then this is to “provide an initial conceptual framework for 
evidencing value in public procurement decision making” (Harland et al. 2007). Their key 
message is that evidence-based medicine for public procurement is particularly important 
for procurement in public sector healthcare provision, but has wider applicability to 
evidencing procurement decisions across complex public sector systems.  
 
“The recognition in medicine that strict adherence to single, scientific methodologies is not 
always appropriate supports some form of contingency approach to choice of evidencing 
method.” (Harland et al. 2007) 
 
The UK Efficiency Review (Gershon 2004) of public sector called for a focus on generating 
efficiency savings in public procurement, so that resources would be released back to front 
line services. It was in response to HITF that researchers at CRiSPS completed some work 
on what evidence based purchasing in healthcare might mean. In the context of developing 
such evidence, Harland et al point out that observational, qualitative and case study 
research is needed in the context of healthcare purchasing practice, but this can be difficult 
to disseminate in context of a randomised-control trial (RCT) community (Harland et al. 
2007). Certainly the challenge of both conducting and disseminating qualitative research in 
a medical community is an issue to consider for medical device purchasing practice too, 
and is addressed further in later sections as well as Chapter 3 on methodology.  
 
Gathering evidence, informing policy, adopting policy measures, and understanding the 
national networks in NHS purchasing, forms part of a whole body of literature in itself. 
Gleanings from such themes have been provided in this section, serving as contextual 
background to the focus in this study, which is purchasing decision-making at the local 
hospital level.  
 
Purchasing Devices at Trust-level  
Given the ever-changing political landscape, this study is not focussed on the policies and 
governance issues within NHS Purchasing. The focus here is what happens on the ground, 
which constitutes a gap in research for the NHS. It can be challenging to describe the exact 




workings at Trust level because it is not entirely clear who really makes the decisions about 
what to buy (PASA 2004). Currently, the procedures in place include the following: 
 
 Larger purchases, e.g. European Tenders: Published in the Supplement to the 
Official Journal of the European Union (OJEU), this is an eight-step process for 
tendering for purchases above a certain cost7  
 
 The NHS Supplier Information Database: The setting up of this arose from PASA‟s 
purchase “once only” principle. It is free to all suppliers and purchasers but being 
on the database does not mean they have been accepted into contracts scheme, i.e. 
not necessarily been vetted or approved by PASA 
 
 NHS logistics: Operate through Electronic Data Interface or email, single point of 
contact. Much of the complexity of trading within NHS Trusts is therefore 
removed; even the supplier delivery performance is monitored. Much of these 
services are now provided by a private outsourced company.  
 
 Pre-purchase Questionnaire: A checklist provided to suppliers, mostly for electro-
medical equipment. Among the information asked is the following: 
 
CE marking or other safety standards (e.g. ISO9001, 12001, 13485)? 
Service/spares, installation information? 
Training required, if provided or not? 
Year product on market? 
Repairs, third party or not? 
Is installation necessary? 
Software upgrades notification availability? 
Ionising radiation hazard? 
Decontamination procedure? 
Will it be reprocessed? 
Can be cleaned/ autoclaved? 
 
                                               
7 This is an eight-step tender and contract process to award competing supplier the contract with the hospital, 
starting from identifying customer needs, to tender development, analysis, clarifying issues with suppliers, 
deciding and finalising on the tender award, and launching the agreement. 




The list is comprehensive but does not necessarily give an indication to the purchaser on 
design safety features to look out for. It is also not clear is how these requirements are 
assessed.  
 
Device Purchasing Process Routes 
In a given Trust, the purchasing process route taken varies according to various factors 
that relate to the device itself. These include: cost, funding source, consumable/device, 
old/new device, and current asset content. All of these factors can affect who is involved in 
making the purchasing decision, how long the decision can take, and what final product is 
selected.  
 
Furthermore, it must be noted that the purchase of a medical device may not necessarily be 
differentiated from other purchases in a hospital, at least not to the end-user or original 
requisitioner. However, to the end-user, this is part of a larger list of any item that is 
requisitioned for use in their department. The NHS Supply Chain, which handles most of 
PASA‟s logistical work, provides hospitals with a database for devices with a 





food and facilities (including office supplies) 
clinical markets (orthopaedics, cardiology, pathology, ophthalmics, renal, 
dental, resonance imaging) 
capital equipment 
 
The Key Facts page does not mention safety once – but more noticeable than that is how 
all products are grouped into one supply chain, until the e-class codification is used for 
tendering purposes, as shown in Table 1. 
 






Table 1: PASA classification for all supplies8 
 
 
As seen in Table 1, „medical equipment‟ is only one category among many other items 
supplied by PASA. Within a particular purchasing department of a hospital, the only 
differentiating factor is that a medical device purchase receives an „F‟ e-class code. What is 
also noted above is that pharmaceutical blood products enter a different category („D‟ e-
class code), which makes it no wonder that the pharmacy supply department is separate to 
medical devices. Yet a pharmaceutical product might be supplied with a set of consumables 
that link to a particular device that falls under F for „medical equipment‟. Communication 
and collaboration are therefore key to achieving standardisation.  
                                               
8 The complete list is available at www.doh.pasa.nhs.uk   (Accessed 01/12/2009) 




On entering a hospital, once this F classification has been made in the purchasing process, 
another degree of categorisation made is made according to whether or not the devices that 
are bought or maintained by the Clinical Engineering Department (mainly responsible for 
maintenance and servicing of devices, introduced later). If this Department is aware of all 
medical devices bought (and indeed, if all items are assigned an F classification on 
purchase) a certain degree of control can be achieved in the full life-cycle of the device. 
Certain „ad-hoc‟ purchases can then be avoided. This means, however, that the Engineering 
team should employ an updated, fully working asset management system.  
 
An example of good practice may be that shown by the US Air-force‟s medical facilities 
(Keller & Walker 2005). They use the Emergency Care Research Institute (ECRI, web 
source) device coding system to manage their asset base. As a starting point, they claim 
that a common nomenclature is important to such a dispersed organisation, since 
information about previous notices need to be fed back to ECRI for dissemination. For 
example, ECRI has frequently produced safety notices regarding intensive care ventilators. 
The ventilator reports, which typically involve a breathing circuit failure or alarm problem 
that can put patients at serious risk, are provided to all Air Force facilities as part of the 
ECRI member information program. “Intensive care ventilator,” a standard term used by 
ECRI, has been adopted by the Air Force for its medical technology inventories. If some 
hospitals were to use a non-standard term such as “breathing machines” or “mechanical 
resuscitators” to describe the same machines, there is a chance that an ECRI safety notice 
regarding intensive care ventilators would be overlooked, and patients might be placed at 
risk. Equally, the same service provided by ECRI can include a purchasing assistance tool – 
a Healthcare Product Comparison System - that allows one to compare device features, 
incident history, device outputs, dimensions, key purchase considerations, and safety and 
use considerations.  
 
Tools such as this by ECRI above may be useful for hospitals, but not all the Trusts used 
in this study use them (ECRI charges for their services and the release of this database). 
Furthermore, if designers are driven purely by regulations; the purchasers have a 
standardised list offered by PASA driven by „purpose of use‟, and yet, the end-users have a 
multitude of other drivers required to make a wise purchasing choice, this leaves a lot of 
responsibility on the various people involved in purchasing to make that choice. There is 
also not enough evidence to suggest that all these stakeholders speak to each other. Cheng 




from the WHO emphasises that all must communicate their needs in the supply chain 
(Cheng 2003) as echoed by the earlier guidance from supply and asset management. 
 
Having set the context of the device market and introduced the challenges of its possible 
routes into the NHS, attention is now turned to the particular challenges of buying medical 
devices and the guidance made available to those responsible for purchasing.  
 
2.3.2  Challenges to Purchasing Medical Technology 
The focus of this research is not the purchase of all medical „technology‟ as has been 
alluded to in general in previous sections, since this could also include new treatments, 
drugs and similar innovations. The US Congress defines „medical technology‟ as anything 
from drugs, devices, surgical procedures, organisational support systems (US Congress 
1982). This division does create a challenge for purchasers but even in setting the 
boundary of the research given how interconnected technologies actually are. For instance, 
the purchase price for a piece of equipment or drug, or fee paid to surgeon is not the whole 
cost of a treatment, this also includes operation costs, implementation costs, supervisory 
personnel, training, insurance, supplies, space in the hospital, and so forth (Gelijns & 
Halm 1991).  
 
However, devices themselves do have particular characteristics compared to other 
„technologies‟. Despite the common coupling of the term „drugs and devices‟, both their 
development and purchasing strategies differ. The device industry is “younger, less 
concentrated, and comprises mostly smaller firms”, and there is much “greater 
heterogeneity of medical devices in terms of design purpose and use” (Gelijns & Halm 
1991). The product life of a device usually is also much shorter than that for drugs; 
competitors may rapidly introduce a slightly modified version of a previous device (Gelijns 
& Halm 1991). An article back in 1998 highlights the poor state of medical device 
evaluations and the dangers of using devices without adequate information. They note that 
many purchasers and providers are unaware that the clinical testing and regulation of 
medical devices is vastly different from that for pharmaceutical products (Ramsey et al. 
1998). In terms of forming evidence bases, randomized trials common in drug studies are 
often difficult or unrealistic to perform for medical devices (Ramsey et al. 1998).  
 




Before establishing the boundary definition for device as will be used in this thesis, these 
challenges in technology assessment are addressed next.  
 
Health Technology Assessment 
“When comparing medical technologies, there is often a complex interplay of advantages 
and disadvantages between various drugs, devices, and medical techniques…Each 
alternative has a different cost, risk, application, and the desirability of each can vary 
widely when viewed from the patient, general population, insurance payer, legal, or 
governmental perspective” (Sloane 2004).  
 
In particular, the field of Health Technology Assessment has emerged to help answer some 
of these complex problems. Technology Assessment is claimed to have started in the US 
public sector (O'Donnell et al. 2009; Banta 2003) with the launch of the Office of 
Technology Assessment (OTA) in 1972, which provided Congressional members and 
committees with comprehensive analyses of “technical issues of the 20th century” (OTA, 
web source). Although closed in 1995, during its establishment it served to assess the 
consequences of technological applications and therefore considered in determination of 
public policy on existing and emerging national problems.  It has also been described as 
being increasingly devoted to more effective dissemination and implementation in order to 
influence administrators and clinicians (Banta 2003).  
 
When the UK then launched their National Institute of Clinical Excellence (NICE), they 
generated global interest due to their transparent review process to determine real „value 
for money‟ to the NHS for each new treatment (OTA, web source). After the OTA, the US 
has produced other bodies that provide a similar assessment service, such as Blue Cross 
Blue Shield Association Technology Evaluation Centre and the Emergency Care Research 
Institute (ECRI). Since then, however, decision support for acquiring equipment was 
needed, and some examples of these emerged later. One such example was a model for 
medical technology assessment programme, including automated technology monitoring 
and evaluation methods using indicators presented as a systems approach (Cram 1999). In 
the Netherlands, a priority setting project for general equipment acquisition was developed 
in 1997 (Banta et al. 1997). A review of these assessment methods in England, Wales, 
France, the Netherlands and Sweden was written by Oliver et al, summarising the reaction 
to these developments from a variety of different disciplinary and stakeholder perspectives 




(political science, sociology, economics, ethics, public health, general practice, clinical 
medicine, patients, and the pharmaceutical industry). They conclude that despite the 
growth of HTA over the past two decades, its influence on policy making, and its 
perceived relevance for people from a broad range of different perspectives, remains 
marginal. (Oliver et al. 2004) 
 
In the UK, the NIHR Health Technology Assessment forms part of the National Institute 
for Health Research (NIHR), and aims to produce “independent research information 
about the effectiveness, costs and broader impact of healthcare treatments and tests for 
those who plan, provide or receive care in the NHS.” (NIHR, web source) But there are 
challenges in achieving value in purchasing decisions even in terms of care provision, let 
alone with instrumentation and technologies. To take some hypothetical examples, value 
can mean: 
 
 Assessing performance – meaning anything from lifetime cost, training, reliability, 
availability 
 Cost per hour (£/hr) of device capability 
 Clinical effectiveness compared to a completely different treatment or technology 
(taking then into account all service and treatment costs at least) 
 
It is no wonder that published literature has addressed the „cost-effectiveness‟ of 
technologies (McAteer et al. 2007). These considerations are also important during the 
product development cycle. To cover some of these aspects, the Multidisciplinary 
Assessment of Technology Centre for Healthcare (MATCH) was created in 2003 (Martin 
2005). It aims to support the healthcare technology sector and its user communities by 
creating methods to assess value from concept through to mature product. For instance 
their work includes a spreadsheet tool to compare costs and patient benefit for new device-
related procedures versus standard care with an incumbent device or other alternative 
(Craven et al. 2009). They have also addressed some of the challenges existing with 
capturing user requirements in the device design development process (Martin et al. 2008).  
 
Once the device is in the market, these considerations must also be taken into account by 
the purchaser. It is yet to be shown whether these tools and assessment strategies are 
adopted by the healthcare community, as different parts of healthcare technologies might 
be purchased by different stakeholders within the healthcare community acting as 




purchasers. For instance, the clinician may be purchasing a procedure or piece of 
equipment, the purchasing office may administer the purchase, and the pharmaceuticals 
associated with the technology purchased may be also arranged separately. These hospital-
based divisions are addressed later in this Chapter and in the findings. The World Health 
Organisation and other experts make it clear that the term “health technology” must 
encompass all potential technical facets, including things, people, and processes (cited by 
(Sloane 2004)). Given such complexities and challenges, a boundary is set for focus in this 
study: the purchase of medical devices only. This is defined next.  
 
Definition of Medical Device  
According to US regulations (FDA), a medical device is defined as: 
 
"an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or 
other similar or related article, including a component part, or accessory which is 
recognized in the official National Formulary, or the United States Pharmacopoeia, or any 
supplement to them, intended for use in the diagnosis of disease or other conditions, or in 
the cure, mitigation, treatment, or prevention of disease, in man or other animals, or 
intended to affect the structure or any function of the body of man or other animals, and 
which does not achieve any of its primary intended purposes through chemical action 
within or on the body of man or other animals and which is not dependent upon being 
metabolized for the achievement of any of its primary intended purposes."(FDA, web 
source) 
 
A Medical Device is defined in Directive (93/42/EEC) as:  
“Any instrument, apparatus, appliance, material or other article, whether used alone or in 
combination, including the software necessary for the proper application, intended by the 
manufacturer to be used for human beings for the purpose of :  
 
diagnosis, prevention, monitoring, treatment or alleviation of a disease, an injury or a 
handicap;  
investigation, replacement or modification of the anatomy or of a physiological process.  
control of conception  




and which does not achieve its principal intended action in or on the human body by 
pharmacological, immunological or metabolic means, but which may be assisted by such 
means.9  
 
The above is a definition that is given to medical device manufacturers for the purpose of 
regulating. In practice, those working in the NHS may address devices by terms that are 
sometimes interchangeable, as noted in the exploratory observations so far: equipment, 
medical device, and medical products. These terms are explored below10 : 
 
Equipment: an instrumentality needed for an undertaking or to perform a service 
Device: an instrumentality invented for a particular purpose 
Product: an artefact that has been created by someone or some process 
 
Each stakeholder in the whole life-cycle of a medical device may also have a different 
experience and hence perspective on a device. These perspectives affect its design, its 
selection, and finally, its use and disposal. For instance, from the manufacturer‟s 
perspective, the classification of medical devices varies by regulatory risk standards. Both 
the USA and EU regulation systems classify devices according to their inherent risks and 




                                               
9 The following products are excluded from the scope of the Directive: 
In vitro diagnostic devices  
Active implantable devices covered by Directive 90/385/EEC  
Medicinal products covered by Directive 65/65/EEC  
Cosmetic products covered by Directive 76/768/EEC  
Personal protective equipment covered by Directive 89/686/EEC  
Tissues or cells of human origin  
Viable tissue or cells of animal origin 
 
10 Definitions taken from http://wordnet.princeton.edu/ 






Table 2: Classification of medical devices according to level of risk, USA regulation 
 
 




Table 3: Classification of medical devices according to level of risk, EU regulation 
 
 
The USA and the EU seem to differ in their intentions in setting safety standards. For the 
FDA, to achieve the standard the device needs to go through pre-market notification 
process, and achieve verification of reasonable safety and effectiveness of devices. For the 
EU, however, an assessment is made of the safety and performance of device according to 
manufacturer‟s intended purpose of use. Both accept a level of risk, nevertheless.  
 
A discussion on the selection of medical devices chosen as case examples for this study is 
found in Section 4.3.3, based on themes that may relate risk to purchasing practice, or 
characteristics relevant to both risk and purchasing priorities. For now, it is simply 




established that the boundary for this research is the medical device as defined similarly to 
the EEC Directive earlier: any artefact designed and intended for use in a hospital setting 
and hence purchased by a hospital for providing clinical care. This would therefore include 
all devices falling under the „F-class‟ category as determined by PASA logistics (Table 1), 
but may include the pharmaceutical products if bought together with devices under „D-
class‟ category, dental and optical equipment (I-class), and diagnostic imaging and 
radiotherapy equipment and services (J-class). However, given the hospitals own 
understanding of medical device to be mainly those under category „F‟, it can be assumed 
that these other categories were not taken into consideration by the respondents when 
providing responses.  
 
2.3.3  The Role of Clinical Engineering 
Much of the literature alludes to the role of the Clinical Engineering, or Electro-biomedical 
Engineering (EBME) department within a hospital, as the crucial link between purchasers 
and clinicians. Identifying the key decision-makers, however, remains a challenge dating 
back through literature.  
 
Identifying Stakeholders in Purchasing 
The literature on identifying purchasing stakeholders dates back to the 1970-80s, when the 
role of the clinical engineer started to be established. Many changes have taken place in 
both procurement policy and healthcare decision-making and these changes could be 
investigated further. Furthermore, the literature on the nurses‟ voice in the purchasing 
process highlights an important potential barrier, which may be a reason for poor 
purchasing practice. Interestingly, however, such articles are also only found in nursing 
management journals, limited a wider audience to truly achieve stakeholder engagement.  
 
Many of the roles discussed in this study are already introduced in the literature but in 
very limited examples: 
 
 Discussion exists on identifying who the true decision-maker is in the purchasing 
process. Identifying a purchaser or the main body responsible for device purchasing 
has been discussed previously and may continue to be part of the questions that 




continue to be addressed today.(Stafford 1978; Bauer & Clark 1975; Trafas 1980;  
Lewis 1979; Harju 1984) 
 
 The role of the nurse in purchasing decisions has also been highlighted, given their 
central role in actually administering care using equipment (Carroll 1992; Raab 
1984). But in practice, their role may also not be recognised and this also forms 
part of the observations collected in this study. 
 
 The importance of teamwork in purchasing decisions appears in later literature 
(Fahlstrom et al. 2006), highlighting the fact that decisions for devices require 
knowledge that sits in different areas of the hospital.  
  
The Clinical Engineer as the Purchaser 
“Biomedical engineers are often called upon to lead a procurement decision because of 
their knowledge of how medical technology works, technical problems with the current 
technology being used, requirements to maintain technology, what products are available 
on the market and their existing relationship with medical technology companies.” 
(Cassano Piché 2005) 
 
The role of the EBME in device selection process has continually been highlighted since the 
emergence of this discipline within a hospital (Moody 1965; Burton 1996; Draper 2004; 
Whitworth 1979). More recently, the role of engineering and procurement in a hospital 
and at strategic level has been highlighted in international publications (Rothnie 2004). 
Their role is seen as key decision-makers in buying equipment, since they work closely 
with clinicians and technicians and finance, and recognise that “various features and 
benefits are offset with risks and limitations”(Sloane 2004). 
 
According to guidance given specifically to the EBME community, the role of the „EBME 
manager‟, whose role can be played by a senior clinical engineer, medical physicist, or 
clinical scientist, they are responsible also for: 
 
1. Purchasing: “It is the responsibility of the EBME Manager to control the 
documentation and inspection of purchases. It is the responsibility of the Quality 




Assurance Manager to ensure that this procedure is carried out.”(EBME, web 
source) 
 
2. Stores procedures: “It is the responsibility of the EBME Manager to ensure that 
a list of all equipment used is maintained in the Department in a professional 
manner and to ensure that the stores are controlled and handled 
efficiently.”(EBME, web source) 
 
The overlap between storage and maintenance, „estates‟, procurement, and EBME within a 
hospital, is therefore significant, making collaboration and communication between these 
departments a crucial feature to consider in this study. This stakeholder group is an 
essential subject for study in this research.  
 
Equipment management 
Guidance for equipment management as a whole is mostly found in regulatory literature, 
rather than published journals. The FDA has put together guidance on incorporating 
Human Factors Engineering (HFE) into risk management of devices, including aspects of 
usability testing (understanding a device in user environment), explaining what HFE 
means, what level of effort is required in implementing its principles, and implementing 
general risk management processes (Crowley & Kaye 2000). All of this guidance is readily 
available to download online. Similar guidance is available for medical device management 
from the British Standards Institute (BSI 2009). The criteria for appropriate risk 
management include: 
 
1. Board level responsibility for medical device management  
2. Medical device group, in accordance with MDA DB 9801  
3. Comprehensive organisation-wide policy on management of medical devices 
including deployment, monitoring and control 
4. Selection and acquisition of devices acquired in accordance with the MHRA and 
NAO recommendations 
5. Access to manufacturer‟s instructions for end-users; statement signed to the effect 
that they have received instructions on the safe use of devices or equipment 
6. All instructions supplier by the user organisation are evaluated for their adequacy 
7. Acceptance checks on newly delivered medical devices 




8. Devices designed for single use are not reused under any circumstances.  
9. Information required to managed devices recorded on a suitable system 
10. Adverse incident recording 
11. Key indicators to show improvements in device management 
 
All points highlight holistic, system-wide considerations for device purchasing and 
management. In particular, no. 4 points out the necessity to select devices appropriately. 
Details on this point state that this should include “a properly planned approach to the 
purchase of medical devices, taking into account the needs and preferences of professionals 
and end-users whilst retaining consistency and control” (BSI 2009). This includes lease, 
renting, in-house manufacture, refurbishment of devices and very comprehensive criteria 
for choice of supplier as well. These criteria also show a heavy reliance on in-house 
processes, controls, checks, and improvements, rather than relying on the supplier‟s design 
of safe devices.  
 
In academic journals, the focus is more on particular types of equipment that may 
highlight some of the challenges in implementing such guidelines. A small article published 
in an Accident and Emergency journal also gives these general guidelines to the 
„purchasers‟ of equipment, aimed at management staff, within an A&E department. The 
same lessons are repeated: conduct regular/annual review of all equipment, maintenance 
contracts, service record, cost of maintenance vs. frequency of use and effectiveness. It also 
recommends building up good relations with charitable organisations, personal 
relationships with suppliers, and the importance of negotiation skills with suppliers and 
specialists within the particular unit (Oakland 1998). An interesting anecdote from this 
paper is the reference to capital funding allocations per department, speaking for their own 
department that the annual allocation for new and replacement equipment works like 
“national lottery”, given the random allocations given per budget holder. Capital and 
revenue funding seems to be a large divide in deciding how devices are purchased and the 
amount of control adhered to the purchase. In this article, the thresholds are as follows: 
 
<£300:   Directly purchased from A&E budget 
£300 - £5000:  Purchased from revenue budget 
>£5000:  Purchased through business plan from capital budget 
 




These figures are similar to those found in the Trusts in this study, and the challenges with 
such funding barriers are also addressed.  
2.3.4  Guidance for Device Purchasers 
Guidance in relation to healthcare has existed in literature for decades and literature on 
this can be found dating back to the 1960s. These are introduced here along with 
discussions of their limitations and implications for this study. These studies are published 
mostly by staff working in equipment management in hospitals and are therefore found in 
their specific care related journals (e.g. Clinical Engineering or Biomedical 
Instrumentation). Some are found in healthcare economics journals. In the case of device 
specific decision-making support, these are mostly published by either nursing staff or 
clinicians themselves and appear in a care-specific journal, and would not necessarily be 
picked up by a more generic healthcare service audience.  
 
Standardisation & Evaluation 
Representatives from the NPSA have advocated the standardisation of product models in a 
hospital, as a way of reducing errors (Lowe 2006), and studies have shown how 
standardisation in procedures and product can reduce medical errors (Paoletti & Casey 
2000). These concepts are not new to those working with equipment, as publications 
advocating both evaluating and then standardising on new equipment purchases date back 
to the 1980s (Pauley 1980a; Pauley 1980b; Ratcliff 1984; Enger et al. 1987; Larson & 
Maciorowski 1986). More recent guidance has focussed on particular case studies and 
gives advice on how to conduct evaluations in practice (Seto et al. 2006; Simpkins et al. 
1995; Gagnon et al. 2004). Seeing their implementation in current practice also forms part 
of this study.  
 
Selection and Decision-making Tools 
Early guidance also exists to give support for decision-making, but most of these are 
applicable to technologies at the time (Schabracq 1980; Shaffer 1978; Fecteau 1995; 
Hostutler 1996; Smith 1977; Simmers 1993; Jackson 1989; Donahoe 1989). In the 1990s, 
asset management and planning appeared in device maintenance literature, mainly 
highlighted the importance of forward planning and taking into account clinical needs 
(Cohen et al. 1995; Dickerson et al. 1992).  As suppliers increased, it was also necessary to 




provide guidance on how to select suppliers (Deboer & Vanderwegen 2003). More 
recently, specific guidance on making decisions on various models of the same device for 
infusion pumps is particularly useful given the large number of errors that occur to do with 
infusion devices (Ginsburg 2005).  
 
Given all this available literature, it is important to question whether or not these 
recommendations are implemented in practice. Themes have been repeated for over 30 
years, but technologies have changed and evolved. Moreover, it is not always clear which 
audience is being addressed with some of this guidance. One stakeholder group stands out 
in the literature: the clinical engineer. This may be one of the key groups for whom this 
guidance is applicable.  
 
Guidance from EBME 
Not only is their role identified in the literature, but also the EBME network itself is a 
source of guidance on purchasing decisions and is a forum for voicing the challenges they 
face. The literature available from the EBME website and online discussion forums are a 
very valuable source of informal information on how purchasing decisions are made, and 
provide questions on how to consider usability, safety, quality and so forth. It is a 
community with a lot of expertise but perhaps not enough of a voice in the rest of the 
healthcare sector.  The discussions centre on crucial topics, such as: 
 
 Risk quantification on different devices being evaluated 
 Keeping clinicians and budget holders „happy‟ 
 Manuals/technical data sharing 
 Controls assurance, quality standards 
 Questionnaires for supplier before purchase (Pre-purchase Questionnaires) 
 Obsolete equipment handling 
 Specific product information 
 
On the one hand, the site shows how rich this knowledge base is within the EBME 
community. On the other hand, it also shows how many of these issues exist and continue 
to be raised among this community.  
 




Noting that practices vary from Trust to Trust, one EBME forum author has modelled a 
process showing key elements that are common throughout purchases within hospitals. 
This gives a clear and simple indication for purchasers that can help them design their 
purchasing process.  The original version of the diagram originates from a website, not a 
particularly tried and tested method, but a straight-forward example of the purchasing 
process11. The site states;  
 
“In designing purchasing processes it's important to take into account both how 
information systems can be leveraged and where Hospital constraints and governance 
exist. Whilst some fundamentals e.g. originating need - communicating the need to the 
supplier - delivery - the payment of the supplier - may exist in most processes - how they 
are deployed can vary depending on the overall strategy of the Hospital and the prevalence 
of, and confidence in, information systems.”11  
 
According to the description given, the process follows the following model. A fairly linear 
model is suggested to occur, based mostly in the actual purchasing “office”: 
 
 
                                               
11 Taken from http://www.ebme.co.uk/arts/procurement/; referring to http://www.bizbodz.com/Supply-
Chain/General-Supply-chain/How-to-design-a-purchasing-process-1.asp   (Accessed 01/12/2009) 






Figure 4: Purchasing administration process, from EBME sources 
 
 
Many of these processes can now be automated too, and some hospitals have adopted such 
new technologies. But, as pointed out in the website text, an automated procurement 
process is usually a strategy and does not reflect reality, as NHS purchasing departments 
“often find themselves in a hybrid where a mixture of technology, partners and culture 
may be unable to accept a fully automated approach and traditional and contemporary 
processes co-exist.” 11  
 
This may well be the reality encountered in many Trusts and is certainly that encountered 
in the Trusts in this study. Ultimately, while the bespoke process cannot be implemented, 
designing elements of good practice may be possible, allowing each Trust to use guidelines 
that suit its particular culture and organisational structures. According to the EBME site, 
the important considerations when designing a purchasing process are:  
 
 How are the requirement identified? 
 What is the authorisation process within the hospital? 
 How will the organisation communicate with its supply base? 




 Is a tender process required? 
 How are costs managed within the process? 
 Which performance indicators/measures can be applied? 
 
These recommendations resonate with the guidelines from performance and operations 
management, as well highlighting the very important first step of requirements 
identification. Once again, it is their implementation in practice, and the ownership for 
these processes, that need examination.  
 
Tools from regulation, management and human factors 
The MHRA website has produced guidance on making a specific device purchase. Their 
recommended questions are (MHRA 2006): 
 
Will the MD do what I want it to do, and is the usage advice included in the 
packaging? Is intended use covered in manufacturer instructions? 
Will it fit in with what I already have available? (E.g. infusion pumps) 
Are intended users trained to use it, and is additional training needed? How many 
need training? Do they include it in price? 
What service and maintenance is needed? Or will this be in-house? 
Do I have facilities to store them? What is needed? What is their shelf live? 
Is it physically compatible with other devices? 
Do I have components needed? 
What is its life expectancy? 
Will it need to be cleaned or decontaminated? Can this be done in-house? 
 
As well as these guidelines for individual product purchase decisions, documentation exists 
for contextualising devices within a design, manufacturing and use life span. Within the 
World Health Organisation‟s documentation on medical device regulations and 
management, one chapter is dedicated to the nature of medical device safety as a risk 
management process that must encompass the life span of medical devices from their 
conception to disposal. The figure used is shown below: 
 
 






Figure 5: Major phases in the life span of a medical device and associated stakeholders,  
adapted from (Cheng 2003) 
 
 
Any of these phases can affect the safety and performance of a medical device, and this risk 
is shared between the manufacturer, vendor, government, user and the patient/public 
(Cheng 2003). Given that the purchasing stakeholders interact closely with those involved 
in the latter steps of this life span („Advertising‟ onwards), this risk is also shared with 
purchasing stakeholders, and the changes of each process are inevitably linked.  It also 
means that system changes in either arena can trigger systems changes in the other.  
 
Not all guidelines appear from regulation and some literature from the management 
sciences also highlights similar principles. The concept of analytic hierarchy process is 
emphasised (Sloane 2004) because “in the case of a medical technology decision, there is 
an ethical obligation to try to honour the patient‟s needs and beliefs first and foremost, but 
other stakeholder perspectives and needs must also often be considered… Few business 
school researchers understand the medical field, but it has been encouraging to see how 
often they can quickly identify and apply their portfolio of well-documented tools and 
techniques once they understand a healthcare problem.” (Sloane 2004) 
 
Literature from other international sources speak about the more generic term Healthcare 
Technology Management (HTM) as follows (Poluta et al. 2005), described as: 
 
 
Planning; Acquisition; Utilisation I (Asset Management); Utilisation II (Risk 
Management); Utilisation III (Maintenance)  
 
 
The use of Human Factors Engineering (HFE) has also been encouraged in selecting 
devices, particularly for infusion devices which appear frequently in medical error 
published literature (Lin et al. 1998; Zhang et al. 2003; Ginsburg 2005; Gagnon et al. 




2004). In Canada, such approaches have been encouraged as well. The University Health 
Network in Toronto, Ontario used HFE to evaluate electrosurgical units on the market. 
This process influenced the purchasing decision, and in the end the chosen product was the 
oldest on the market and had the fewest new features, but it was deemed to be the most 
usable and had the highest acceptance by clinical end-users (Cassano 2003). HFE was also 
used by the Veterans Health Administration to compare the usability of various infusion 
pumps in order to inform procurement decisions (Wiklund et al. 2002).  
 
A study conducted by Johnson et al (Johnson et al. 2005) has identified what role patient 
safety currently plays in the medical device purchasing process. The study involved looking 
at three sites where purchasing of infusion pumps occurred. The observations were based 
more around sociological influences and disconnects within the system, but the findings 
were interesting as they showed consistency across the three subjects. “Serious limitations 
in the selection process” at each site were the main conclusions. They claim to also be in 
the process of producing guidelines for purchasers to look out for patient safety 
considerations in their future selection processes, these would be interesting to look out for 
in future. Various stakeholders must be taken into consideration when selecting a device. 
These have been identified after a study on infusion devices, as: 
 
nurses (who program the pumps) 
physicians (who write the orders) 
pharmacists (who write the orders) 
biomedical technicians (who repair the devices) 
quality improvement staff 
unit managers (who supervise the nurses) 
patients 
trainers for device use 
administrators accounting for their costs and maintenance 
 
The symptoms for driving change in purchasing, as exemplified by this study, are very 
similar to those experienced in the UK. While stakeholders usually recognise the 
importance of patient safety in purchasing decisions, the understanding of what this means 
is lacking. The size of the hospitals can reveal variances. Problems identified in Johnson‟s 
study included: 
 




 Sometimes not a huge range of devices is considered until problems occur with that 
model  
 No purchasing teams included end-users 
 No formal methods for assessing safety issues that could arise from design of device 
interface (mostly only technical safety issues) 
 Bias in a „preferred‟ pump, which then influenced the justifications made for 
choosing that model 
 Limited HFE considerations (“ease of use”, “ease of programming”) but overall 
inconsistencies in that understanding of patient safety 
 Inability to define or articulate those factors with a direct connection to patient 
safety 
 
These social, cultural and skill-set based issues also remain at the forefront of observation 
for this study to see if similar issues arise.  
 
 
2.4  Healthcare and Design for Patient Safety 
Aim: To introduce previous knowledge on general process improvement measures and 
how to approach patient safety and healthcare improvements with „design‟ and „systems‟ 
concepts  
 
2.4.1  Measurement of Safety 
At least 44000 (up to 98000) people die each year in USA in hospital as result of medical 
error, which costs between $17 - 29 billion per year in hospitals across the country (Kohn 
et al. 2000). Currently most talk of patient safety is based around describing what happens 
when our devices or systems in which they are used are not safe. Quantitative indicators of 
patient safety incidents have served the healthcare community as a straight-forward way to 
assess its performance. For instance;  
 
“A breakdown of the latest figures show that in two thirds of cases - 303,016 - there was 
no harm to the patient, while a quarter - 122,246 result in low harm, which included 
minor injuries from things such as falls resulting from poor safety practices. Another 




28,521 - or 6% - resulted in moderate harm and 5,717 - 1% - in death or severe harm, 
which is classed as permanent injury or disability”(BBC 2009).  
 
Hence, in this school of thought the measurable criterion for assessing the extent of safety 
is to look at medical device errors. However, patient safety is partly affected by medical 
device errors which are both user errors and design errors (Lowe 2006). A combination of 
qualitative and quantitative data exists for research trying to „decrease medical device 
errors‟ as a means to improve patient safety (Karsh & Alper 2005). The methods for 
understanding and analysing errors and risk are introduced here, as a background to the 
design and qualitative approaches adopted.  
 
Medical error and device use 
Patient safety incidents have been referred to by different terms. A few basic definitions of 
the terms used by different research communities are presented below: 
 
 An error is defined as the failure of a planned action to be completed as intended 
(i.e., error of execution) or the use of a wrong plan to achieve an aim (i.e., error of 
planning) - Institute of Medicine, USA (Kohn et al. 2000) 
 
 An error is defined as the failure of a planned sequence of mental or physical 
activities to achieve its intended outcome when these failures cannot be attributed 
to chance - James Reason (Reason 1990) 
 
 A patient safety incident is defined as any unintended or unexpected event that 
leads to death, disability, injury, disease or suffering for one or more patients – 
National Patient Safety Agency (NPSA 2003) 
 
Medical device error analyses come in different forms. It can be measured by the extent of 
harm (Tan 2002), or by the presumed cause of error (Ward & Clarkson 2004), such as 
device-related errors or user-errors. Kletz in his book on human error bases his findings on 
the theme that it is difficult for engineers to change human nature, and it is therefore 
necessary to accept people as they are and instead remove opportunities for error by 
changing the work situation, either through the equipment design or by the method of 
working (Kletz 1991). These errors can therefore be skill-based, knowledge-based, or rule-




based depending on the intention of the user, or the inherent skills and training. 
Rasmussen‟s model of human behaviour also assumes the three types of behaviour 
(knowledge, rule and skill-based) (Rasmussen 1983).  
 
Understanding error and behaviours towards devices constitute part of the knowledge that 
an intelligent purchaser would need, given the role of devices in patient safety incidents. 
This re-emphasises the importance of training and competence in device use.  
 
Reporting and learning from incidents 
Assessing the value of technological intervention versus the risk of patient harm is a 
challenging problem but may well constitute the role that a risk manager, or anyone 
responsible for introducing the equipment to a hospital, needs to play. The challenge is 
then to measure the success criteria for patient safety in these terms. The traditional 
approach is to take a look at the number of patient safety incident counts, as has been 
shown before and typically quoted and used by both the NPSA and the NPSF. The USA 
Food and Drug Administration (FDA) site pages regularly display incidents that have been 
reported back to them, similar to those shown on the NPSA website. Research conducted 
by the National Audit Office (NAO) shows that the most common incidents reported are 
(in this order) (NAO 2005): 
 
Patient injury (due to falls) 
Medication errors 
Equipment related incidents 
Record documentation error 
Communication failure 
 
It is through these reports that patient safety is currently assessed. However, several factors 
about this system need to be considered due to limitations in relying on reporting systems. 
Firstly, they do not allow for a hierarchy for urgency of addressing each error, and 
secondly, the records give no indication on the use of the incident reporting systems. 
According to a study by Barach and Small, reporting systems do not necessarily reflect the 
real extent of harm to the patient (Barach & Small 2000), and there exist too many 
instances of underreporting in most hospitals (Leape 1994). Based on the largest review of 
the system, the National Audit Office found little evidence of improvement in the NHS due 




to complaints. They conclude that there is a lack of learning from complaints, and 
providers are not making clear to end-users that services are being improved as a result 
(NAO 2008).  
 
At the moment no taxonomy for reporting types of incidents has been identified, it is the 
World Health Organisation that is currently working on this. The Medicines and 
Healthcare products Regulatory Agency (MHRA) and NPSA had previously suggested a 
„single-data entry point‟ for reporting system, but this project never took off either. In the 
UK, therefore, Trusts currently still have to report incidents to more than one organisation. 
A number of local and national systems are in place for sharing lessons learnt, but most 
are under-used. Research has also examined the aviation, rail and recreational diving 
industry for ideas on how reporting systems can be improved (NAO 2005).  
 
Harm, Risk and Safety 
One method of addressing errors is to identify their causes, as has been done in previous 
sections, and then be able to predict the probability that these happen, to avoid those 
situations in future. It is not possible to estimate those due to poor training or instructions, 
lack of physical or mental ability or lack of motivation. But it can be assumed that they 
will continue in an organisation at the same rate as in the past, unless there is evidence of 
change (Kletz 1991).  
 
Formal risk management has become a requirement for a range of industries, and has 
affected developments both in design practice and in research in design and in the social 
sciences (Clarkson & Eckert 2005; p. 291). The ISO guide to risk management vocabulary 
defines risk management as “co-ordinated activities to direct and control an organisation 
with regard to risk” (ISO 2002). In practice, various industries have developed their 
management processes to mitigate risks according to their requirements. Early studies came 
from the nuclear, aerospace and construction industries where the focus was on risk to „life 
and limb‟, while later studies developed around project and technical risk in the design of 
software systems, the defence and construction industries, aerospace, nuclear and medical 
engineering, as well as in even more uncertain industries such as flood and coastal defences 
and the oil and gas sector (McMahon & Busby 2005). The characteristics for each of these 
industries have led to the adoption of particular methodologies or frameworks for risk 




management. Although they may differ, frameworks developed for risk analysis and 





The methods adopted can be both qualitative and quantitative. The methods will not be 
discussed in detail here, as no particular method was used in its entirety for this study due 
to the context of the research. Methods include fault-tree analysis, event-tree analysis, 
decision-tree analysis, influence diagrams, Failure Modes and Effects Analysis (FMEA), 
Root-cause analysis (RCA), Human Reliability Assessment (HRA), and various others 
developed for specific contexts and purposes.12   
 
In healthcare, a number of Human Reliability Analyses (HRA) has not necessarily been as 
well accepted as it has in other industries, though their potential has been defended (Lyons 
et al. 2004). Similarly, the use of FMEA and RCA has been advocated in various 
healthcare publications (Senders 2004). In the USA, the National Centre for Patient Safety 
(NCPS) adopted a prioritisation scoring method, the Safety Assessment Code Matrix. This 
is similar to a risk matrix in that it gives scores based on severity and probability of 
occurrence. The feedback methods for these are based on RCA methods that are outlined 
by the front line staff.  In the UK, the NPSA has published Risk Assessment Guides (NPSA 
2006a), which explain what risk assessment is, its importance and use in industry and 
healthcare, and a practical approach on how to do it. The document points out that risk is 
inherent in various aspects of the healthcare delivery process; namely in organisational 
strategy and business planning; financial planning; projects and service developments; 
purchasing; the design of services; and the treatment and care delivery. 
 
The value of risk assessments, or their current method of implementation, has been subject 
to scrutiny, however. Nieva and Sorra (Nieva & Sorra 2003), claim that cultural changes 
                                               
12 The reader is referred to BSI standards: (BSI 2008), (BSI 1996b) and (BSI 2009) for a comprehensive 
understanding  of medical device risk analysis guides. 




are far more important given the flaws in quantitative methods, given inherent flaws in any 
reporting systems and retrospective analyses:  
 
“Analytical methods such as root cause analysis (RCA) and failure mode effects analyses 
(FMEA) will not succeed in uncovering latent sources of error if staff, bound by an implicit 
“code of silence” and a fear of challenging the institutional hierarchy, are uncomfortable 
with exposing weaknesses in processes for which they are responsible. Even benefits from 
new technologies designed to improve safety, such as computerised physician order entry, 
may not be realised if they are not accompanied by cultural and process changes”(Nieva & 
Sorra 2003).   
 
 
If RISK = CONSEQUENCE x PROBABILITY, there is value in at least understanding 
either the consequence or probability in a qualitative manner. As argued by Redmill, the 
usefulness of such methods, he argues, is “not in the values derived but in the fact that the 
process forces us to think deeply about, and therefore better understand, the risks” 
(Redmill 2002). This resonates with the viewpoint taken for this study. Here the focus is 
on the consequences that can occur when good purchasing guidelines are not followed – 
these lead to risks in the service. It is acknowledged that even risk analyses themselves, 
although invaluable for mitigating potential hazards, present subjectivity in their 
assessment. The methods are therefore surveyed, but the study focuses on what is learnt 
during the process of identifying risk rather than quantifying the risks themselves.  
 
2.4.2  Healthcare Design  
“The operation of a health service depends upon a complex interaction between the 
patient, the environment in which care is provided and the people, equipment and facilities 
that deliver the care.”(Sir Liam Donaldson writing in (Rosenthal et al. 1999)) 
 
Design, human factors, and ergonomics have already been introduced to healthcare 
contexts. There are examples of successful uses of HFE methods in safety-critical 
industries, for instance the use of task analysis used in control room designs and 
operations (Higgins et al. 2002), and the example of St Joseph Hospital‟s design for patient 
safety as reported by the National Patient Safety Agency – reported to have been designed 
with „patient safety‟ as the key driver (NPSA 2006b). More publications are encouraging 




the use of the word „design‟, for example quality by design (Nelson et al. 2007) and safety 
by design. Design approaches have been demonstrated in use to improve healthcare 
delivery practice (Wagner et al. 1996) and „re-designing‟ healthcare services (Smith 2001). 
Plsek in a publication on re-design in healthcare claimed that this is simply a „natural 
extension of the incremental improvement efforts underway in many healthcare 
organisations today” (Plsek 1997).  
 
Human Factors in  Purchasing 
The Human Factors Informed Procurement (HFIP) Process evolved from the inclusion of 
human factors methods into the procurement process (Cassano Piché 2005). The paper 
does not specify how the HFE principles were selected, it just states that, it was seen 
„which methods most contributed to an understanding of the safety and adoption 
implications of each product‟ to arrive at their model. The process steps include assembling 
a multi-disciplinary team including EBME, identifying the function needs, selecting 
different vendors, conducting task analyses or flow-charts of how the device would be 
used, consider the training, conduct clinical walk-throughs and even usability testing. All 
these recommendations are good in principle, but they also recommend having a human 
factors specialist accompany the hospital staff during this process, which is not feasible for 
each decision. Some decisions may also have tighter timescales.  
 
Process of designing a purchasing process 
The purchasing process forms part of the healthcare delivery system. Therefore, if the 
healthcare system is to be improved, the purchasing process is one potential area for 
improvement. Hence, the design of both sub-systems should be aligned to promoted 
patient safety. Similarly, both the medical device and the system in which it operates need 
to take patient safety into account in their design. The Design for Patient Safety (DPS) 
report recommends taking a systems/design-led view to improving services in NHS 
(Department of Health 2003) (Figure 6). Following from the discussion above, in the 
idealistic sense, purchasing for medical devices could also be viewed within the context of 
the model shown in this figure. 
 
If the purchasing process is viewed as „the product to be designed‟, the model corresponds 
in the following manner: 





1. Designers of the purchasing process build a knowledge base of purchasing practice. 
2. Based on this knowledge, the requirements for designing the purchasing process are 
defined. 
3. The purchasing process is designed. 
4. The system around the process is designed; iteratively with step (3), the design of 
the purchasing process. 
5. The new purchasing process embedded into the medical system is delivered. 
6. The process is evaluated (feeding back to the requirements). 
7. Safe medical care is provided (further building the knowledge base). 
 
Management of risk, engagement of advisory panel, and promotion of design for 
patient safety underlie all these activities (Figure 6). 
 
 






Figure 6: A model of a systems-based, user-centred approach to healthcare design, adapted from 
(Department of Health 2003) 
 
 
The cycle is continued as further knowledge around purchasing practice and safe care is 
accumulated. This could be one model of an idealised design process for purchasing, when 
the process is to be designed from a „blank sheet‟, as seen in Figure 7.  
 
 










However, there are challenges to implementing systems-based approaches, particularly 
given ongoing practices in the NHS. The DPS report claims that such approaches are 
lacking in current practice in the NHS (Department of Health 2003). Also, a recent study 
in the UK showed that purchasing in the NHS does not currently respond to ergonomic 
principles and guidelines (Cole 2008). Unlike other safety-critical public sectors, such as 
defence, fragmentation is the dominant tendency in the purchasing of medical technologies 
(Phillips et al. 2007). Similar practice is seen in the USA. In a recent study it has been 




shown that while stakeholders usually recognise the importance of patient safety in 
purchasing decisions, the understanding of what this means in practice is lacking (Johnson 
et al. 2005). They also suggest that sociological disconnects contribute to the complexity in 
the purchasing process.  
 
In presenting both models in Figure 6 and Figure 7, the intention is to give an idealised 
view of how new „designs‟ of processes in healthcare, and in this case purchasing, could be 
approached, in line with good engineering design practice. This sets a standard for the 
approach of the contributions made to „design‟ sciences in this thesis. It is important to 
note, however, that the actual contribution is largely a „descriptive‟ study as indicated in 
Figure 2 in Chapter 1. In other words, while the study begins to provide recommendations 
for future designers of device purchasing systems, its main contribution is in „building a 
knowledge base‟ and „defining the requirements‟ (steps in Figure 6) for future process 
design activities.   
 
Validation of Purchasing Design Process 
In Design Process Improvement (Clarkson & Eckert 2005), the design activity is 
introduced as a complex set of interactions between different stakeholders. Once a product 
exits the design box and enters the purchasing stage, a similar set of interactions occur – 
between the suppliers, the purchasing process, the people using the device and the product 
itself.  The process of designing a purchasing process can be likened to a design process 
from other contexts. This would require that the process is subject to both validation and 
verification, as portrayed by Alexander et al. (Alexander et al. 2001). Just as a product 
design process is subject to these steps, here is a suggested „design process for a purchasing 
process‟ version: 
 










This version is adapted from Alexander et al.‟s diagram on medical device design process 
validation (Alexander et al. 2001). It is intended for product design process, rather than a 
“process design process”, but the principles for designing a product and designing a 
process both require similar good design practice. When comparing this model back to the 
Design for Patient Safety model in Figure 6, these very same elements are present and 
theoretically can be applied to a healthcare process design. Broadly speaking, validation is 
ensuring one has "built the right product" and verification is ensuring one has "built the 
product as intended”. In this case, the purchasing process is the „product‟.  It is noted here 
again that these principles remain as standards set for future process designs.  
 
The concepts of „validation‟ and „verification‟ can also be used in a different way. Just as 
design processes require checking at the various design phases as in Figure 8, a purchasing 
process requires its own checking at various purchasing stages. This would imply ensuring 
one has "purchased the right product” and “purchased the product as intended”. In this 
case, the device is still the „product‟ but the design activity is replaced by the purchasing 
activity. These ideas are returned to in the latter chapters to test both the way in which, 
and the extent to which, these process design concepts can be applied to a healthcare 




setting and to this research. An understanding of healthcare and its context is primarily the 
first step before these ideas can be adopted.  
 
 
2.5  Summary of Implications of literature for this study 
 
The literature related to this thesis falls under a variety of disciplines, but serves different 
purposes. Lessons from purchasing theory and operations management serve to identify 
pointers towards good practice in these well-established disciplines, even if they mostly 
relate to other contexts. Turning to patient safety and healthcare improvement sources 
then serves to give context and understanding of the current system under study. Finally, 
pointers from healthcare design and process improvement literature serve to introduce the 
approaches that can be used to analyse these types of environments and provide tools for 
improvement. The main points from each of these sections are repeated below.  
 
From Purchasing Theory, Operations Management, and Process Improvement 
Simplified processes for purchasing exist in theory and can be drawn upon to compare 
current practice. The context of the specific purchasing environment, however, needs to be 
taken into account. For instance, in safety-critical industries, controls & checks, as well as 
expertise judgement are needed on decisions at particular touch-points in the process. 
According to more general guidance, the importance of a proactive and engaging 
purchasing manager is emphasised, who brings together end-users with sales. Appropriate 
risk evaluations and control of existing inventory is also important. In terms of project 
management, the guidance suggests to have clearly defined goals, sufficient resource 
allocation, control mechanisms, adequate communication channels, and troubleshooting 
mechanisms. Performance indicators are one way of indicating improvements, but this 
requires establishing what those performance measures are in the first place. Finally, 
continuous improvement cycles preferred to breakthrough improvement for this study.  
 
The NHS itself also has resources online for providing guidance on what channels are 
available to purchasers. However, there is a lot of material to cover and not all of it is 
available in a cohesive form. This resonates with the earlier comments made by 
representatives from PASA themselves, stating that the true entry points in the NHS are 




unknown to suppliers and that the real decision makers are not known. More knowledge 
is required of what actually is translated to local practice as opposed to national agencies. 
A lot of emphasis is placed on evidence-based purchasing on the local level, where 
appropriate risk decisions can be made and the true value of new technologies ascertained. 
While this is useful for making individual decisions on new technologies, this still does not 
address the process of purchasing itself.  
 
From Medical Device Purchasing 
It was noted that the need exists to define a medical device as separated from general 
medical technology. There is complexity associated even in making this distinction due to 
interconnectedness of drugs, devices, consumables, technologies, and procedures. The way 
PASA classifies their devices (with its changes along the supply chain) by the time the local 
purchasing decision is reached, the criteria for these classifications have changed, resulting 
in the device not really differentiated from the rest of the purchases in a hospital.  
 
Guidance exists for purchasers and other EBME departments.  Some are outdated, but the 
sources for these are within a limited community. Elements of good practice from these 
sources include: standardisation, evaluation, integrating nurses into decisions. What can 
also be ascertained from literature is the focus on EBME and the large role they play in 
connecting expertise.  
 
From Patient Safety & Healthcare Design 
Measurement of device error is one good way of assessing patient safety but this in itself 
also requires subjectivity when speaking about harm or consequence. Design approaches 
bring together many of these concepts - from the qualitative, quantitative, organisational 
methods -to a healthcare context.  Examples include service design, process quality, user-
centred design, and experienced-based design. Safety is also examined in design sciences in 
the context of quality.  
 
Summary of main topics 
Much of the operations and management literature speaks about stakeholders and their 
engagement. These concepts can be explored further, given that there are so many 




references to its importance. Both process knowledge and literature suggest that 
understanding the stakeholders in an organisation is key to progress. This can be taken 
further by also examining their drivers and barriers and resources used to make decisions. 
If performance indicators are to be used, it is important to establish what those indicators 
entail. Process improvement and validation/verification both have control mechanisms, 
understand the complexity factors, and perhaps connect these to some of the cultural and 
attitudes that are specific to a healthcare community. These emergent themes presented 
here as „topics to explore‟ which lead to assumptions about current practice that are to be 
explored further.  
 
 
Table 4: Factors to explore in research, following literature analysis 
 
It is in the context of these parameters or themes that the study is conducted; to 
continuously allude to good practice and theory. The study is not limited to these themes, 
however, as an open-ended approach is conducted especially in the Exploratory Studies. 









RESEARCH PROCESS:  







The term „research process‟ here refers to the totality of the chosen steps within the 
execution of research. This chapter describes the approach taken following an introduction 
to the challenges faced in this research project.  
 
 
3.1  Overview of Research Process 
 
A framework for a research process has been suggested by Sim and Wright in their book 
on healthcare-specific research (Sim & Wright 2002). This has been used as the framework 
for the description of the research process described in this chapter, as diagrammed in 
Figure 9: 
 






Figure 9: Components of a research process, adapted from (Sim & C. Wright 2002) 
 
 
Section 3.2 describes the theoretical starting points with respect to the research. This can 
be equated to Hay‟s framework for decomposing a research process into individual 
building blocks dealing with different aspects of a scientific enquiry (Hay 2002): the 
theoretical starting point is the „paradigm‟ for the research (understanding what 
„knowledge‟ is out there to be acquired for this research). The research questions and 
methodology are based on this paradigm. Section 3.3 then gives the details of the design of 
the research and the particular methods employed. Both these sections are preceded by a 
discussion of the challenges particular to this research project, to provide the context upon 
which the latter discussions are based.  
 
3.1.2  Research Challenges 
Research in a healthcare context is subject to unique challenges with regards to 
methodology. Allusions to „design‟ approaches in healthcare by previous researchers have 
already highlighted some of these challenges and warn against some of the pre-conceived 
ideas of research and systems approaches in the healthcare community: 
 




Methods in the healthcare published community 
Leape, Berwick et al question traditionally used formal evidence methods in healthcare 
that place heavy emphasis on data from randomised control trials (RCTs) (Leape et al. 
2002). They claim that achieving safer care has three agendas, all of which are necessary: 
“identifying what works (efficacy), ensuring that the patient receives it (appropriate use), 
and delivering it flawlessly (no errors)”. But in order to identify what „works‟ they state 
that formal scientific proof according to evidence “lacks validity” and is neither necessary 
nor sufficient for recommending new safer practices in this particular context. “Reducing 
the types of intravenous infusion pumps used in a hospital from 7 to 1 or 2, for example, 
reduces errors. [It] has not been in a randomised controlled trial” (Leape et al. 2002). The 
use of other measures and improvement processes, such as the PDSA cycle introduced 
earlier, are encouraged, given that “healthcare processes do not need a pre-existing 
hypothesis to be tested, nor randomisation, power calculations, and large samples. We 
need just enough information to take a next step in learning” (Berwick 1996). However, it 
is still important to create rigour in these other methods and produce evidence of 
improvements to the healthcare community through other means. The challenges for 
published qualitative findings in medical journals has been highlighted (Greenhalgh & 
Taylor 1997), and while the culture may be changing, it is important to retain rigour in 
qualitative research to compete with many of the more quantitative studies.  
 
Application of improvement methods from other safety-critical industries 
Some studies have stated that healthcare differs in practice to other industries, and 
particular sensitivity is required in application of any models to this context (Olsen et al. 
2005). Firstly, it is pointed out that in many studies the focus is on the workers‟ safety, 
rather than the product (Flin et al. 2000). It could be argued, therefore, that healthcare 
provides an extra layer of complexity as the „product‟ of its service or process is also a 
person (the patient). In general, the healthcare service is considered more personnel-centred 
than other industries (Spath 2004). A recent article in the British Medical Journal also 
suggests that mistakes in healthcare are on a different scale from the level of error tolerated 
in other industries (Elwyn & Corrigan 2005), suggesting that they cannot be assessed by 
the same methods for risk analysis. Reports from the Department of Health and quotes 
from the Chief Medical Officer suggest that healthcare can still learn from these industries,  
 




“Although it is a rare occurrence, pilots regularly rehearse engine failure in simulators. So 
when faced with a real situation habit takes over.  Simulation enables people to train for 
rare events that do not occur often, in real life.” – Chief Medical Officer (Donaldson 
2009) 
 
Systems, Design, and Complexity in healthcare studies 
Design in healthcare services is not a new concept, but may have varying definitions of use 
and applicability. It is of course recognised that design activities already occur in 
healthcare service planning, but the terminology employed in the community may be 
different to that of design research. Plsek comments on current design activity:  
 
“The usual approach to design in healthcare is often at too high a level, it is assumed that 
the people involved will work out the details as they go along, little consideration of what 
might go wrong is involved, and little provision is made for the inevitable stresses that 
workload and urgency will place on the process” (Plsek 1997). 
 
Complexity and systems are also used in healthcare already. One of the ways in which the 
term „complexity‟ is used is in reference to the patients themselves; e.g. a „complex patient‟ 
would be one with extra needs and multidisciplinary clinical needs and social care needs. 
Organisations often seek to address problems of coordination by increased standardization 
with checklists, algorithms, or detailed information packets (Young et al. 1998). Problems 
in integrating such services and stakeholders arise when unremunerated hours are spent 
coordinating care activities, such as referrals and mental health issues (Antonelli & 
Antonelli 2004).  
 
A more in-depth complexity perspective is adopted by Capra, who suggests that 
understanding the patterns or informal networks within the system is equally important, 
and that successful improvement requires integration and change in all three layers of a 
system: structure, process and outcome (Capra 2002). Traditionally studies have focussed 
mainly on layering the structures (physical or administrative) and the re-design of 
processes. Such an approach requires both qualitative and quantitative investigations, with 
a focus on „failures‟ to understand complex systems (Matlow et al. 2006). Giving the 
example of a child undergoing a tomography scan, complexity science offers methods to 
create coordination of patient care from the healthcare service through to social care, but 




studies are needed to actually understand the subtle complexities of care by way of 
ethnographic or similar qualitative studies. Flowcharts are also good ways to document 
current practice, but Plsek warns that “simply constructing a flowchart is no guarantee 
that the (re)design process will be much different from past processes” (Plsek 1997). The 
support for approaches advocated in design research and systems theory is present but 
what this means in practice still requires communication with the healthcare community.  
 
Access to Data 
Obtaining access to data in healthcare can be a huge challenge to researchers. In many 
cases, ethical clearance is needed and the design of the study must be stated upfront. For 
access at the Trusts, ethical clearance was waived due to the limitations of the scope of the 
study (at the time of application). Although mostly qualitative social science methods are 
used, this research was not aimed to result in an ethnographic study of the people involved 
in the interviews. Therefore all interviews, observations and input elicited from NHS staff 
were used as data to inform the „as is‟ situation within the purchasing process. Since this 
study is confined to medical device purchasing, the NHS staff involved included: EBME, 
nurses and clinicians who interact with the devices, risk managers for procurement 
decision-making, and procurement staff.  
 
Establishing stakeholder sample 
While the obvious stakeholder base for this study are the „purchasers‟ administering the 
orders for medical devices, both the Literature and the Exploratory Studies have shown 
that they form only part of a larger stakeholder base. This adds not only to the complexity 
of the process itself, but presents challenges in obtaining a valid data sample in researching 
the process.  
 
Achieving stakeholder engagement 
Having established a stakeholder base, achieving engagement with them provided a further 
obstacle to the research. The flexibility and open engagement in Trust A was a sharp 
contrast to the limited engagement in Trusts B, C, D and E, mainly due to the limited time 
available to develop a trustworthy and honest relationship with the collaborators.  
 





The data was obtained in partial data sets, obtained from each Trust as shown in the T-
shaped diagram in Figure 1, Chapter 1. Therefore, to truly achieve generalisability and 
validity, it was necessary to triangulate observations from any one collaborator with 
insights from other Trusts.  
 
No pre-existing methodological research framework  
As established earlier, there was no pre-existing methodological framework for such a 
study. The subject itself lies in a multitude of disciplines and could have been addressed 
from either an economical, operational, or clinical standpoint. Taking a systems or design-
led approach provided a means by which various perspectives could be considered while 
still making a valuable contribution to design research in healthcare.  
 
The specific way in which some of these challenges were addressed in implementing the 
research is addressed in design and methods in Section 3.2.3. The next section introduces 
the general research approach.  
 
 
3.2  Research Approach 
 
For this project, the scientific inquiry consists of capturing views, perceptions, and 
elements of current practice of different stakeholders in relation to purchasing medical 
devices. This largely involves social issues and stakeholders' views on their world and 
system. Therefore, although the approach and framework of the research is to examine the 
field of study as a „system‟, which is arguably a technical approach, the approach to the 
inquiry itself tends towards the social sciences. The theories behind such social science 
approaches therefore require some explanation and are introduced in these sections. The 
approach to the research consists of three sections: establishing the paradigm of research, 
to then lead to the creation of appropriate research questions and methodology, as 
introduced earlier in Figure 9.  
 




3.2.1  Research Paradigm 
With reference to Thomas Kuhn‟s use of the word „paradigm‟ (Kuhn 1962) in his work, 
Guba later defined a research paradigm as “the starting points or givens that determine 
what inquiry is and how it is to be practiced”, whilst warning that these are „human 
constructions‟ and, therefore, “subject to all the errors and foibles that inevitably 
accompany human endeavours”. (Guba 1990) 
 
Adopting a particular research paradigm fundamentally influences later decisions in the 
research process. These may differ greatly, and dictate different ontological, 
epistemological and methodological lines of thought and action in research. Generally 
speaking, the ontology refers to our ideas about what exists, whether there is truth „out 
there‟ waiting to be discovered and explained. Epistemology relates to the philosophic 
inquiry in the nature and grounds of knowledge – understanding how it is that we know 
what we know. Finally, the methodology refers to the conceptual and logical elements of 






Table 5: Research paradigm characteristics, adapted from (Guba 1990) 
 
 
Generally speaking, the first paradigm, positivism, is based on a belief of „how things really 
are‟. As Guba described, the nature of science is to “discover the „true‟ nature of reality 
and how it „truly‟ works” (Guba 1990). Generally speaking, classical sciences fall under 
such categories. Post-positivism is a modified version of the positivist stance, with an 




understanding that although there is a reality „out there‟, given human frailty, the 
conclusions made about such realities will be flawed. Critical theory and constructivism 
stray further from this approach to a more subjective approach, which, in the extreme 
case, assumes that all our perception of knowledge is relative to the way we understand it 
and that our sense of „reality‟ can change according to this understanding. 
 
At first glance, the research paradigm for this research sits closer to the less objective 
paradigms: post-positivist, critical theory, or constructivism. The ontological stance taken 
is close to that of „critical realism‟, where one can acknowledge the existence of a reality 
but at the same time take into account the extrinsic influences present in the individuals‟ 
perceptions and cognitions, and hence their responses (Bryman 2001). Given that the study 
is largely based on respondents‟ views on the process, and an inquiry into the need for 
future improvement, a positivist view is not the dominant view taken. However, while the 
aim is limited to assessing findings based on the stakeholders‟ accounts of current practice; 
the study still aims to formulate a picture of current practice relating to the collective truth 
of what happens in practice. As noted by Robson, within the social sciences relativistic 
approaches are distinguished from the positivistic traditions (Robson 2002). These include 
„constructivist‟, „naturalistic‟ or „interpretive‟ – all of which reject the view that „truths‟ 
about the social world can be established by using natural science methods. An extreme 
adherence to relativism may therefore imply a complete disassociation from natural 
science. As a potential solution, Robson introduces the term „realism‟ in a different way to 
Guba‟s definition above. He claims that „realism‟ can “provide a model of scientific 
explanation which avoids both positivism and relativism” (Robson 2002), quoting various 
studies where the potential for its utility has been shown in economics, criminology, 
international studies, geography, medical education, nursing, organisational analysis, 
political science and sociology, among others. Realism in this definition has been seen as 
particularly appropriate for research in practice- and value- based professions such as 
social work. For realists, in Robson‟s terms, there are social objects, which can be studied 
scientifically, but the methods chosen must fit the subject matter (Robson 2002). Generally 
speaking, a realist approach integrates both the subjectivist and objectivist approaches in 
social theory. This means that “social structure is at the same time the relatively enduring 
product, and also the medium, of motivated human action… Social structures such as 
language are both reproduced and transformed by action, but they also pre-exist for 
individuals” (Robson 2002).  
 




In summary, for this study the ontological stance is closest to that of a realist (in Robson‟s 
terms), and the epistemology tends towards modified objectivist, since there are no pre-
determined values on „how healthcare should be conducted‟ being assigned to the enquiry. 
Similarly, the ideas behind systems engineering principles and approaches, although tested 
elsewhere, are also not claimed to be the „true‟ and only way of addressing the issues faced 
in healthcare purchasing; they are simply one method for putting forth the problems raised 
and discussing their potential for creating improvements.  
 
The next section describes how the literature review created a starting point for „viewing 
the world‟ of purchasing practice in healthcare. The preliminary conclusions drawn at this 
stage served to draw up research questions.  
 
3.2.2  Research Questions 
The question that is investigated at the highest level in this study is repeated here: 
 
What are the characteristics of a medical device purchasing process 
that effectively focus attention on patient safety? 
 
A set of questions derived from this question is needed to facilitate the data collection 
process. Based on preliminary evidence gathered from the literature and direction 
described in the first chapter, two very general statements can be inferred from the 
literature, in light of some general topics or factors that influence current practice: 
 
1. Challenges to current practice in medical device purchasing exist, because of wide 
range in stakeholders‟ knowledge and skills, cultural differences, and external 
structural influences and pressures on the process.  
 
2. Medical device forms an integral part of a larger equipment management and 
healthcare delivery service and can therefore affect the efficiency of, and add risks 
to, this service. 
 
 
Each of these statements leads to a particular set of research questions. The first refers to a 
general examination of current practice with a particular focus on different stakeholders 




within the system. The system boundary or focus here is the purchasing process itself and 
the decision-making that occurs within that process. The second statement also involves 
examination of the current system, but with a deeper focus on the internal decision-making 
processes of purchasing, with the specific aim of finding potential inefficiencies in the 
process. Therefore, the purchasing process is also viewed as a sub-system of the general 
device management system within a hospital. This itself is a sub-system of the healthcare 
delivery service. The focus of these two statements in relation to their associated systems is 
diagrammed in Figure 10. The boxes and colour relate to the original Design for Patient 
Safety Framework shown in Figure 6, and act to put this particularly study into a larger 





Figure 10: Device Management system elements and relation to healthcare delivery system 
 




Due to the different focus required by each statement, three separate sets of research sub-
questions were designed. The first (indicated as 1 in Figure 10) addresses the general 
workings of current practice in medical device purchasing in the NHS. The second (shown 
as 2 in Figure 10) consists of linking current practice to the identification of potential risks 
to the healthcare delivery service. This second statement is addressed firstly by re-visiting 
the factors that influence current practice through evidence of inefficiencies within the 
purchasing process and device management; and secondly through an investigation of the 
types of impact that the purchasing process can have on the healthcare delivery service. 
Finally, though not indicated above, an analysis of how such factors could be managed to 
improve on current practice is conducted in the third research question. In the context of 
the diagram above, these questions address the internal constituents of the purchasing sub-
system, the interaction between the purchasing sub-system and its device management 
system, and finally its influence on the healthcare super-system. These general questions 





Table 6: Research Questions relating to statements to explore main research question 
 
 
The first question is constructed such that they will lead to general basic learning of 
current practice. The insights gathered during collection of data for this question, however, 
that may elicit further insights that provide the basis for analysis that leads to the wider 
question of purchasing implications in healthcare practice, which leads to a more direct 
STATEMENTS TO EXPLORE RESEARCH QUESTIONS
  1. What is current practice in medical device purchasing?
    2. (How) does current practice present risks to healthcare delivery services?
    3. Where are areas for improvement on current practice?
Medical device forms an integral part of a 
larger equipment management and healthcare 
delivery service and can therefore affect the 
efficiency of, and add risks to, this service.
MAIN RESEARCH QUESTION
What are the characteristics of a medical device purchasing process
 that effectively focus attention on patient safety?
  Challenges to current practice in medical 
device purchasing exist, because of wide range 
in stakeholders‟ knowledge and skills, cultural 
differences, and external strucutural influences 




philosophical contribution of the research taken in the second and third questions. 
Therefore, Questions 2 and 3, although alluded to in the evidence gathered, require some 
inductive analysis, to produce answers that are generated through discussion. The specific 






Given that a general direction of research has already been established through the 
statements concluded earlier, which were the real influence on the research questions, it 
must be made clear here that the research is not intended to be completely open-ended. 
Current practice is assessed, but in light of particular parameters that guide the research 
(though not limited to these parameters). These parameters or „factors to explore‟ were 
listed by the end of the literature review in Table 4 in Chapter 3, but are now listed as an 
empty table, which is populated through each new set of results, shown here in Table 7.  
 





Table 7: Factors considered to answer Research Questions (initial empty template) 
 
 
This table template is filled through each new set of results in Chapters 5, 6, and 7 to 
indicate which data sources (Literature, Exploratory Studies, etc) have contributed to 
learning in those particular areas.  
 
3.2.3  Research Methodology 
Methodology refers to the general principles of investigation that guide a study, based on 
its underlying theoretical and philosophical assumptions (Sim & Wright 2002). Ultimately, 
research aims to provide a new contribution to knowledge, usually referring to a field of 
interest. In this case, the field of interest is the purchasing of medical devices, using the 
context of the NHS. The research strategy describes the approach taken in order to reach 
its conclusions.  
Two different strategies are commonly used: deductive and inductive. The deductive 
approach starts with a hypothesis; a preliminary theory that is then tested for validity in 




the course of the research process. Popper argued that a hypothesis is only considered to be 
true until it is proved be false (Popper 1959). In a real world scenario it is far more 
complicated to provide a controlled environment in which to test a hypothesis rigorously 
(Eisenhardt 1989). Inductive strategies do not start with a hypothesis; but rather generate a 
theoretical framework of understanding where none previously existed (Sim & Wright 
2002).  
 
No explicit theory for purchasing in healthcare is adopted in this study. Certainly guidance 
is available on how to manage the process and pointers gathered in the literature, but not 
an overarching theory as such. Given this gap, a more inductive strategy was used. 
However, the findings constitute a very first glimpse and description of current practice 
and, due to limitations of access to healthcare settings, would also not claim to provide 
grounds for proving nor providing new theory in terms of purchasing and supply of 
devices in the NHS. However, what they do provide is an understanding of current 
practice, an analysis of the possible reasons for such behaviour according to external 
drivers and regulations on their practice as well as their present conditions. All of this 
provides a framework to raise awareness about current practice and give the foundation of 
future work in making improvements. In line with good design practice, this work also 
forms another example of how design practice works in researching one particular 
healthcare setting or system. Chapter 7 introduces feedback from participants as part of 
validation of the results presented, with their perspectives of how such findings can make 
an impact to future practice.  
 
Despite a lack of a specific theoretical standpoint on purchasing in healthcare per se, it is 
important to recognise the existence of any biases that affect this study. As pointed out by 
Bowling: 
 
“Values are inherent in natural and social sciences from the inception of an idea to its 
development as a viable research project, to the choice of research method and the 
synthesis of the whole research process and results, as well as from the decision of a 
funding body to sponsor it to the decision of journal editors to publish it.” (Bowling 
2002). 
 
In an attempt to make these „values‟ in this research explicit, the underlying assumptions 
that have guided the approach to the inquiry are introduced next, including the use of 




systems theory, and the view of purchasing practice as a cultural phenomena; views which 
then guide the research design.  
 
Systems Theory 
Although earlier allusions to more holistic approaches to problem-solving, i.e. systems 
approaches, may have appeared in earlier philosophies and thinking, one of the more 
modern founders of systems theory was the biologist Ludwig von Bertalanffy (Von 
Bertalanffy 1973). As he points out in a survey of these approaches, these problems are “a 
contemporary expression of perennial problems which have been recognised for centuries 
and discussed in the language available at the time”. By recognising the interconnectedness 
of single parts and their processes in biological systems, von Bertalanffy called for the 
“systems theory of the organism”, which was then taken on to apply also to organised 
entities such as social groups, personalities, or technological devices (Von Bertalanffy 
1973). 
 
In one comprehensive survey of systems theory and methods, Ropohl defines systems from 
different perspectives. From a structural point of view, a system includes a set of elements 
and a set of relations between these elements (Ropohl 1999). Functionally, a system can be 
considered an entity, sometimes called black box, which transforms inputs into outputs, 
depending on specific internal states; the kind of transformation is called a function (in the 
descriptive meaning of the word). The hierarchical conceptualisation of systems is that one 
regards the different elements as subsystems, and the original system is in itself a subsystem 
of a larger super system. From these very basic definitions it is possible to view the 
healthcare delivery process as a system. For the purposes of this study, however, the 
purchasing process is our system and the delivery of care its super system as seen 
previously in Figure 10.  
 
What is comprehensive about Ropohl‟s paper is his reference to polarities of systems 
theory. He argues that systems theory provides a form of “unity beyond specialisation”. 
This is particularly useful for solving problems as it is able to cope with the confusion 
between different expert languages, for instance in its use of graphic representations which 
“illustrate complexity much better than uni-linear verbal language” (Ropohl 1999). This is 
particularly helpful in a healthcare setting, where the types of stakeholders involved are 
making decisions for the same purpose, but may have different backgrounds, training and 




even agendas in their particular line of daily work. Such a unifying perspective is almost 
indispensable. From a pure science or clinician perspective, where some research and 
practice is conducted in a specialised way by isolating elements for deeper studies, this 
might seem an attempt to over generalise issues and therefore lose the focus on particular 
problems. However, systems theory is not introduced to abolish such approaches, but to 
provide direction and context to see the connections between these independent parts. In 
systems approaches in healthcare, one may also be faced with the criticism that models do 
not capture the full complexity and complete picture of the task, process, or service in 
question. While no argument is provided here to support or disprove this notion, the 
pragmatic modelism approach is taken, with the idea that while systems might be largely 
human-made models, “in reality there do exist objective entities to which the models 
correspond” (Ropohl 1999). 
 
Application of Systems Theory to Purchasing 
If purchasing is defined as the simple act of buying and selling, the boundaries of a 
purchasing system could be placed in a very narrow context. However, as seen from 
Exploratory Studies, they encompass much more than just the administrative task of 
ordering a device in one department. Two other systems terms are defined here in 
establishing the scope and boundary of this study: stakeholder and domain. 
 
Stakeholder:   The underlying stakeholder theory concerns stakeholders‟ roles and actions 
with respect to the entity they have a stake in (Friedman & Miles 2006). Stakeholder 
theory has developed significantly but the definition of a „stakeholder‟ as first described by 
Freeman is largely maintained by the published community (Friedman & Miles 2006) as 
“any group or individual who can affect and is affected by the achievement of the 
organisation objectives” (Freeman 1984). In this study, therefore, such stakeholders had to 
be found, which formed the first purpose of the Exploratory Studies. All those affecting or 
affected by the purchase of medical devices in the hospital were considered, even if not all 
used to the same degree in the data collected. The literature helped point out the role of 
EBME as a stakeholder group, along with those in purchasing departments, clinicians and 
nurses.   
 




Domain:   In systems theory, domains are used to refer to groupings based on higher-level 
abstractions. The „healthcare provision‟ domain, for instance, can refer to a single ward, or 
the totality of healthcare services.  
 
In his book on environment-behaviour research, Zeisel, subtly acknowledges the need for a 
more holistic view of systems and organisations by providing tools for collaboration 
between designers and social scientists, and hence increase collaborations for other groups 
with similar varying backgrounds (Zeisel 1984). In what he calls mass design, designers (be 
it of products or services) have two clients: those who pay for what is built and those who 
use it. The user client, he claims, has no choice and no control, which is true for the 
healthcare setting, since the patient has no overall control of the process they enter. 
Zeisel‟s model describes a relationship between clients, designers and users in architecture. 
In the medical device purchasing scenario the system boundary is a little different: The 
paying client is the budget holder, but funded by a higher finance body, and the user client 
is the operator who originally requisitioned the device. 
 
An adaptation of the model leads to the abstraction chosen to depict the stakeholders‟ 
interactions in this research as shown in Figure 11. Wittner adapted this model to show 







Figure 11: Interaction gaps between stakeholders, adapted from (Wittner 2009) 




The remoteness of healthcare professionals and designers is known to be a major cause of 
usability problems when it comes to medical devices, as pointed out by Ward and 
Clarkson (Ward & Clarkson 2004). This is shown as Gap 1 in Figure 11, which was the 
focus of other studies on device design, and much of the focus on HFE principles in the 
design of medical devices. The focus of this study, however, is the gap between purchasing 
and healthcare users (Gap 2 show above). The insights provided in this research may also 
provide information on the influence of device design or healthcare provision design on 
healthcare services, but the focus here is to understand the other side of the supply chain, 
and recognise that purchasing is an important, yet poorly understood, contributor to safer 
patient care.  
 
Purchasing Practice as a Culture 
Many comments made during Exploratory Studies suggest that cultural barriers impede 
collaborative practice in purchasing. This section explores approaches that address these 
barriers.  
 
The definition of organisational culture is given as “a complex framework of national, 
organisational, and professional attitudes and values within which groups and individuals 
function” (Helmreich & Merritt 1998). According to Nieva and Sorra, who have done a 
study on the different ways to measure organisational improvement, adopting a safety 
culture is more useful in eventual effective improvement. They conclude as follows,  
 
“While a variety of levers – clinical training and guidelines, information technology, 
organisational structures and industry regulations – are being pushed in healthcare 
organisations to improve patient safety, the belief is growing that an institution‟s ability to 
avoid harm will be realised only when it is able to create a culture of safety among its 
staff” (Nieva & Sorra 2003).  
 
This may well include practice during purchasing decisions, especially given its 
multidisciplinary nature. Part of what was realised in the Exploratory Studies is the cross-
functional nature of purchasing decisions in healthcare. In particular, respondents pointed 
out the need for managers and financial decision-makers to be aware of the complexities of 
medical device purchasing. Lonsdale and Watson present a model supplemented by a real-
life case that shows how it applies in practice and can help managers interpret their 




environment: “It was shown… [that] whilst the fragmentation of [our hospital‟s] demand 
for pathology equipment emerged for a number of reasons, some technical and 
organisational in nature, politics and power significantly amplified the problem”. They 
conclude that “organisational power has been shown to be critical to the decision-making 
process”(Lonsdale & Watson 2005). 
 
A look at cultures in the healthcare profession cuts across perspectives from the delivery at 
point of care, right through to management of hospitals. Foucault in his philosophical 
account of the clinical hospital development challenged the way we view the medical 
profession by questioning its empirical nature: 
 
“The clinic - constantly praised for its empiricism, the modesty of its attention, and the 
care with which it silently lets things surface to the observing gaze without disturbing them 
with discourse - owes its real importance to the fact that it is a reorganization in depth, not 
only of medical discourse, but of the very possibility of a discourse about 
disease”(Foucault 2003).  
 
In modern publications we are encouraged to understand the progression of healthcare 
delivery from a more holistic diagnosis, to what has now become a division of „objective‟, 
clinical medicine, and „alternative‟ therapies (Seale et al. 2001). Such divisions in practice 
from clinician to nurse, to allied health professionals, to divisions in engineering and the 
„technical staff‟ that maintain equipment cannot be ignored in the context of making 
improvements. These greatly affect the culture, if not at least the mindset, of those making 
purchasing decisions. If one were to provide recommendations following this study, this 
could also be a tool that increases cultural awareness, or in this case, the importance of 
good purchasing practice awareness. For instance, in the case of the MAPSAF (introduced 
in Section 2.2.4), some anecdotes relating the use of the tool comment on the validity of a 
tool that, at a minimum, raises cultural awareness (Ashcroft et al. 2005).  
 
Cultural aspects, however, can also be combined with systems theory. As pointed out in a 
commentary on US healthcare systems, creating a culture of safety might be important, but 
creating a „culture of systems‟ is “a more fundamental challenge… The greatest barrier to 
patient safety and safety culture is the inherent fragmentation of the US system of care. 
Safety will improve when the underlying system of care improves”(Shortell & Singer 
2008). 




Cultural and structural factors are therefore both considered in the „systems approaches‟ 
here, both in the analysis of current practice itself and in providing tools and 
recommendations for future. The final state of a system may be reached from different 
initial conditions and in different ways. An organisation with a particular set of cultural 
attributes may be successful in achieving patient safety, while another organisation with a 
different set of cultural attributes can also potentially achieve the same levels of success 
(Nieva & Sorra 2003).  
 
 
3.3  Research Design and Methods 
 
Having established a general approach to the research and drawn up research questions on 
which to focus the study, this section addresses the research design and methods to 
implement the research. 
 
3.3.1  Research Design 
Research in the healthcare domain is subject to varying expectations in terms of its 
methodology, design, and outcomes. The community largely refers to evidence-based 
practice and seeks research outcomes that either directly influence both clinical outcomes 
or at least provide impact to current practice. Sim and Wright point out that in order to 
sustain an evidence based mode of practice, the evidence needs to be: up to date, objective, 
verifiable, relevant and applicable to practice, and intelligible (Sim & Wright 2002). Such 
criteria are also applicable to research if it is to create the same rigour to other healthcare-
based research. Before the design and methods are introduced, a mention is made of how 
the particular research challenges faced in this study were addressed.  
 
Addressing Research Challenges 
Taking an approach by Sim and Wright as a simple list to describe the research methods 
employed, the general design is summarised as followed: 
 
Design to employ      Non-experimental  
Variables to study      Qualitative 




Setting       Naturalistic (not controlled) 
From whom or what     Group study (partly comparative) 
At what time points to collect data   Cross sectional  
 
The research methods depend on questions asked, as continually reinforced by Robson 
(Robson 2002; p.80). The value of using qualitative methods has been identified in 
particular in relation to research on healthcare technologies: 
 
“One of the major strengths of qualitative research lies in its emphasis upon understanding 
the phenomenon of interest holistically. Whereas many quantitative researchers aim to 
isolate causal relationship from the context in which they occur, qualitative researchers 
avoid such context stripping and place complexity at the centre of their research. Such 
attention to context is particularly relevant to Health Technology Assessments insofar as it 
offers a bridge between the discoveries that participating patient, clinical and/or 
organisations management strategies are effective under experimental conditions, and the 
efficient implementation of such findings in clinical settings”. (Leape et al. 2002) and 
quoted in (Nieva & Sorra 2003) 
 
A few pointers to note during this study, given its adoption of rigorous qualitative 
methods, are discussed below. 
 
Data sources 
Given the more exploratory nature of this project, opportunities for access were obtained 
to ensure a broad understanding of practice. Three collaborations emerged by making 
enquiries with relevant contacts: 
 
PASA project „Purchasing for Safety‟ on infusion device purchasing practices for a 
generic broader view of purchasing practice (Three NHS Trusts B, C and D). 
 
Honorary research contract with one Trust (referred to as Trust A here) to 
examine in-depth practices for general medical device purchasing 
 
Invitation to a Scottish NHS Trust for examination of their procedures to evaluate 
infusion pumps (Trust E), used as a case study.  




Flexible and fixed research design 
Robson refers to two general approaches to the research methods employed: fixed and 
flexible designs (Robson 2002). With the above-mentioned three specific opportunities, the 
methods adopted required avoidance of bias and pre-conceived expectations on current 
issues in medical device purchasing. In particular, it was important to first gain an 
understanding of where the general issues in purchasing lay, for all Trusts. Therefore, a set 
of Exploratory Research studies were conducted at the start, where open-ended questions 
were used and „blank-sheet‟ brainstorming methods undertaken (Chapter 4). This indicates 
that a more flexible approach was taken. Furthermore, to allow for cultural and subtle 
contextual drivers within current practice alluded to earlier, the use of semi-structured 
interviews was preferred, rather than fixed surveys.  
 
Sampling 
Sampling can largely influence the bias in the research and the method should be 
questioned appropriately. Of the available methods (theoretical, probabilistic, non-
random, and opportunistic), considerations were given to the research questions (Stake 
1994; Robson 2002). The questions are not testing a theory but aim to gather a true 
picture of current practice at grass-roots level. It was learned during the Exploratory 
Studies that each Trust operates in a specific way and displays its particular culture. A 
random sample of Trusts would not necessarily shed light on all current practice in the 
NHS. Furthermore, a large study encompassing many Trusts would limit the time and 
depth required to create true understanding of current practice. The types of sampling 
methods adopted are therefore „opportunistic‟; since an opportunity to enter and work 
with a Trust is a necessary requirement for access to healthcare as discussed earlier; and 
„within case study sampling‟, where opportunities within each case are used to sample data 
further (Hammersley & Atkinson 2007). While remaining opportunistic, a systematic 
approach is still adopted within the study to retain the rigour in the research and results 




The term validity can refer to any feature of the inquiry that ensures „trustworthiness‟ of 
the results. Robson points out that this can include accuracy of the description of the 




study, valid interpretation of the phenomena, or not considering alternative theories to 
explain the results (Robson 2002).  
 
Strategies can be adopted to address such threats to the research. In particular, prolonged 
involvement with the subject material/participants can help create validity, as well as peer 
debriefing and member checking (both pertaining to sharing the results of the study back 
to the members and re-visiting the same context at a future time). In particular, a concept 
called iterative triangulation is applicable to this research. This involves “systematic 
iterations between literature review, case evidence, and intuition” in order to derive 
conclusions from case studies (Lewis 1998). Robson recommends using negative case 
analysis but these methods were not employed in this research as the observations made 
were not cases that needed to be „tested‟ but rather described. Such concerns were also 
avoided by ensuring that results were presented back in various forms to stakeholders both 
separately in the same Trust, and across other organisations (Chapter 7). 
 
Dependability 
Also referred to as reliability in more positivist circles, dependability refers to the stability 
of results over time. One recommendation is to use audit trails to at least demonstrate the 
conditions under which these particular observations were made. Clear context of the 
situations under which the data was gathered are therefore noted in each results chapter.  
 
Confirmability 
Confirmability refers to the potential biases and subjectivity that may arise through the 
research process. A large consideration for this study is the effect of the researcher on the 
process being examined, particularly in the case of Trust A where ongoing collaboration 
was established. Such interactions can affect interpretation of information in the course of 
a process that involves interaction between research subject and the observer/researcher. 
Miles and Huberman recommend taking a self-reflective approach by expressing potential 
bias and assumptions, consideration of possible and alternative conclusions, and the 
presentation of results together with the underlying original data. For this purpose, as seen 
in the Exploratory Studies, transcript excerpts are also included as quotes from 
respondents (Miles & Huberman 1994).  





Generalisability or transferability refers to how well the findings could be applied to other 
settings. The intention was not to provide results that are generalisable across all hospitals 
or NHS Trusts, but that with the models provided and frameworks derived, a working 
model to both describe and improve current practice is designed. The response to these 
models, together with the conditions under which such models work, by showing the 
context where they were developed, provide the background to allow critics to assess its 
applicability to their own setting.  
 
This particular study may be subject to criticisms as to its generalisability, as it has already 
been observed that purchasing practice can vary from Trust to Trust. However, gleanings 
from the Exploratory Studies already suggest that stakeholders do feel some dissatisfaction 
with current practice, and that some of the factors that influence current practice are 
embedded within the cultural context of the NHS as an organisation. The study therefore 
can only claim to paint a picture of current practice, within the current political climate 
existing in the healthcare system. However, some of the common factors emerging from 
the samples can be compared to other studies and their learning in global settings.  
 
Ethical Conduct 
Ethical problems arise in social research as a result of “conflicting sets of values concerning 
the goals, processes or outcomes of an investigation which involves humans” (Kimmel 
1988).  
 
For the purposes of this study, the exact scope of the study was presented to the Research 
Ethics Committee for each Trust involved in the study. Although formal ethical clearance 
was waived since the Committee decided this served as an „audit of current service‟, due 
consideration of ethical issues were considered in the design of the study. In particular the 
guidance given by Sim and Wright served as a guideline to the types of issues that were 
kept in mind in the design of the study (Sim & Wright 2002): 
 
Informed consent 
Privacy and confidentiality 
Anonymity 
Deception 




Risk of harm 
Exploitation 
 
All participants in the study approached voluntarily, following the establishment of a 
research contract with Trust A. For the studies at Trusts B, C, and D, the participants had 
already given consent to the study as part of the PASA project. Trust E was initiated by 
invitation, and participation of the eventual participants themselves was also voluntary. All 
personal details were kept confidential and are anonymised in this thesis. The aim of the 
study was stated clearly at the start of each interaction to avoid deception. Although the 
ultimate real effect on healthcare practice, or specific detailed effects on the service as a 
result of the research process, were not monitored, the intent of the research to improve 
long-term healthcare service and delivery was communicated to all participants. 
 
3.3.2  Methods for Data Collection 
The following are a description of all the methods employed to collect the data and 
conduct analyses.  
 
Systems Analysis 
A publication on systems analysis in healthcare describes how to apply systems theory in 
practice and execute systems analysis in healthcare. They propose a method “to analyse a 
system so that system wide problems can be uncovered and solutions implemented” (Karsh 
& Alper 2005). 
 
Step 1: Decide on system boundary for analysis (e.g. entire medication system or 
nurse communication system). In this case, this would be the purchasing process, 
which currently means the purchasing of all medical devices in the NHS, but as 
applied to a particular Trust as a case study (Trust A).  
 
Step 2: Produce a preliminary system map. This is similar to a workflow diagram, 
including decision points, and identification of people, processes, policies, and 
other factors involved.  
  




Step 3: Use preliminary system map to identify human resources required to carry 
out analysis (ensuring  end-users, policy-makers, and experts are all represented). 
 
Step 4: Use team to produce an initial scan of the system and identify missing 
information. This involves engaging stakeholders in interviews to verify the scan 
and then turn to external factors that may be influencing the system. 
 
Step 5: Put boundaries on system under study and ensure it is well representative 
of factors needed (e.g. bounding the medication process to include only the day 
shift may not capture differences between shifts)  
 
Step 6: Determine performance expectations for each step in the system. This can 
serve to define failure, risks involved, weaknesses, and hazards.  
 
Step 7: Begin formal data collection to revise and collect the system maps. Use 
time studies, administrative databases, maintenance records, structured 
observations of the process, and interviews of stakeholders involved.  
 
Step 8: Analyse collected data to (a) identify weaknesses, variances, and any series 
of events that can cause the system to fail, and (b) prioritise the identified problems 
for re-design  
 
Step 9: Develop control strategies to address hazards identified above. A hazard 
control matrix could be developed as exemplified in the original text.  
 
Step 10: Conduct system analysis on the re-design of the hazard-control ideas that 
the team develops. Only then can pilot testing and implementation begin. By 
separating system boundaries, identifying all stakeholders involved in a process, 
and then following the people, products, and process pathways, one is then in a 
position to identify where potential hazards lie. Such a distinction allows them to 
be correctly analysed and reviewed for avoidance in future.  
 
Trust A provides the context in which to try these steps given the open access to the 
relevant stakeholders. A version of this process was followed in the process-map exercise 
with Trust A leading to an analysis of risks in the process, described in detail in Chapter 6.  




Case Study Research 
The purpose of case studies can be to describe a problem, to solve it, to interpret critically, 
or build theory (Yin 1993). Case studies are found frequently in design research literature, 
as they are empirical studies that investigate contemporary phenomena with multiple 
sources of evidence, where the boundary between phenomena and context is unclear. Yin 
suggests that in order to produce valid results, case studies need to include project 
objectives, field procedures, case-study questions, and report guidelines (Yin 1993). Given 
the small sample size for this whole research project (five Trusts in total), the whole study 
may be considered a „case‟ in itself, adhering to the guidelines indicated by Yin. The 
specific examples illustrated in Chapter 6 are therefore not called Case Studies but rather 
Case Examples as they do not have rigorous research methods and serve rather as 
examples that illustrate evidence previously formed in the field work shown in Chapters 4 
and 5.  
 
Workshops 
In the Exploratory Studies, various methods were used in a workshop setting, briefly 
explained below: 
 
 Brainstorming: used with open ended questions on essential themes to be addressed 
in the research  
 „Blue-sky thinking‟: used to note down each participants‟ belief in the ideal 
scenario, untainted by any previous conceptions 
 MAPSAF exercise: used to test the usability of a maturity grid as a form of 
assessment 
 
Such methods were appropriate in the initial stages of the study given the lack of specific 
direction of the research. They helped understand the main issues among participants and 
allowed for reflection on what research questions could feasibly be pursued.  
 
Questionnaire and Surveys 
As a way of confirming some of the first findings, and the conclusions made in the 
Exploratory Studies, a questionnaire was designed pointing out these very same issues. 




These have taken into account some guidance on how tools and questionnaires and 
surveys should be developed.  
 
A review by Nieva and Sorra gave some pointers about how to design tools, pointing out 
that “more evidence is needed about the validity of safety culture assessment tools; how to 
use assessment data to initiative and sustain safety culture change, and how it must be 
combined with other patients safety information in making decisions about ways to 
improve patient safety” (Nieva & Sorra 2003). Requirements for selection are that the 
following criteria for suitability of the tool must be taken into account: 
 
 the domains of culture that are assessed (in this case, purchasing) 
 the types of staff who are expected to complete the tool (perhaps purchasing) 
 the setting for which the tool was developed 
 the availability of reliability and validity evidence about the tool 
 
The questionnaire designed for this study incorporated some of the questions from the 
NPSA infusion device purchasing toolkit; a list of questions that guide infusion device 
decisions. The questionnaire used in its final version is included in Appendix II.  
 
Interviews 
Given that the study aims to focus on both explicit and implicit issues within purchasing 
practice, and relies heavily on the perceptions of people involved in current practice, 
interviews were chosen as the main method for data collection. Robson distinguishes 
between structured and unstructured interviews as the former having more rigid questions 
and direction and the latter more open-ended, leaving the interviewer with little control of 
the process (Robson 2002).  
 
Given the combined use of questionnaires and diagramming tools, the methods used here 
are semi-structured interviews. Although there is a general structure and guideline used 
(e.g. the questionnaire in one instance, and the use of diagrams to initiate discussion in the 
other), the interviewer is left free to modify the questions according to the responses given. 
This allows for in-depth and rich data to arise from the interaction, while keeping the aim 
of the meeting focussed.  




Diagramming and Mapping Methods 
Using diagrams and mapping methods both as illustrations of current practice and as 
methods for data collection are common in many practices. An advantage of process 
mapping is that each activity can be systematically challenged in an attempt to improve the 
process. (Slack et al. 2007; p. 105). Crilly et al suggest the use of diagrams as a graphic 
elicitation tool, or as interview stimuli (Crilly et al. 2006), a method employed for this 
study. However, the choice of diagram and modelling method is also vast. A study 
focussing solely on the applicability of modelling techniques to a healthcare setting (Jun 
2007) noted the importance of using the correct process model for the right context to be 
investigated. In this study, flowcharts were found to be the easiest diagrams to understand 
by healthcare professionals, also the ones used the most extensively, though other 
diagrams might point out hazards and risks in the process better. Given the variety of 
stakeholders interviewed and their differing experiences with diagramming methods, the 
most important criteria was for them to understand the diagrams and feel comfortable 
with their use. For the purposes of this study, the diagrams serve as tools not to describe 
the process accurately, but as graphic elicitation tools to engage the healthcare 
professionals. For this reason, the usability of the tool was more important than its ability 
to accurately depict the situation. Simple flowcharts, developed over time into process 
maps, were therefore chosen in favour of the many more sophisticated and complex 
models available.13   
 
Recording and Transcription  
Interviews and workshops were recorded and transcribed for later analysis. In the cases of 
workshops, where many people were present, it proved more difficult to identify the exact 
speaker and so more generic statements describing the topics of discussion were noted 
instead. While such transcripts are good for analysis of what was mentioned in an 
interview, and gathering responses to diagrams shown to the respondent, extra notes were 
sometimes necessary to capture the gestures and objects pointed at during the interview.  
 
                                               












Coding and Analysis 
The problem with qualitative data analysis is that it is done with words or text, and not 
with numbers, making it more difficult to “move around and work with” (Miles & 
Huberman 1994). The purpose of coding in this case is to be able to classify and synthesise 
data for analysis, so that one is able to „move it around‟ and also allow for the process of 
data “selecting, focusing, simplifying and abstracting” (Miles & Huberman 1994). The 
process of coding, however, can also be viewed as part of analysis and theory-building. In 
a pure grounded theory approach, for instance, a completely blank empty code list is the 
starting point for research, and the research process itself allows for codes to emerge from 
the data and steer the direction of the research (Glaser & Strauss 1967).  
 
The approach taken here is more closely related to an approach suggested by Bryman and 
Burgess, where instead of using an empty code list, a limited number of preliminary codes 
are drawn up (Bryman & Burgess 1994). Following the literature review and Exploratory 
Studies, such a code list did emerge from the data and this was use as a guideline for future 
coding. Allowance was made, however, for new codes and themes that may not have been 
expected from this first list.  
 
In this study, comments were collected around the research questions asked. That is to say, 
the respondents were given freedom to comment around the questions or interviews or 
diagrams, and these comments were collected and analysed together with the very direct 
explicit answers to the research questions. These original 167 quotes and comments made 
by the participants that shaped the conclusions in this study were selected to then design 
the final framework noting the important aspects of purchasing practice. The issues/codes 
were then assigned a stage in the life-cycle of a medical device within a hospital, also based 
on data that was collected during the process mapping. These exact developments are 
explained in more detail in Chapter 7, but an overview of how this coding was conducted 
is shown in Figure 12: 
 





Figure 12: First stage in development of framework from original data 
 
 
Once the issues were clustered according to each life-cycle stage, these were listed under 
their respective headings, without the original quotes (i.e. using only the Code/Category 





Figure 13: Second stage in development of framework 
 
 
Finally, when reviewing each life-cycle stage, some of the further insights and observations 
drawn from the study were added to each column for completeness.  
 




3.3.3  Data Collection 
The Sources of Data came from the following collaborations:  
 
Trust A: Collaboration with a Trust (Trust A) that provided most of the detail in the data 
and deeper understanding of the healthcare context.  
This collaboration allowed for complete freedom of engagement with relevant stakeholders 
in medical device purchasing. A combination of open-ended interviews, semi-structured 
interviews, and participatory research methods were used. 
 
Trusts B, C, and D: Collaboration with a PASA project on Purchasing for Safety, 
examining the safe purchase of infusion systems.  
Initial engagement of participants was organised entirely by PASA, and the study was 
limited to infusion systems (drugs and devices). Three workshops were held to elicit main 
issues regarding only device purchasing (included as Exploratory Studies) and the same 
participants were subsequently used for telephone interviews in Summary of Current 
Practice I. 
 
Trust E: Invitation to a Scottish NHS Trust to examine the process of evaluation of new 
infusion pumps for the Trust for standardisation on a model.  
The Trust was in the process of standardising its patient-controlled analgesia pumps for a 
particular area of the Trust and was in the process of conducting evaluations involving 
four medical device suppliers. The same questionnaires were used as the basis of semi-
structured face interviews and subsequent telephone interviews.  
 
A comparison of the five Trusts studied is shown in Table 8:  
 






Table 8: Comparison of Trusts used for data collection 
 
 
The graphical overview of the research process (with approximate time lines) is shown in 
Figure 14 and the full list of data together with the methods used to collect the data is 
listed in detail in Table 9. As described in that section, the first set of data (Set 1) was a 
result of a more continuous and independent collaboration with Trust A. Set 2, however, 
was initiated through the collaboration with the PASA project did not allow for as much 
flexibility as Trust A. The methods used, therefore, were mostly opportunistic and most 
appropriate given the time constraints of the participants. Set 3 took place at Trust A and 
was also an opportunity taken to meet medical devices sales representatives visiting the 
Trust. Finally, Sets 4-9 collectively contributed to the analysis and are described in their 
relevant chapter stages as shown in Table 9. 
 
 







Figure 14: Graphical overview of research process 
 






Table 9: Full list of data and methods used for study 




3.4  Summary of Research Process 
 
The overall research paradigm adopted here is a realist approach, in the absence of an 
overarching theory for medical device purchasing processes. The study also adopts systems 
theory as a way of approaching the subject, choosing the purchasing process as the system 
and the delivery of care its super system. In a healthcare setting, where stakeholders come 
from many backgrounds and may differ in culture from one organisation to another, such 
a unifying systems approach helps paint a common picture to illustrate the process.  
 
The methodology follows an inductive strategy to provide a description of current practice 
and, due to limitations of access to healthcare settings, would also not claim to provide 
grounds for proving new theory in terms of purchasing and supply of devices in the NHS. 
However, what they do provide is an understanding of current practice, an analysis of the 
possible reasons for such behaviour according to external drivers and regulations on their 
practice as well as their present conditions. The methods chosen take into account 
potential bias and the importance of a systematic approach within opportunistic sampling.  
 
Furthermore, in line with good design practice as forms the basis for the approach to this 
research, the work forms another example of how design practice works in researching one 
particular healthcare setting or system. This is demonstrated not only through the 
overarching framework already presented in Chapter 1, but by the mapping methods 

















Given the lack of substantial literature to describe current practice in purchasing, coupled 
with the lack of appropriate guidance from the Department of Health on suitable 
purchasing practice at the local level, this study had to begin by firstly exploring the need 
for new practice at all. Therefore, a set of Exploratory Studies was conducted before 
formal data collection to inquire, on a very general level, how medical device purchasing is 
practiced, and whether or not there is the need for improvement on current practice, and 
what, in theory, this improved practice would look like. A more open-ended approach was 
adopted at this phase, to elicit findings that could then be confirmed through other 
methods in Chapters 5 and 6.  
 
This chapter is divided into three parts:  
 
1. An overview and starting point, where an initial conceptual vision for purchasing 
medical devices was shared with key stakeholders 
2. Description of methods and results from initial observations at Trust A, along with 
experiences of involvement with initial stages of PASA project at Trusts B, C, and 
D 




3. Description of methods and results from initial studies of medical devices issues, 
from workshops and dialogue with medical device sales representatives 
 
 
4.1  Overview of Exploratory Studies 
 
The research questions introduced in Chapter 3 are now repeated as a reminder of the aim 





Despite keeping these questions in mind, however, this Exploratory Studies expanded 
beyond the focus of these questions. The shaded area remains the focus, but elements of 
other questions, shown in grey, were also drawn. This was done to ensure that contextual 
factors in the wider system for purchasing were kept into account before more focussed 
studies were conducted in subsequent chapters. Sections 4.1, 4.2 and 4.3 therefore address 
their own sets of generic questions around purchasing practice, but they keep in mind the 
key pointers identified in the literature. These pointers are shown again in Table 10, with 
added data to show the evidence gathered and shown in this chapter and in the literature.  






Table 10: Data gathered from Literature and Results I (Exploratory Studies) 
 
 
4.1.1  Starting point for Exploratory Studies 
The unknowns in the study at this point were as follows: 
 
 The exact roles and names of the stakeholders who are involved in the purchasing 
of medical devices in any given Trust, other than the contacts initiated through the 
EBME Team and Procurement manager at Trust A 




 Any standard set of processes or procedures followed in any given Trust 
 The scale of the asset base in any given Trust 
 Variations in practice between Trusts 
 An appropriate detailed interview approach and a sample on which to focus 
 
What was known, were those pointers from the literature and theory pointing to some of 
the elements of good practice in general purchasing scenarios, as well as theoretical ideas 
for how a holistic approach to purchasing could be practiced in a manner that is safe for 
healthcare users. Furthermore, following the literature review, conversations with key 
stakeholders were held to gauge where research could be initiated. Described in the next 
section are the results of such conversations.  
 
4.2.1  Guidance prior to Exploratory Studies 
In order to initiate the conversations, a theoretical model was presented to these 
stakeholders resulting from analysis of the literature and the „vision‟ for the research 
direction, as shown in Figure 15. This shows a vision of the recommendations gathered in 
policy, advocated in this research: a virtuous circle with appropriate communication 
pathways between stakeholders in the medical device supply chain. The diagram was 
developed following conversations with stakeholders in the initial steering of the research, 
namely from Association of British Healthcare Industries (ABHI), PASA, NPSA, CRiSPS, 
and previous researchers looking at purchasing in the NHS. A similar model is presented in 
earlier work by Zeisel on design communication (Zeisel 1984) as presented in Chapter 3.  
 






Figure 15: Conceptual framework of a virtuous circle for medical device purchasing 
 
 
Figure 15 was presented at conferences at the start of the research and published in an 
article aimed at medical device sales companies (Ward & Hinrichs 2006)., which was 
received by one respondent as “an article that people will empathise with”, Delta 
Consultants. The sympathetic feedback received gave confidence that the direction of the 
research and the conceptual vision would address existing problems. Figure 15 served to 
elicit comments that shed light on some of the research questions, but initially helped guide 
a focus for the research sample. As a result of the guidance given by these individuals, the 
chosen research focus is centred on the following stakeholder groups: 
 
 purchasers (which may include other people involved in purchasing and device 
management),  
 end-users of devices,  
 interactions between these stakeholders, and  
 device sales representatives 
 
The „other channels‟ diagrammed in Figure 17 refers to any general routes for feedback 
either through national agencies of the NHS and informal feedback gathered from 
manufacturers from users. These were not addressed in detail in this study as most of the 
data was gathered within the Trusts to show current practice at grass-roots level.  




The details of the comments gathered from these stakeholders are presented next; but an 
overview of what they demonstrate can be summarised in the following main points: 
 
 That the purchasing of medical devices does present some challenges 
 That improvement measures for medical device purchasing could be 
adopted 
 That complexities in both the device industry itself and the purchasing 
process may welcome a more holistic, systems approach 
 
On the challenges to current practice in device purchasing 
Part of the challenges to current practice are the changes in policy that have affected the 
culture of NHS purchasing, as well as the increasing demand for new technologies in 
medical practice. As commented by PASA themselves, many changes were occurring within 
their organisations at the time;  
 
There are a lot of changes going on in purchasing, telling you about PASA is not 
going to be useful necessarily  
PASA 
 
Purchasers have also changed in the way they are viewed within a hospital, given that end-
users would have a degree of purchasing authority on their own,  
 
In the old days purchasers were out the loop because end-users would specify 
directly and have a degree of purchasing authority on their own, and purchasers 
were just paper pushers effectively.  
ABHI 
 
To a degree, this culture might still exist in practice and this is something to investigate in 
this study. With the advances in technology, it has meant that all purchasing stakeholders 
are faced with more choice and intelligent purchasing is required;  
 
I think the medical device industry seems to be going into the stereo of the 80s - 
how many buttons can we get onto the box? (Graph equalisers, etc.) In the private 
sector everyone understands that – iPod, iTunes, you have 4 user buttons for an 




incredibly complex bit of kit - whereas 10 yrs ago with computer, that was a 
complete barrier.  
NPSA 
 
Intelligent purchasing also implies making patient safety explicit in decision-making;  
 
Patient Safety should be implicit in everything. But it has to be explicit before it can 
become implicit… When we show nurses two infusion devices with keyboards 
going down the different ways, they never even thought about it. They‟re stunned, 
literally... No incident [report] will go back and say ”part of the error was that I 
thought the „1‟ was a „7‟”.  
NPSA 
 
However, the ABHI is also keen to maintain open innovation within the medical device 
industry and not create further blocks through purchasing; commenting how they could 
potentially act as „drags‟ on the system;   
 
There‟s casebooks of examples where products, customers first approach is “I 
don‟t need this, I don‟t need this”. Most products face that initially. The whole 
system has a high degree of inertia involved. So the salesman's first job is to say 
there is a need for it. Then the adoption process is generally very long and slow. 
And at the end of that process if you ask the end-user, would you go back and use 
what you were using before? And the answer is „God, no!‟ And so the system is in 
a steady state but requires inertia.  
ABHI 
 
On potential improvement measures 
While little comments were made about the process of purchasing, the ABHI representative 
commented vastly on the purchasing stakeholders themselves. There is a sense of the 
necessity for empowerment and training within the purchasers as a way towards intelligent 
purchasing;  
 
…I think that is a good idea so that the incentive is evolution, and big cultural 
evolution, because the [advanced] buyer is a different one to the [less advanced] 




buyer… the [advanced] buyer is somebody who has sophisticated capabilities, he is 
able to interact with clinicians and manages in a way that adds to the value. 
ABHI 
 
In terms of a process that represents „best practice‟, direction was sought from CRiSPS,  
but the feedback gained was that this is usually only relevant in context. Strategic 
purchasing guidance mainly exists on an operations level;  
 
There are no real „must reads‟ on purchasing, none that are very good anyway. Nor 
template maps of purchasing in the NHS. Though you may be able to get things for 
operations level.  
CRISPS 
 
It was also recommended to follow the developments that are more localised, such as the 
Centres for Evidence-based Purchasing (CEPs) 
 
They are the key for addressing 'value' in purchasing decisions. I would say it is 
useful to keep an eye on them and on their progress... they might be able to answer 




On the value of a systems approach  
In general, the comments made from these key stakeholders while introducing the above 
framework were sympathetic towards a more holistic, systems approach to purchasing;   
 
The whole systems approach is needed because they [purchasers] are disconnected 
from the end-users…I think that line between purchasing and end-users is weak.  
ABHI 
 
It was suggested to tackle specific cases within the system for deeper insight;  
 




The medical device industry is so vast. How can you go from pacemaker to 
catheters, and have the same risk factors? – Because of the nature of the field, it is 
advisable to choose a set of case studies to focus on. 
Natasha Browne (author of (Browne et al. 2004)) 
 
At the moment there are about 17 different subsystems for procurement, plus 
collaborative procurement hubs, DoH directorates, and Trusts themselves. It‟s very 
complicated. There is no point in really trying to get to grips with it all as there is 
so much politics involved too. What is more realistic is to follow one device 
through, use it as a case study, in one clinical area. 
 CRISPS 
 
The NPSA stakeholder was keen to see developments that would aid decision-making;  
 
What I would like to see in the end product of this project are answers to the 
following questions: 
What info is needed when making purchasing decision?  
What is the vehicle for delivering that information to the purchaser? 
How is the vehicle populated, updated, and vetted? 
NPSA 
 
Having taken this guidance and direction, the rest of the Exploratory Studies focussed on 
the contacts made within the Trusts themselves. These results are presented next; first the 
studies at the people and processes NHS Trusts themselves, and then a set of workshops 
and observations focussed on devices. 
 
4.2  Studies at NHS Trusts 
While bearing the potential challenges, complexities and potential improvement measures 
in mind, these early interactions at the NHS Trusts continued to expand on the themes 
pertinent to device purchasing. The methods are described first, followed by the learning 
gathered throughout the studies. 
 




4.2.1  Overview of Methods  
Studies at Trust A 
Trust A was the first contact made for which an honorary research contract was set up. 
This meant that there was full access to members of the Trust involved in the purchasing, 
training, and selection of devices throughout the Trust, except for clinical staff. This Trust 
helped answer the overall questions of how equipment is managed in the hospital from the 
moment its need is identified to purchase to use.  
 
Given such flexibility and full access, the method used for this Trust was a series of 
interviews used to develop maps of the purchasing process. The developments of these 
maps are included in Appendix III. It was through the use of these diagrams that other 
issues were captured and participants were given the context to comment on their process 
and eventually identify risks, control measures, and potential improvements to the process. 
This development is captured in Section 6.1 of the results.  
 
Studies at Trusts B, C, and D 
The aim of this section was to explore the issues raised through the literature, to gain an 
understanding of how different Trusts approach their purchasing processes and what 
challenges they face. Given the limited access available to these Trusts, and the fact that it 
was conducted in the wider context of the PASA project itself, the method used for this 
stage was a three-part workshop involving stakeholders from various segments involved in 
infusion systems purchasing. Representatives from the local Collaborative Procurement 
Hubs were also invited to participate given their interest in the PASA project.  
 
These first workshops were divided up into three parts: 
 
1. Understanding the stakeholder groups involved in purchasing infusion device 
systems and their communication paths for decision-making 
2. Sky-blue thinking: establishing an ideal purchasing for safety scenario 
3. Trial of tool for improving current practice (Based on MAPSAF, maturity model 
described in Chapter 2).  
 




The workshops were advertised by PASA aimed at those involved with purchasing of any 
part of the infusion system. The stakeholders targeted included: 
 
EBME staff 
Pharmacy (management role, purchasing function) 
Risk Management/link to Clinical Governance 
Medical device training 
Medical device technical services 
 
The details of the workshops will be described together with the findings. During all of 
these exercises, a number of codes emerged that dictated future research questions. These 
were based on comments made on the participants not in direct response to any of the 
questions asked, but gave an indication of the characteristics of the stakeholders involved 
in purchasing. A discussion on the findings and emerging themes follows.  
 
4.2.2  Current Practice: Purchasing Stakeholders  
Involvement with the above Trusts solved the very first step required for this research – 
establishing who the purchasers are, and what general processes are undergone. The 





Identifying the purchasers (Stakeholder definition) 
It became clear in early conversations with the Trusts that those „purchasing clerks‟ 
ordering equipment were not the sole stakeholders responsible for the whole purchasing 
process. When using the term „purchaser‟, hospital staff usually mean those who conduct 
the actual administrative act of buying equipment – usually belonging to the „logistics‟, 




„procurement‟, or „supplies‟ department within the Trust. Other observations made at this 
stage included: 
 
 Other groups involved with equipment purchase are those responsible for 
maintaining them; these fall into „Medical Physics and Clinical Engineering‟. They 
also include those running the equipment library and, in some cases, a person or 
group running training for devices (usually infusion pumps) 
 
 Training programme structures differ in hospitals. Some are incorporated into the 
Clinical Skills department, which is exclusively for clinician‟s training. They usually 
fall within the clinical governance/risk remit, which are also responsible for dealing 
with incident reports and links to the NPSA.  
 
 Some Trusts have appointed „medical device coordinators‟ for coordinating 
equipment use on the wards, and „medical device technical services‟ staff, who are 
responsible for specific equipment within a ward/unit 
 
All these roles vary in terms of organisational hierarchy within a Trust, and as far as could 
be deduced at this stage, this is not consistent across Trusts. The full list of stakeholders 
and roles identified are listed below: 
 






Table 11: Key to stakeholder identifiers throughout the research (with colour codes) 
 
 
The establishment of this list meant that for the rest of the exploratory phases, participants 
were chosen from among these roles; which served to identify the main issues to be 
investigated further in this study. Further findings on characterising these various 
stakeholders are described next.  
 
Knowledge and skills (Device knowledge & competence) 
One of the first observations made in this study was the different skills base present among 
all potential purchasing stakeholders, which is not surprising given that „to purchase‟ is not 
within their background (clinical or otherwise) training. But these varying levels of IT, and 
device-use competence can affect both the process of purchasing as well as the processes of 
using these devices safely.  
  




Not all staff are IT skilled. Remember we did a survey on our staff about IT skills? 
They are really not ready… 
TRAIN.clin_C 
 
Medical device training is separate from clinical skills in other hospitals - purely for 
medical students…What I do is primarily for nurses, not the clinical school, but 
Trust staff…Clinical students should [be trained on devices used here] but because 
it‟s not actually their job to do it, it's not one of those things. 
TRAIN.tec_A 
 
The simulation suite - it is primarily for doctors, although nurses occasionally get 
to use bits of it I think but not as well as the doctors do I don‟t think.  
TRAIN.tec_A 
 
Furthermore, the knowledge base about particular device features for a purpose sits within 
different parts of the larger organisation. Is a medical device a consumable or equipment, 
and what kind of knowledge is required to purchase it? Not only are these questions 
answered differently by each stakeholder group, but whether they are asked at all is also a 
varying factor.   
 




Our 'buyers' are 'purchase order clerks' really… Procurement operational staff (4 
members in this team) are not interested in what the product is, to be honest, they 
may have some products that have been standardised though …We in procurement 
do not have the technical knowledge to understand what the equipment needs or 








Drivers for purchasing decisions  
Given the varying knowledge and skills base among stakeholder, along with the fact that 
they reside in different parts of a hospital, the expectations and drivers for making 
decisions are also varying factors. For instance, when it comes to actual devices, the 
training provided by suppliers is a large factor in their expectations, but these expectations 
are met differently by suppliers:  
 
Training for „pharma‟ is different….If pharmaceutical preparation had difficult 
technique or involved manipulations that were difficult, you do not have 
pharmaceutical industry to train you …It does depend. Some companies do do 
training. But as you say it‟s the  exception rather than rule.  
PHA_D 
 
The expectations of how a device operates, and its associated manuals, were also factors 
mentioned: 
 
Ideally, I want a syringe pump with an ON simple button, don‟t want mode 
executive standby, I want it to go through self test in English and tell me what‟s 
happening, with a self-test failure code I can look up, a good clear setup so I can 
wipe any information, etc... 
TRAIN.tec_A 
 
People say do you train on the [Brand Name] pump? I say „Which one? We've got 
six.‟ They say the pale blue one. I say „They're all pale blue!'  
TRAIN.tec_A 
 
I got asked 'that is a nice cable but it's not long enough to reach patient'. I 
thought, 'it doesn't need to reach the patient'!  
TRAIN.cl_C 
 
Culture and mindsets 
The participants also pointed out characteristics of their particular Trust‟s culture, and the 
culture of individuals within the organisation due to varying backgrounds. This can have 
implications on the way the organisation operates and adopts new measures:  





An Australian nurse comes over and somebody tells her to do something, she'll 
quite happily turn around and say 'Why? Why am I supposed to do that? I haven't 
been trained to do that, what's the rationale for doing that? With the [Asian 
nurses] if somebody told them to do something and it was the boss they would do 
it, regardless of whether they were safe doing it and they didn't actually see it as 
being a problem for them if they got it wrong.   
TRAIN.tec_A 
 
Putting the infrastructure into place is pretty hard because you are dealing with 
cultures. Now hospitals have cultures, all large organisations have a culture which 
basically means we've done this way and this is the way we‟ll do it to the day we 
die and you have to change the culture in order to make that type of system work, 
because the culture does not support that type of thinking because the Trust, and 
I'm sure it's not just ours, they work like silos so each department works separately 
from the rest, instead of them pulling together as a team they are in self-
preservation.   
LIB_A 
 
With the inception of incident reporting, some organisations have struggled to be open to 
admitting to incidents. Varying comments were also made on „blame culture‟ in the 
nursing sector: 
 
No I don‟t necessarily think that pharmacy has the same blame culture that nursing 
has generally. It‟s been more tolerant of that and still supportive.   
PHA1_D 
 
Staff generally feel safe reporting incident…There is an open culture…  
RISK_C 
 
There is emphasis on reporting incidents, nobody‟s fault. But they still get blamed. 
And there are a number of times when I haven‟t reported an incident simply cos I 
know what will happen to the member of staff that is involved. 
PHA_D 
 




Finally, a point was made about the value of individual initiative: 
 
Paediatrics - one of the reasons they‟ve got standardisation is they got people in 
their area doing this and who talk to the companies asking what deals they can do. 
… Partly because the funds are available to Paedricts, partly because of her attitude 
and assertiveness I think she [the manager] can get better things.   
TRAIN.tec_A 
 
Summary of findings on the stakeholders 
To collect the overall knowledge base for each stakeholder group interviewed in Trust A, a 
summary of the types of questions asked by each group during purchasing decisions was 
collected from the interview transcripts, as sampled by the quotations above. These sample 
questions asked by the different stakeholders are depicted in Table 12.  
 
It can be seen from the list that these questions focus on very different aspects of decision-
making for device purchases. EBME in particular seems to maintain a more holistic process 
knowledge, while the end-user does not focus on the whole process but rather its intended 
use.  
 







Table 12: Variety of questions asked by different stakeholder groups involved in the purchasing 
process, Trust A 
 
 
The key findings from studying and characterising the purchasers themselves are listed 
below: 
 







4.2.3  Current Practice: Purchasing Process 
The research question generally addressed in this section is also to do with current 
practice, but with a focus on the purchasing process. As a means of introducing the 
participants and obtaining an overview of the purchasing process, workshops were held at 
Trusts B, C, and D, which required participants to name their role and indicate in which 
part of that process they were involved. They were also invited to comment on current 




practice and their attitudes towards purchasing in their Trust. These findings were based 
on the results of these workshops and compared to observations made at Trust A. 
 
Description of the process (Process Knowledge) 
By combining the process maps developed with Trust A, shown further in Appendix III, 
and confirming these with a few stakeholders at the other Trust, meta-level steps or 





Figure 16: Overview of the main sub-processes that form part of medical device purchasing 
 
 
The development of these diagrams are described further in Chapter 6 as it is these process 
maps created with Trust A that led to an eventual risk analysis workshop to elicit potential 
risks in the whole purchasing process. Figure 16 is simply one example of how the various 
stages of the process can be clustered. The justification for including these particular steps 
form part of later analysis as described in Chapter 6. 
 
While collecting the data needed to create the above diagram, various observations were 
made about the process knowledge scattered throughout the organisation. The first 




observation was that there seems to be a variety of process knowledge among the different 
stakeholders, mainly relating to their particular role or place in the system. This is 
especially true of the end-users who initiate the purchase:  
 
The end user or requisitioner will not know if its capital or revenue, nor if it's 
something that‟s been ordered before - no way to capture this 
information/knowledge base due to changing staff too.  
ENG.snr_A 
 
Departments with more experience and those that have been through process 
before know that device is capital/revenue and know of the process 
FIN.proc_A 
 
In particular, all stakeholders that held a role in EBME claimed to have a holistic overview 
of the process. They also claimed that they hold most of the knowledge base of the whole 
medical device purchasing process. Roles such as budget holder and requisitioner also were 
mentioned as those played by end-users, as identified earlier: 
 
Knowledge base of how all this works lies mostly with us,  a handover would be 
required if we left. 
ENG_A 
 
Budget holder can be: service delivery manager, budget holder - they check a) kit 
appropriate for their dept and b) can they afford it.  
FIN.proc_A 
 
Tiered stakeholder base for purchasing includes requisitioner, budget holder, and 
approver.   
ENG_A 
 
We don't have systems in place that are structured in committee terms or so all 
those areas are involved with me.  
ENG_C 
 




At Procurement we check cost centre, expense coding, if authorised, the value of 
the order, preferred supplier or suggested supplier, price, check price with supplier  
FIN.proc_A 
 
Another observation was the different understandings of the elements of equipment 
management processes present in the hospital. For instance, the presence of an equipment 
library, as an alternative to acquire particular types of equipment, is not known to all. In 
one Trust this knowledge seems to have simply evolved over time: 
 
When the library was first started there was no formal agreement as to what the 
library's obligation was and what the wards' obligation was, so over the last three 
years there's been somewhat confusion and people… they're not quite sure what's 
going on so they develop their own rules, as a result equipment that leaves the 
library doesn't necessarily get put into the collection point... you might find 
equipment that's sitting in cupboards or obscure places which doesn‟t end up being 
circulated... eventually it turns up in medical electronics…sometimes a year later.   
LIB_A 
 
If you ask anyone in a Trust do we have a library they would say “no”. But 
actually yes we do! 
PHA2_D 
 
It is not a surprise, therefore, that some participants see the need for understanding their 
own systems: 
 
We just need to map our communication systems.   
RISK_C 
 
Communication routes (Stakeholder engagement) 
Most of the Trusts showed that the roles for the various stages of the purchasing process 
can vary, but essentially narrow down to:  
 
 The end-users at ward level (those who requisition for the device) 




 The approvers of the requisition (which may have two hierarchies: the budget 
holder and, in some cases, another „final approver‟) 
 The EBME team (involved if a new framework or standard purchase is to be 
implemented; though in some Trusts they are always the „final approver‟ as above) 
 The procurement department (handling the administrative task or ordering the 
device from the supplier or completing the tender process) 
 Goods receiver (this may be a separate bay part of the estates department or, in 
some cases, a medical-device specific bay dedicated to EBME) 
 The electronics lab (usually part of EBME, in charge of asset testing the device and 
registering it before its use, as well as subsequently maintaining the device).  
 
The stakeholders involved in purchasing come from different directorates within the 
hospital, and therefore are likely to have a different knowledge base and skills base, well as 
different managerial and clinical imperatives. Yet, in a given hospital, various roles can 
take on the role of „requisitioner‟, „budget holder‟ and „approver‟ depending on their 
organisational hierarchy within the hospital.  
 
Furthermore, during these initial interviews participants offered information about whom 
they communicated with, particularly while describing their particular process steps. 
Although not all relevant communication routes were explicitly sought out during these 
interviews, certain routes were indicated as being those used regularly. Such responses gave 
the impression that those responsible for ultimately maintaining the equipment and then 
training the end user to use it safely, may not necessarily be the ones involved in every 
decision. The following are attempts to diagram the communication routes as depicted in 
Trust A between the various stakeholders: 
 











Particularly in Trust A, major disconnects in communication and stakeholder engagement 
were expressed. These disconnects exist in other Trusts when buying devices that have 
pharmaceuticals as their consumables and yet follow a different purchasing route: 
 
 
„Goods-in‟ have no contact with original order/requisitioners…Once goods come 
in, our involvement ends, we only know of lost equipment cos user will query it.  
FIN.proc_A 
 
This is why we are taking this [the project] forward.. They [end-users] don‟t know 








I standardise in purchasing process if its delivery of pumps or giving sets; I don't 
really deal with drugs. But sometimes it's part of the device or package. 
TRAIN.cl_C 
 
Issues of compatibility with pumps and drugs, is not thought through properly. 
ENG_C 
 
I don't know who makes decisions on what to buy and why they do not consult us. 
ENG.clin_A 
 
I was 'ish' involved in trial in the fact that I was aware of it but it was Procurement 
who would drive the tendering thing and Engineering might device criteria for the 




Shown next are some sample quotes of how the process works and currently used controls, 
or the lack thereof. This is related not only to the lack of compliance with control 
measures, but to the absence of an overall process owner for purchasing, given that the 
responsibility resides within various stakeholder bases.  
 
I don‟t know if it‟s about patient safety or about control procedures…they‟re loose 
enough for people to work around things.  
RISK_C 
 
There is no procurement subgroup because there is already a procurement process  
well-established in place. (Q: Who is in charge of it?) Who is in charge of it?… it is 
a process. So... you have to make a bid using that process. If you don‟t make a bid 
using that process you don‟t get your money... I don‟t think there is a single person 








If you can make sure they don‟t order things you don‟t want them to…You want 
to make it mandatory…People purchase “outside the process”.   
ENG.snr_C 
 
(Someone) can still go out and buy something else… pharmacy is a bit like that…  
TRAIN.clin_C 
 
I think people order stuff by mistake.  
RISK_D 
 
Yes but there are some rogue behaviours on the sidelines.  
TRAIN.clin_C 
 
Even if controls are placed within the hospital, some comments suggest that suppliers also 
have a role to play in acting outside this system: 
 
In the past reps have come in and tried to sell something.  
TRAIN.tec_A 
 
Pressures on process 
A major challenge is the vast amount of demands on equipment management services: 
 
The library exists because the demand for services varies from ward to ward. And 
this can vary at different times of year too.   
LIB_A 
 
There's not enough people to do all the repairs … in [two mentioned Trusts] they 
had similar asset base to us and their medical electronic department had 14 people 
working (we have 7), plus 10 in anaesthetics (we have 3).  
ENG.clin _A 
 
Up until recently we've probably got about 800 requests in the last 6 months that 
we haven't been able to supply.  
LIB_A 













Another major challenge for most Trusts is the auditing of all their equipment, shown by 
sample comments: 
 
Our data is not complete - we would have to know every time a piece of equipment 
is used on a patient and then transferred to another patient and we're not capturing 
that information, all we're capturing is information on requests that are put into 
the system and whether we can supply or not, but we don't have the actual usage 
on the devices because, as I said, the pickup area on the wards, they put the 
equipment there, but they can take it away from there as well and use it on another 
patient, so I've got no idea of the duration of each loan.  
LIB_A 
 
We did an observational audit of all critical care units.... and on all of our Trust‟s 
network. And 85% had problems. That was in 2005.  
PHA_D 
 




So this device [pointing to database screen] went to Main Theatres in 2005 and has 
yet to be returned... so we've got a piece of equipment that‟s been up in medical 
electronics for 11 months.  
LIB_A 





The respondents also displayed some dissatisfaction on how different groups in the 
decision-making process have different priorities, especially in terms of managing budgets: 
 
A lot of the time we cannot do what we want cos the budget is not there, but that 
might be changing as people focus on clinical quality.  
RISK_C 
 
Lots of potential cost benefit analysis could benefit legislation… but that doesn‟t 
take place.  
TRAIN.tec_A 
 
I put in a request to get that equipment purchased but unfortunately the Trust is 
not forthright with giving us money. It's been relieved as we've got an injection of 
£350000 to buy equipment… but that is to replace items that were faulty and 
retired, but there's no funding to replace faulty items that can't be re-used, so stock 
is depleting...  
LIB_A 
 
4.2.4  Potential Risk and Areas for Improvement 
This last sub-section served to question firstly the need for improvement, and to also 
discuss ways in which the stakeholders themselves viewed a better purchasing scenario for 
medical devices.  
 
Vignettes of inefficient purchasing decisions 
The first set of comments included here highlight further pointers and issues arising with 
purchasing decisions directly from respondent‟s comments: 
 
We have a fluid chart, there's supposed to be a standard fluid and people are 
supposed to have observations done hourly on fluids, so if they're having an 
infusion either through a pump or under gravity, you're supposed to have 
observations of it, but what happens is that people will just write how much is in 
the bag and then put an arrow down to when it‟s supposed to go through, not 




actually looking at how much has gone through each hour....no one ever uses the 
volume display because there‟s no requirement, it‟s not written into procedure for 
them to actually use the volume infused display!  
TRAIN.tec_A 
 
I've sometimes waited around a whole day for supplier to deliver at certain time.  
ENG.snr_A 
 
Approval of PPQ can take weeks if sitting on somebody's desk. 
ENG.snr_A 
 
Lots of delays, days to weeks varying on resources in my team and that of 
requisitioning department, lots of backwards and forwards. We also question 
requisitioner or engineering checking if PPQ available or question supplier who 
direct us back to engineering. 
FIN.proc_A 
 
This was what we purchased, we only purchase that type cos our  syringe pumps 
go down when calibrated... The ones that aren‟t calibrated the end-users have... 
they don‟t know what rate to set for delivery. For some strange reason when they 
run out of them, they substituted for that syringe. We only found out when end-
users made errors. Not cos they didn‟t know how to use it, not cos it didn‟t fit... 
But cos when they tried to fill it, the middle bit came out. Our end-users couldn‟t 
even fill the syringe. They didn‟t get to use them. 
ENG.snr_C 
 
There was a case recently where somebody was taking blood pressures and all the 
readings were low, it was a dodgy machine, either the cuff was broken or 
something else, but rather than query it or check it manually or highlight it to the 
nurse in charge she just wrote down the numbers and moved on to the next 
patient, so all these patients had low blood pressure according to the machine and 








There are also examples of good practice in specific ward areas: 
 
[Trust A] has a Point of Care Testing (which includes blood glucose measuring and 
arterial blood gas measurement) devices are managed by Biochemistry. The blood 
gas machines have been set so that a valid identification number is required to be 
able to login and use the machine and  the staff ID badge number will be used for 
the purpose. Validation of the number requires attendance at initial training and 
then update training each year or so and I believe there is the option of refusing 
access if training has not been attended and recorded in time. 
TRAIN.clin_A 
 
A similar system has been introduced as part of the blood tracking system that has 
been introduced recently. Staff with barcodes on their ID badges have attended 
training in the BARS blood system and are able to scan documentation, gain access 
to the blood fridges and scan the units themselves. Absence of a barcode precludes 
following the correct procedure for removal of blood from the blood fridges and 
alarms will be triggered if the emergency procedure is followed. 
TRAIN.clin_A 
 
Identifying an ‘ideal case scenario’ 
Participants were asked to write down three criteria for the ideal „purchasing for safety‟ 
scenario on post-it notes. During the next exercise, the workshop facilitators clustered 
these responses into categories for a new maturity grid or purchasing for safety 
framework.  
 
Using the categories emerged from the clustering exercise resulting from post-it notes, a 
blank maturity grid was put up for discussion. Rationales for levels of maturity were 
discussed. This included a codification of suggested practices (using framework building on 
literature, anecdotes, and summary), and feedback was asked for the development of 
model for a purchasing perspective. 
 
Participants were asked to prioritise 4 sets of practices into a 4 x 4 grid, along with 
rationale for maturity level. The results of establishing an „ideal‟ purchasing for safety 
scenario, or the benchmark towards which Trusts can aspire to; is shown and summarised 




in the following two diagrams: Firstly, a simple high level sketch of the steps needed for 
ensuring safe equipment in hospitals; and secondly, what resources are required locally and 





Figure 18: Stakeholder-developed diagram of ‘ideal’ route for purchasing medical devices 
 
 
This basic diagram shown in Figure 18 shows how an ideal route should look like 
according to the participants. Both Standardisation and Evaluation refer to terms used 
widely by the NPSA (Lowe 2006) and adopted by the healthcare community (Pauley 
1980a; Pauley 1980b). To standardise is to decide on a particular device model for use 
within a ward or throughout the hospital. A device evaluation process usually precedes this 
standardisation (in an ideal scenario) and refers to the process of testing out a selected 
number of device models before its selection. Evaluations can take on various forms in 
hospitals – from a single „show and tell‟ day where end-users (mainly nurses and clinicians) 
are invited to attend and assess the suppliers‟ devices, or it can incorporate a trial for a set 
period of time when the suppliers provide the hospital with their device for use. These 
various forms and their challenges were investigated further in both Trust A and E and 
described in Chapter 6.  
 




However, a selection of comments were collected that related solely to the characteristics 
of an ideal process, along with its potential challenges.  
 
Ideally, equipment library should manage all revenue devices, but doesn‟t.  
ENG.snr_A 
 
Hopefully in future we will have a catalogue to deal with requests.  
FIN.proc_A 
 
The utopian would be a customer service point for all the wards, the wards would 
not necessarily, they would have equipment that would be on their wards, ...so if 
anyone wanted to know about any equipment or anything like that they‟d use us as 
a first point of contact and we would act as a bit of a buffer zone for medical 
electronics. But that would depend on all the three elements, us, medical 
electronics, and the ward working towards a common goal - and at the moment we 
don‟t.   
LIB_A 
 
When the Trusts merged, we had to re-standardise.  
ENG.snr_C 
 
You need flexibility but within any standardisation.... When we standardise, it 
must be hand in hand with training programme. Our staff move between clinical 
areas.   
PHA1_D 
 
The problem with standardisation is how do you achieve it? Let's say 1000 beds 
and we want 500 pumps, each costs between £1500 and £4500 depending on 
version… but they don‟t officially exist on capital asset register cos it costs less than 
£5000. But to standardise you need £100,000 all at once and that money doesn‟t 
actually officially exist. But cos total cost is over £30,000 it still goes out to tender 
- which means trial at least 3 devices before we can do it.  
TRAIN.tec_A 
 




We ended up telling wards that if you are buying a syringe pump you must buy this 
one.. .which actually made things worse for me because now I had to teach three 
pumps on a daily basis rather than just two as we're still using them… But, 
standardisation is a good idea - makes my job easier! 
TRAIN.tec_A 
 
Although standardisation is welcomed and its concepts understood among the purchasing 
community, the challenges mainly refer to the allocation of appropriate funding for 
standardising. The challenge faced is that much equipment that could be standardised does 
not fall into capital expenditure threshold, and yet the amounts needed to secure these 
contracts would require sums within capital ranges. The engagement of Board Level and 
Management for such decisions are required, but this means even more importance on 
defining the requirements for the new device type and developing a case for its clinical 
benefit and value.  
 
While speaking of the ideal case scenario, common themes among the three Trusts emerged 
for individual, collective and national support, which would encourage good practice such 
as standardisation and evaluation. The main common areas for support needed were 




Figure 19: Stakeholder-developed list of considerations needed to improve purchasing practice 




Although very theoretical and sketched out within the space of an hour in these 
workshops, the thoughts brought forward resonate with some of the recommendations for 
good practice suggested in the literature. Although national support is not within the remit 
of this research, the individual and management support will be areas considered for 
improvement measures in later discussions (Chapter 6 and 7).  
 
Adopting improvement measures: Trial of MAPSAF tool 
This final exercise in the workshops involved the use of Manchester Patient Safety 
Assessment Framework (MAPSAF) to elicit cultural issues and attitudes towards achieving 
purchasing for safety. As emphasised in the description for MAPSAF, this is not a 
benchmarking tool but is mainly used as a means of self-assessment. The matrix used is 
available in Appendix I.  
 
This exercise was conducted in a slightly modified manner to the standard or intended 
procedure. The participants in the workshops were asked to imagine themselves as a 
„purchasing team‟ to gain the „purchasing perspective‟ on their maturity with regards to 
patient safety practices in their daily work. They also were asked, if possible, to give an 
assessment of what they felt their management organisation would score on the same 
matrix. A few reflections on the process of conducting this exercise are as follows: 
 
 Trust B was the only one that had previously conducted a MAPSAF assessment on 
their own and so the results of this exercise could be compared to those results. 
Trust C only managed to assess itself as a purchasing team, and Trust D completed 
both an organisational and purchasing assessment.  
 
 Participants expressed difficulty in imagining themselves as a purchasing team as 
required to complete the exercise. As noted earlier, while there may be a suggested 
regular set of stakeholders involved in purchasing decision-making, they still 
belong to different directorates within the hospital, hence would not necessarily 
consider themselves a team.  
 
 The format of the maturity grid in the original MAPSAF (see Appendix I) involves 
descriptions of various stages in the maturity scale rather than the use of a Likert 
Scale. Participants expressed preference for a Likert Scale.  




 Furthermore, MAPSAF was not known to all participants, even if their Trust had 
already completed one previously.  
 
Some of these sample quotes are shown below: 
 
Well, different groups will allocate differently. I mean risk management group will 
say we are D, but... in pharmacy or procurement we may think we are C or D...but 
in actual fact as an organisation we might be much lower.  
TRAIN.clin_D 
 
I think actually that some parts of Trust are running at D when it comes to 
purchasing, I would say, there is more, sort of D-ish behaviour than A or B if we 
are talking about the team.  
RISK_C 
 
I think it might be B then. We don‟t have a risk based procurement training 
programme.   
PHA1_D 
 
Overall, the main difficulties in using this tool in this quick exercise were the absence of a 
true purchasing „team‟ that is responsible for assessing maturity with regards to 
purchasing, and the difficulty in applying some of the wording to a purchasing for safety 
context. However, the exercise itself, that is to say, the process of assigning a level of 
maturity or competence to a task or a set of criteria, was easily followed. The potential for 
a future design of a capability or maturity tool was recognised, but this involves the initial 
stages of assessing its requirements as completed in the rest of this study.  
 
 
4.3  Study of Medical Devices 
 
Having examined over the stakeholders‟ views in the last two sections, these next third set 
of findings summarised here relate only to medical devices themselves, and their handling 
within the purchasing process. In this section of the Exploratory Studies, the potentially 
different views of stakeholders involved in the device supply chain were explored. The 




experience of each stakeholder with the device, the factors that affect its design, its 
selection, and finally, its use, all form part of the underlying context for this study.  
  
4.3.1  Observations from Devices Sales Representatives 
A showcase was held at Trust A to compare different competing suppliers of patient 
monitors. This is one example of an „evaluation‟ that can take place in a hospital, before 
the actual trial takes place between selected models. Clinical staff as well as technicians 
from the EBME department were invited to visit each stall throughout the day; and submit 
an evaluation form with their opinions on the various devices viewed. 
 
Although mostly clinical staff were invited, the event was poorly attended. A few senior 
clinicians were present (those with a personal interest in the devices they were to use), as 
well as the nurses who regularly used them. EBME expressed their disappointment with 
the turnout. The evaluation forms served as a guideline for questioning, but participants 
largely asked their own set of subjective questions – drawing on their experience with 
errors with devices and usability issues. Whether or not these had been reported or entered 
a record in their internal systems was almost irrelevant. 
 
The suppliers themselves were very enthusiastic, energetic and were keen to point out 
especially the following features: 
 
The type of applications for their monitors (mobile/transport, recovery) 
Features such as mobility and transportability 
Battery life and backup 
Robustness (“Watch the way I drop it to the floor and it doesn‟t break”) 
 
This particular part of the supply chain is an interesting group to examine; why they point 
out what they point out, and whether or not this is what the purchasers need to hear – 
and, ultimately, whether this leads to better, safer, devices being bought – are questions to 
be answered. It seems there are some similarities but not entire cohesion between the 
expectations of purchasers and the comments made by suppliers. Some sample comments 
are listed below: 
 
 




For new device expect it on market for at least 2 yrs.       
ENG.snr_A 
 
We had problems with [Brand name] pumps…. But that is more about how people 
tried to use it. Unless you have something inherently designed in the product that 
makes it flawed, it‟s more about how it‟s used and not designed.   
RISK_C 
 
CE process approval doesn‟t mean anything…   
ENG.snr_A 
 
Given some of these differences in expectations, in the next set of data collection (Results 
II, Chapter 5), stakeholders are asked what their drivers are for individual purchasing 
decisions, in line with the  first set of research questions.  Some of the above aspects such 
as usability and CE marking are covered in the questionnaire, introduced in Section 5.2.  
 
4.3.2  Preliminary Analysis with Engineering Design Researchers 
In order to reflect on some of the concepts gathered so far in relation to medical devices, a 
workshop was held with researchers from the Engineering Design Centre on exploring 
different features of products that may affect purchasing decisions. Participants at the 
brainstorming session were asked: 
 
 What are manufacturers‟ drivers and incentives for designing for Patient Safety? 
 Who is responsible for patient safety? 
 What are the drivers for designing for safety in different stakeholder groups? 
 
The workshops did not provide final answers to the questions, but they did lead to 
questions that needed answering before those above could be answered: 
 
Who is responsible, the manufacturer/designer, purchaser, or end-user? If this is a 
collective effort, do we act as if it is a collective responsibility? 
 
To what extent should/can a patient understand risk? Does this depend on the 
patient‟s education, or on the type of device/area of clinical practice? 




The main discussion, therefore, centred around stakeholders, from the suppliers, to 
purchasers, to end-users and patients. This was an attempt to brainstorm ideas on the 
responsibilities that each of them have in the supply chain. The participants collectively 
helped draw Figure 20 below for discussion, based roughly on the original diagram 





Figure 20: Adaptation of original device supply chain to discuss roles of various stakeholders 
 
 
The drawing started with three main stakeholder groups: purchasers, suppliers and end-
users (defined as clinicians and operators of devices). Those receiving the service, i.e. 
patients, were then added, and it was noted that „purchasers‟ actually include clinicians as 
well as purchasing administrators. This workshop highlighted the potential role that end-
users (operators) and care receivers (patients) play, and it was noted that they might also 
play a part if they are empowered to take ownership of medical device selection processes. 
This may of course apply more to operators unless we refer to home-use devices or patient-
specific devices such as dialysis/infusion devices. In these cases it is the patient that has 
some say in the type of device they feel comfortable using.   
 




It was also pointed out that the main drivers for suppliers are the regulations placed upon 
the device design, with a suggestion that this is even more influential than hospitals 
purchasing power. It was agreed that in general, this pressure works well and ensures 
certain safe design constraints are adhered to. Those who purchase, however, may require 
further education drivers to recognise features in device that transcend these regulations. 
Potential research questions were therefore established: 
 
 What do purchasers need to look out of beyond regulatory „safety‟ marks? 
 How can purchasers be both facilitated and educated to note such features? 
 How can end-users (operators) of devices be empowered to contribute to 
purchasing decision-making? 
 
Some of these considerations were taken into account in further interviews and elaborated 
in the discussions in latter chapters. What follows is a discussion on the devices chosen for 
this study, and the research and analysis that took place to make these choices.  
 
4.3.3  Choice of Devices for Study 
Given the variations in products and in device features, the choice of devices to focus on 
for this study required some thought. One way of selecting the device is to look at those 
with the most mention in terms of device error; i.e. those that have received „device alerts‟ 
from the MHRA. The MHRA has provided alerts for the following (MHRA):  
 
2002a In vitro diagnostic devices (does not come into contact with patients but if 
used incorrectly, the misdiagnosis can have harmful implications) 
2002b IVD at point of care 
2002c Decontamination of endoscopes (has shown infection before, though hard 
to detect back to endoscope, “highest risk” of serious clinical infection) 
2002d Benchtop Steam Sterilizers  
2003 Infusion Systems  
2003 (05) General 
2003 (06) Community equipment loan stores 
2005 Reporting incidents, importance of. 
 




Staff engaged so far in the Exploratory Studies have also provided some guidance about 
the types of devices that would require most investigation in reference to purchasing and 
safety. These various classification methods are explored below: 
 
Device complexity 
It was suggested to study equipment with varying levels of complexity – internal workings 
complexity, since this is one major differentiating factor when it comes to servicing and 
repairing in-house. An ECG machine, for instance, is considered complex and varies in 
design if it is for home use or for hospital use. Patient monitors are not too complex but 
used everywhere and present different problems.  
 
Unit cost: capital or revenue-funded 
Another major observation for this stage was the different routes each device can take even 
in the same hospital. In particular, members of Trust A pointed out these various product 
routes, depending on the device cost, where it is used, where its funding comes from, and 
so forth. 
 
The general practice with revenue devices is that orders are ad-hoc, standardisation 
occurs with capital expenditures/devices that are managed by us/ have central 
management/library too.  
ENG.snr_A 
 
MEC/Capital are where larger issues lie. Revenue seems fairly straight-forward 
except for Goods-in issue. 
FIN.proc_A 
 
Capital items we get to see mostly, but revenue ones sometimes we wonder why 
they purchased that? 
ENG.clin_A 
 
Only capital programmes are managed by device committees.  
ENG.snr_C 
 




But not all capital equipment is approved through MEC - and I've never 
understood why certain capital expenditure goes through MEC for approval and 
some don't.  
FIN.proc_A 
 
Procurement strategy [is] dependent on value of the order   
ENG.snr_A 
 
These divisions were expressed as obstacles to obtaining funding for much-needed new 
purchases, similar to the thoughts presented while discussion standardisation of devices 
under the capital threshold.  
 
Consumables 
Consumables are usually provided in a contract with the devices, but may also be a 
completely separate set of purchases initiated and controlled by individual wards. Issues 
with connectivity arise if these are not coordinated, as expressed by some participants:  
 
But when it comes to consumables that come with devices we cannot make a 
decision on them cos it comes with the contract.. It is very clever of them.   
TRAIN.clin_C 
 
Consumables get managed by individual wards  
LIB_A 
 
Some hardware comes with consumables but wards don‟t necessarily stock them  
LIB_A 
 
There needs to be a better link between pharmacy and purchasing which seems to 
be missing.  
TRAIN.clin_C 
 
Mapping device routes varying in funding routes and consumables requirements would 
therefore constitute interesting variations.  
 




Some of these features were collected and also presented to workshop participants at the 
EDC. Firstly, the participants were asked to come up with a list of features that potentially 















The group was also given the following list of features that may be considered in relation 
to purchasing and patient safety. Those in red were the ones that the majority ticked as 
„relevant to consider to the purchasing of devices in terms of patient safety‟. The initial list 
was put together through a brainstorm session with fewer EDC members, but this final 
selection was a majority vote at the workshop. 
 





Table 13: Features most relevant to medical device specifications for purchasing (in red) 
 
 
This provided a good starting point for the future questions:  
 
Are such features considered? If so, in what format and with what degree of 
importance?  
 
If some of the other features are considered, for what reason, what are the 
motivations for choosing some characteristics to be more important than others?  
 
It was clearly an area for further investigation and therefore chosen as part of the analysis 
in the interviews. It also helped decide which devices to take as case studies. Combining 




the observations so far, it was therefore decided to choose devices using the following 
criteria: 
 
 Representation from devices which are funded from capital and revenue streams 
(this would affect „cost incurred‟, and „type of contract‟ as above) 
 Devices that are both distributed around the hospital (i.e. purchased for the 
hospital in bulk), and limited to one particular ward/clinical specialty (this would 
include „type of contract‟ and potentially „suppliers available‟) 
 Devices with varying degrees of complexity (this would incorporate different 
„training required‟ and potentially the degree of risk) 
 







The choice for these was partly opportunistic, but also took into account the diversity of 
features introduced in this section. The following table elaborates on the way these three 
devices vary, using parameters arising from the above discussions that were possible to 
obtain within the study. 
 









4.4  Analysis of Learning from Exploratory Studies 
 
These Exploratory Studies help identify and expand on the main factors influencing 
current practice in medical device purchasing, especially those that may be responsible for 
inefficiencies in the process. It is therefore hypothesized, at this point, that due to some 
anecdotal evidence from the Exploratory studies and findings from literature, that these 
factors can also influence the healthcare delivery service. Furthermore, it was established 
that further research is needed in understanding the current communication and 
interaction pathways among purchasing stakeholders. 
 
4.4.1  Factors influencing Current Practice 
The factors influencing current practice are discussed in light of anticipated research 
questions to be constructed for the rest of the study.  




Stakeholder definition, Stakeholder engagement 
During these preliminary findings, a more holistic understanding has been established of 
who the purchasers are. The other stakeholders involved were also introduced from the 
maintenance and training staff. This gives some guidance as to the stakeholder domain 
that can form the boundary for this research.  
 
Device knowledge & competence, Drivers & Resources for decisions, Process knowledge 
However, the process knowledge for each person can vary from holistic process knowledge 
to a more specific view. The stakeholders also vary in skill, competence, habits, language 
and understanding of the different components of the purchasing process. All these could 
be investigated further to gain a deeper understanding of what may be motivating the 
decision-making process regarding devices. 
 
Pressures on process, Inventory management, Goal alignment 
Although a very generic perspective on the process itself for each hospital has been 
diagrammed, each one varies when examined in detail. Mapping of processes has already 
brought up challenges in the current system, including the auditing of equipment, the large 
demands on training and maintenance and lack of system controls. Appropriate 
stakeholder engagement in all parts of the process may also be lacking which can lead to 




General ownership and control of the process has been suggested to be lacking. The results 
also seem to show that there are variations in current practice due to unknown factors; 
these factors are to be investigated. They may be due to the product variations or the 
people involved in decision-making. External factors, such as policy drivers and the 
influence of the supply side are also part of the considerations that could be made. 
 
Culture and mindsets 
Lastly, while recommendations could be made for a more ideal process, challenges exist to 
reach such ideals that largely include the cultural barriers that need to be overcome with 
regards to both equipment ownership on behalf of the end-user, and management on those 
with more holistic process knowledge.  
 




4.4.2  Factors considered for Improvement 
A second set of observations relates firstly to suggestions arising from the stakeholders on 
how to improve current practice, the suggestions of which resonate with policy and 
guidance found in literature. Their appearance in this list is a testimony to the participants‟ 
perception that such measures are missing in current practice. By way of eliciting how 
participants may respond to improving on those measures, the MAPSAF tool was used as a 
way of assessing current practice in purchasing „teams‟. 
 
Despite some consensus of how to improve current practice, challenges to improve the 
system exist:  
 
 A degree of flexibility to standardise on device models is needed depending on 
ward needs 
 The capital/revenue funding divisions creates barriers to achieving standardization 




4.5  Summary of Conclusions from Exploratory Studies 
 
The factors that influence current practice from both the literature and these Exploratory 
Studies were found to include some of those identified in the literature as seen at the 
beginning of this chapter, in Table 10.  
 
It can be established from these initial gleanings on purchasing practice that challenges 
exist and are acknowledged by all stakeholders. The exact nature of these challenges are to 
be investigated in further detail, as it cannot at this stage be ascertained how these 
challenges relate to or affect the safe delivery of patient care.  
 
 
The next three chapters each serve individual purposes: 
 
 




Chapter 5 – Results II: Observations of Current Practice 
This is closely linked to this chapter, where the very same concepts and topics 
explored here are now investigated but with more focus. The methods employed 
are therefore more structured (semi-structured interviews and questionnaire).  
 
Chapter 6 – Results III: Case Examples  
Serving as examples of current practice, this chapter highlights particular instances 
where purchasing practice has had an influence on healthcare delivery or has 
displayed elements of poor practice.  
 
Chapter 7 – Synthesis and Framework for Improvements 
Drawing on the elements of good practice, this chapter suggests measures that 
could be used to improve on current practice and proposes a framework for 
implementing these improvements.  
 


















This second set of results corresponds to the first research questions, with the aim of 
obtaining more empirical evidence of current practice in device purchasing. These results 
correspond largely to the results from the questionnaire developed following the 
Exploratory Studies, as well as additional interviews gathered while at Trust A. The 
Exploratory Studies have already established who the stakeholders are; but these 
stakeholders‟ roles, their resources used in decision-making, and adopted control measures 
were investigated in more detail in this section. The results presented in Results II answer 
general questions on current practice, followed by an analysis to decipher whether such 
practice can lead to risks to the service and whether it is inefficient. 
 
The addressed research questions are repeated below. It was mainly intended to find those 
shaded in grey, but some responses contributing to the other questions boxed in grey were 
gathered as well.  
 






The results presented in this chapter mainly answer the questions in Research Question 1 
above. However, given some of the inductive analysis that takes place in the later 
discussions, parts of the arguments that help answer question sets 2 and 3 are also 
addressed. An overview of the factors noted in this study of Current Practice is presented 
first, followed by the methods for obtaining these results. The details of the results 
themselves are then presented, culminating in an analysis of these results that lead to the 
second set of results in Chapter 6.  
 
 
5.1  Overview of Current Practice 
 
Table 15 gives an overview of the factors that are considered in this section of the analysis: 
 





Table 15: Data gathered from Results II (Observations of Current Practice) 
 
 
5.2  Methods for Results II 
 
From the main set of methods described in Chapter 4, the specific methods used in this set 
of results, Results II, were: 
 





 Telephone Questionnaires (at Trusts B, C, D, E). See Appendix II for copy of 
questionnaire.  
 Triangulation with previous semi-structure interviews and continued observations 
at Trust A 
 
The exact source of the set of data for the telephone questionnaires and the original 
stakeholders observed in all Trusts is shown in Table 16. Each respondent has been 
grouped into four categories, which correspond back to the original stakeholders identified 
in the Exploratory Studies: Engineering, Clinical, Training or Risk. The table shows the 
four categories into which each respondent was grouped.  
 





Table 16: Source of data for Results II (Observations of Current Practice) 
 
 
It must be reiterated here that all these respondents were chosen as part of the PASA 
project in the case for Trusts B, D, and C; and a separate evaluation project at Trust E. 
This implies that most of them were selected due to their involvement in the Purchasing for 
Safety project whose focus was on infusion systems purchasing. However, their answers to 
the questions were chosen only when respondents referred to „general medical device 
purchasing‟. For this reason, the results are presented not as direct responses to the 
questions asked, but as responses clustered under particular topics, which correspond to 




the research questions. The questionnaires served as a guide for interviews, but the method 
was strictly semi-structured; the respondents were given the freedom to comment around 
the subject. Furthermore, in order to present the results as more generic indication of 
medical device purchasing, as opposed to specific infusion device purchasing, the data was 




5.3  Factors affecting Purchasing Practice 
 
The findings are divided into the three categories as addressed in Table 15, and are 
discussed in their groupings: stakeholders, decision-making factors, and other elements of 
the purchasing process.    
 
5.3.1  Stakeholders 
Less emphasis was placed on characterising stakeholder in this part of the study due to the 
data already existing from the initial Exploratory Studies to characterise stakeholders. This 
section mainly comprises of the roles of the stakeholders in the purchasing process, and 
hence their engagement in the process.  
 
Stakeholder Roles in Purchasing Process 
These results correspond to the responses to the very first section in the questionnaire (see 
Appendix II). Interviewees were asked to indicate the particular steps in which they took 
part in the purchasing process. As a frame of reference, an initial role assignment table was 
drawn up based on the observations made previously at Trust A. This original list is shown 
in Table 17: 
 






Table 17: Responsibilities of different stakeholders in the purchasing process steps at Trust A 
 
 
This was then used as a baseline to compare with other Trusts, as seen in Table 18. For 
Trusts B, C, and D, the study was limited to infusion systems, the clinical input was limited 
to pharmaceutical staff. For Trust E, most clinical staff were nursing staff.  
 
Given the low number of respondents (not statistically significant) and the sampling 
strategy imposed (respondents were selected by the Trusts), the data serve as indicators of 
the conclusions made. Instead of providing numbers of those involved in the various parts 




Table 18: Involvement of stakeholders in each step of the purchasing process for Trusts B, C, D and E, and their comparison to expected involvement as 
compared to Trust A (rightmost column) 
 




The key observations pertaining to the stakeholders‟ roles were as follows: 
  
 Involvement in the purchasing process, or the roles played in the purchasing 
process varies across Trusts.  
 
 For some Trusts, those involved in training staff on devices used are already 
involved at purchasing devices selection stage, but not in all Trusts and not for all 
devices.  
 
 In one instance, the training coordinator for skills in using devices has no say at all 
in purchasing decisions 
 
 Despite an interest in device alerts and incidents, stakeholders from the Risk 
management department of Trusts are not involved throughout the process.  
 
 Trust A displayed evidence of back and forth communication between their 
maintenance („Engineering‟) and purchasing („Procurement‟) departments 
 
For the steps: Picking up the orders from goods in, Conducting acceptance tests on new 
devices, Entering devices into a maintenance/EBME asset register, Entering devices into a 
financial asset register, and Delivering injectable medicines or devices to the unit or ward 
requesting it; these were confined to Engineering staff as expected. In the case of 
consumables, the pharmacy stakeholders may be involved in delivering these to relevant 
ward. 
 
Results suggest that there may not have been a common interpretation of the process steps 
involved. „Entering devices into financial asset register‟ is clearly a task for the finance 
department but was ticked by respondents from Engineering and Technical services. 
 
The interviewees made the distinction, however, that they would only be involved in 
purchasing decisions if the device related to their pharmaceutical/clinical product. It was 
also noted that this involvement varies a little according to the Trust.  
 
Only Engineering respondents admit to being involved in pumps and devices, and perhaps 
a slight involvement for purchase of the syringe set or consumable (depending on the 




supplier model), and strictly only pharmacy staff are involved in choosing the 
pharmaceutical medicines. It can also be pointed out that many of the other stakeholders 
did not state that they were involved in any of the above processes, despite having a similar 
role to their equivalents in other Trusts. Again this brings to mind the understanding of the 
word 'to purchase', which seems to have a different meaning to different people. In many 
cases, it is understood to be strictly an administrative process, administered by the 
'procurement' or 'logistics' department, whereas some respondents displayed a more 
holistic understanding of purchasing. 
 
What emerged during this study was the importance of the roles of medical device 
coordinators. This is not commonly defined for every Trust, but it roughly describes a 
person who is involved in either trialling of new products or training staff in a new model.  
 
Stakeholder engagement 
Respondents were asked to scale their view on current practice in involving the following 
stakeholders in the purchasing of infusion devices only (as this is what they had most 
experience with): patients, nurses, clinicians, a national agency (e.g. Collaborative 





Figure 21: Extent of involvement in infusion device purchasing process for stakeholder groups at 
Trusts B, C, D and E 




The key observations pertaining to stakeholder engagement were as follows: 
 
 In almost all cases, patients were selected as „never (directly) involved‟ unless the 
patient will have direct contact with the device (e.g. PCA pump) 
 
 Nurses and clinicians are often involved.  
 
 National Procurement (or an equivalent national agency) is involved if they have an 
established contract for that device.  
 
 Engineering and Procurement are, of course, always involved in decision-making. 
 
 Pharmaceutical purchasing procedures are tightly regulated, controlled, and has 
guidance from larger consortiums. They even have a separate purchasing stream in 
Trusts.  
 
Respondents offered extra comments on stakeholder engagement, mostly pointing out how 
key stakeholders are not involved in decision-making.  
 
Someone in training should have more of a say in purchasing equipment... I think 
only senior staff are involved in evaluating products. But that is where we go 
wrong. I think ward-based staff need to be involved. Senior staff who are 
experienced are usually consulted. I think what‟s missing is that the person actually 
working with the device should be involved before it's put in service.  
TRAIN.cl_E1 
 
I'm not involved in the process… certainly don‟t know the... If for instances I 
wanted to buy five pumps that were not standardised I would have to go see the 
Director of Finance with a written evaluation and probably sit there and have to 
scream and say I want those pumps as opposed to anything else… 
TRAIN.tec_B 
 
I've never been asked for information on the error rate of a specific pump. … [if 
asked] we could [provide that information] 
RISK_D 




I place orders for drugs but not for devices, procurement don't get involved 
because drugs don't come under that.  
PHA_D2 
 
Choosing the device is a combined effort. 
ENG.tec_D 
 
They also point out that involvement of stakeholders is a dynamic process that is 
dependent on the device and its operator. Patients are normally not involved unless it is a 
device that they would have to operate themselves: 
 
Unlike a lot of other pumps, with the PCA pump, there is patient participation 
because the patient is activating that infusion device… so that will be a factor in the 
trial - what the patients feel about activating the device.  
CLIN.nurs_E5 
 
…[Nurse involvement] depends on the product.. Yes for infusion endoscopy, but it 
depends on the responsibility held by the ward. 
ENG.snr_E 
 
We would like to involve patients but, with all due respect, it's almost like asking 
your patient which needle they expect to be stacked with. 
TRAIN.tec_B 
 
Involvement depends on who is the primary user of the equipment. Some 
equipment is for personal use by the patient in which case they would be involved. 
ENG.snr_C2 
 
We only involve the patients if they are physically using the pumps.  
CLIN.nurs_E4 
 
Finally, observations were made on the importance of noting the separate procurement 
routes or strategies operating with the purchase of one device. For instance, if a device also 
requires extra equipment, consumables and pharmaceuticals, various purchasing bodies 
are involved.  








Summary of learning about stakeholders 
The key learning from this section is summarised in these bullet points: 
 
 The different roles played by the stakeholder group groups in each purchasing 
process step were assigned (Table 18). 
 
 The results strongly suggest that not everyone involved in the process has a clear 
understanding nor consensus about who makes decisions and who is involved.  
 
 Patient involvement is device-dependent. This gives us clues about who is perceived 
to be an 'end user' when it comes to purchasing. And also, who is perceived to be a 
'purchaser'. To some, this means the administrative tasked assigned to the person 
making the order. To others, this is a collective term.  
 
 There is an inconsistency of interpretation of roles in medical device purchasing 
among different stakeholders 
 
 Clinical input is divided from the rest of process, but is present at the start (except 
for pharmaceutical products, where „risk department‟ is involved) 
 
 There is less involvement of patients for infusion device purchase, but 
acknowledgement of necessary involvement of Nurses and EBME (more than 
Clinicians and Purchasing) for decision-making. 
 
5.3.2  Decision-making 
Resources for making purchasing decisions 
Respondents were first asked to indicate with which guidance they are familiar, or may 
have previously used as reference for making purchasing decisions. The exact list of 




resources referred to are those in the second question of the questionnaire in Appendix II. 




Table 19: Number of respondents who used or are familiar with available resources 
 
Table 19 highlights some key observations:  
 
 „Regulatory‟ guidance, such as that from MHRA and NICE, all are guidance with 
which they were familiar, but guidance from PASA or Royal colleges varies. 
 




 Purchasing documents (e.g. Pre-purchase questionnaire, PASA documentation, 
BIME device evaluation data) are almost unknown to pharmacy respondents. 
 
 The differences in resources used give another indication of the separation of 
maintenance/engineering staff and those based more on the front-end or 
pharmaceutical management.  
 
Drivers for making individual purchasing decisions 
These responses correspond to the fourth question on the questionnaire in Appendix II. 
The results are not statistically valid, and there were also differences in interpretation in 
many of the phrases used in the questionnaire. However, the key findings are shown here 
as they did show a few trends worthy to note: 
 
 „Device history‟, „quality‟, „safety‟, „robustness‟, „ease of use‟, „after sales support‟ 
and „reliability‟ ranked high no matter what the role 
 Supplier image or brand generally not important 
 Technical/engineering staff recognise importance of working relationship with sales 
representative 
 
Below are some of the sample comments that illustrate these findings: 
 
I would always concentrate on the user first rather than the design. I compare 
medical devices to cars, and I've my car in the car park now and the car park is not 
doing anybody any harm, it‟s only likely to do any harm when I get in the car and 
drive it.  
ENG.snr_C2 
 
CE marking doesn't give any indication of quality or safety or reliability.  
RISK_C 
 
If we have two products then one we have experience with working with the 
company and we've got on OK with … we'd like to use them again.  
TRAIN.tec_D 
 




I wouldn‟t go with a company if it didn‟t give me any training. 
TRAIN.tec_D 
 
During these responses, some further comments were made that did not relate directly to 
the questions asked during the interviews, but served to highlight issues further and 
provide insights into the situation.  
 
Firstly, the knowledge of the resources available was not common to all, as pointed out 
earlier.  
 
I'm aghast at how many people have not seen MHRA guidelines… it's the ward 
level people who don't know.  
ENG.snr_C1 
 
A member of the risk department points out the intrusion made by sales representatives on 
their control processes:   
 
We want purchases to be independent and neutral and want to avoid reps coming 




Medical device coordinators are not used by all Trusts but can play a key role in 
establishing links between the clinical and technical considerations of device purchase and 
use. They usually purchase “for the Trust” and have a particularly holistic understanding 
of device needs. However, respondents were not always sure who this medical coordinator 
was for their own Trust, and different names were given for the same role.  
 
Device committee that‟s me, and…[Engineer‟s name] 
ENG.snr_C1.  
 
Maybe it is him…  
TRAIN.tec_B 
 








I think there is a committee… you'd have to ask [ENG.snr_C1]  
RISK_C 
 
Medical device coordinator comes under the realm of clinical engineering team  
RISK_D 
 
Culture and mindsets 
The questionnaire also invited respondents to comment on changes in the NHS, and 
changes to purchasing practice. This was to elicit the attitudes and mindsets of current 
stakeholders with regard to current practice, and gauge willingness or need for 
improvement further.  
 
Respondents were first asked whether or not change was necessary, and the response was 
overwhelmingly positive, although some claimed the changes have already occurred and 
safety is being taken into account in decisions, from their personal perspective:  
 




We do have some quite well defined procurement processes and I think increasingly 
they are taking safety into consideration which is good…  
ENG.snr_C 
 
National awareness campaign is hugely important to raise awareness. To engage 
people and recognising that there are significant benefits in taking a national 
approach [or] a sub-standardised approach at things.   
PHA_B 
 




We almost need to identify champions across the NHS who can actually support 
the NHS Trust with a lot of these things, so we've got a sort of patient safety 
coordinators in each of the regions… actually working with individual Trusts to try 
and support the introduction of new equipment or help us with business cases... 
PHA_C 
 
Using collaborative procurement hub is good way to assess risk…  
PHA_C 
 
[Conferences] enables the targeting of key people.  
RISK_C 
 
An online resource kit and to bring together many of the aspects that you would 
have, and I suppose want to use these tools to measure and help plan the next 
processes out.  
RISK_C 
 
[We need] more about PASA structure because Trusts do try and comply with 
those things, people who are looking after patient safety have to compete with the 
Board's attention, finance...which has much higher national priorities.  
TRAIN.tec_D 
 
I think we need more honest thorough the whole NHS (honestly admit when we 
are having a hard time implementing good practice)  
RISK_D 
 
I'll tell you what you need; you need purchasing for safety champions - -individuals 
in Trusts who can engage people in a tradition, working in a clinical area where 
they can influence the vision.   
PHA_D2 
 
Summary of learning on decision-making influences 
The key learning from this section is summarised in these bullet points: 
 




 Dispersed use of any national guidance among the stakeholders but heavier reliance 
on internal policies, measures, and human resources to control the management of 
devices. 
 
 Not all „purchasers‟ are familiar with all guidance available, and this varies 
according to Trust area 
 
 What “purchasers” rank as important for making purchasing decisions relates 
mostly to the training and maintenance given by the supplier. Little value is given 
to the internal capacity of their workforce to comply with training and usability 
requirements. The expectations lie slightly more with the supplier. 
 
5.3.3  Process Elements 
Control measures 
The group that was most interesting in its responses was the EBME department. This is the 
one group that assumes most control of the process. The general idea seems to be that 
EBME has the know-how with regards to medical equipment specifications; that they are 
the ones to turn to. They also seem to think that others are likely to buy „oddities‟ unless 
they have some control of the process. It is also within their remit to keep abreast of new 
products on the market.  
 
In some instances it was commented that the presence of policies may not necessarily make 
a difference in practice, as end-users would still purchase outside of these policies;  
 
I would've thought there's a policy for purchasing but I haven‟t seen it. I‟d like to 
think there is.  
TRAIN.cl_E1 
 
It‟s not a policy but it should be. It would stop ad-hoc purchases. For 17 yrs I've 
been doing this and we've been trying to stop ad-hoc purchases. It's getting better 
but still happens… whether it's revenue or capital, device purchases have to come 
through the committee, so that's how we ensure control at the moment. 
ENG.tec_E1 




No reason to make it [device management] a policy, it doesn‟t add any clout!   
ENG.snr_C1 
 
We have a medical device policy … they cannot initiate a purchasing process 
without going through medical device committee so it's already monitored…  
TRAIN.tec_B 
 
I think we‟ve got a policy that lays down standardisation.. We've certainly got a 
process....nothing can be purchased from the Trust unless it's been signed off by 
the guys who run the medical devices committee and that will go through 
[TRAIN.tec_B] because the make sure the training implications are there…  
RISK_B 
 
The control the Trust has got is [useful]. .. People can't go off and just by 
anything… process doesn't just rely on [TRAIN.tec_B], I mean there's a 





What is considered far more useful, which resonates with the literature, is the 
standardisation of product models and the use of libraries, as means of controlling the use 
of devices: 
 
Standardisation is a must really… 
RISK_B 
 
Before we opened the equipment library we used to get lots of errors cos we 
couldn‟t get hold of equipment, but actually people would hide in their places and 
when you actually did that with library we found that some equipment hadn't been 
used for a month... 
TRAIN.tec_B 
 




Reporting and feedback 
Incident reporting features in the patient safety literature as a crucial element for both 
measuring and improving patient safety. While the culture of reporting has increased, its 
quality and true efficiency is questioned. Many of these incidents relate to device reporting 
and, and this aspect of device management was therefore also questioned with the 
participants. Overall, the response was not in favour of current reporting systems, despite 
recognising the general importance of feedback for future purchases:  
 
These people [clinicians] don‟t have time to do it. They already have jobs which are 




I think medical staff are generally less willing to have a complaint to make but I 
don‟t know how effective it is in terms of assistance or feedback and how reliable it 
is.   
CLIN.pha_C 
 
There's by no means a 100% recording. If we stop to record every time, you know, 
the prescription would be very slow, getting too slow… hopefully errors are picked 
up but they're not all recorded. .. Only the very severe errors are put onto the 
computer database.   
RISK_C 
 
It could always be better and it depends on the quality of investigation… 
RISK_ C 
 
Incident reports that relate specifically to medical devices can be more complex to report 
given that the cause of error can be difficult to assess, as noted by the respondents:  
 
Medical device failure is the one that is reported on the most, and particularly to do 
with infusion devices…. People will be blaming the machine as well.   
TRAIN.tec_D 
 





Respondents on the front end, such as nurses, tend to put auditing measures in place to 
keep track o their equipment, suggesting a sense of ownership of the device in the ward;  
 
I do that personally [monitoring pumps]. We tend to name our pumps, they all 
have different names so that can then be monitored. 
CLIN.nurs_E1 
 
We do in pharmacy keep their stock levels and then we audit them to make sure 
that the levels are correct 
PHA_B 
 
We are trying to have a sort of agreement between management of equipment 
between hospitals from the community….. it's quite a big issue in terms of tracking 




Some of the problems in tracking have also to do with the disjointedness of the different 
asset management systems in hospitals.  
 




The use of the equipment library was also favoured but with mixed feelings on its value: 
 
I would also like to think there's a library. My background is in acute and I know 
there is a librarian for the neo-natal department - looks after massive room with all 
equipment, he's fantastic… 
CLIN.doc_E 
 
I don't think we should have an equipment library I am totally against that. (Q: 
Why?) Well, the concept of having to go somewhere to get something you use all 
the time … is daft. If you only use equipment rarely, that‟s fine. But if they only use 




it rarely they shouldn‟t be using it, they should know how to operate it... and my 
view is that wards should get equipment resourced... in general terms... wards are 
quite apart physically. And to have senior nurses running around in hospital trying 
to find pumps is daft. They should put the pumps where they were used… and OK 
if you have a very large amount of pumps you should be able to borrow them.. But 
you don‟t need to have a library set up. If you look at costs to set up equipment 
library you have got to have a librarian and another librarian for support ... and if 
u just put money into having more pumps you wouldn‟t need the library…. (Q: 
What about speciality specific libraries for those specialties that run the whole 
time?) Yes sometimes they do... The sick children‟s hospital has an equipment 




For a scheme like an equipment library to work, however, it was noted that support from 
management is needed, and a coordinated effort throughout departments. This is mainly 
due to the differences in device use – from their frequency of use, to handling required, 
training, and distribution throughout the hospital.  
 
Generally it probably would get rid of a lot of barriers. In pain [department] ones 
we probably have a library because we store them somewhere and epidural 
recovery, all go back to the bay, controlled by the pain team. So no one clinical 
area owns the PCA pumps, they are controlled by pain team. So that works for us. 
But for rest of hospitals, pumps should perhaps be used in library.  
CLIN.nurs_E2 
 
I‟m not sure if we want [a library]. If it has equipment that is electronically tagged 
that would be completely different from having one that is central within hospital. 
There are times in specialist areas that they would have devices that weren't 
currently in use. … I think u could have it for general use in areas, but specialist 
areas really need their own stock.  
CLIN.nurs_E1 
 
Don‟t know if a central one [has one] but certainly each hospital will. We have 
one. In general it depends as there are many different devices. With regards to PCA 




and epidural which I deal with, they are held in particular areas and labelled 
accordingly. Nurse or midwife will fill out where it went. I think with some other 
infusion pumps probably each ward has own store and know where to go to if they 
want to borrow more. A central one…I guess probably [ENG.snr_C1] would have 




In one instance, the library actually was claimed to contribute to a reduction in device 
incidents, although this was only shown anecdotally: 
 
We have an equipment library on each site so you have to say it's been an 
enormous success. We've seen a reduction in the number of incidents related to 
lack of equipment, complaints about the lack of equipments. So phenomenally 




Comments alluding to the alignment of goals, both within the organisation or hospital, 
and nationally, received mixed responses. The introduction of „targets‟ and „objectives‟ 
were not always favoured, and the structures within the organisation were sometimes seen 
as impositions on improvement on good practice.  
 
We have so many targets and objectives set for us as an organisation that I think 
you would be in great danger of damaging the profile really of the project and in 
wrapping it up in a target because it would just then become one of many and I 
think if you had an awareness campaign, you'd be much more likely to engage 
clinical staff and they are the people you‟ve got to engage in there.   
RISK_D 
 
People have a pretty good understanding of what is good practice and a strong 
desire to improve on practices but they‟re inhibited by structures within the 
organisations and often a lack of understanding.  
TRAIN.tec_D 








Overall, however, the importance of aligning goals, and establishing a common vision for 
safe purchase, was welcomed.  
 
Summary of learning on process characteristics 
The key learning from this section is summarised in these bullet points: 
 
 Management of devices varies considerably among Trusts 
 
 Not every Trust has the same elements of an asset management system (e.g. library, 
device trainer/coordinator), and the reasons are mostly „historical‟ 
 
 Improvements or changes in practice are attributed to key individuals; many other 
practices are „historical‟.  
 
 Differences in practice driven by Device Type & Individuals involved 
 
5.4  Summary of Conclusions from Results II 
 
Answers to the first set of research questions were collected directly from the data and are 
summarised next.  The intention was to answer those shaded, but glimpses of other boxed 
ones found too.  
 








The answers to these questions are summarised below.  
 
1. Who are the stakeholders and what are their roles in purchasing? 
 
 A purchaser usually refers to the person who places the order, but in practice 
incorporates roles in Engineering (Maintenance), front line staff (User) and clinical 
governance (Training). 
 Patient involvement is device-dependent. There is less of involvement of patients for 
infusion device purchase, but acknowledgement of necessary involvement of Nurses 
and EBME (more than Clinicians and Purchasing) for decision-making. 
 There is an inconsistency of interpretation of roles in medical device purchasing 
among different stakeholders. For instance, the 'end user' may also be the 
„purchaser‟. However, to some stakeholders, a „purchaser‟ means the administrative 
tasked assigned to the person making the order. To others, this is a collective term. 
 
 




2. What type of knowledge and competence do these stakeholders have? 
 
 True knowledge of equipment ergonomics, safety and design (beyond regulatory 
indicators, focus on quality vs. cost assessment) is scattered among stakeholders, 
and device use competence is not adequately monitored. 
 Clinical input divided from the rest of process, only at start (except for 
pharmaceutical products, where „risk department‟ is involved) 
 The awareness and use of national bodies and agencies varied among stakeholders. 
In general, PASA is known to anyone from Finance, Procurement and Engineering, 
but not really to those towards the front-end of device use. This includes names of 
the agencies themselves (such as Collaborative procurement Hubs, or Pre-Purchase 
Questionnaires) 
 End-users are not always aware of the options available for replacement equipment 
(e.g. ward storage options, neighbouring wards loans, use of equipment library); 
nor of whom to turn to for advice on purchasing decisions, and their available 




3. What are the resources and drivers for purchasing decisions? 
 
 Each device has its own characteristics that determine its criteria for choice, as well 
as stakeholder engagement.  
 What “purchasers” rank as important for making purchasing decisions relates 
mostly to the training and maintenance given by the supplier. Little value is given 
to the internal capacity of their workforce to comply with training and usability 
requirements. The expectations lie slightly more with the supplier.  
 Dispersed use of any national guidance among the stakeholders but heavier reliance 
on internal policies, measures, and human resources to control the management of 
devices. 
 Internally evaluated equipment or use of BIME recommendations help guide device 








4. What other factors influence current practice? 
 
 Communication of requirements to supplier from consumable to drug to device 
exists in some cases. 
 Adopting new devices through trials preferred, as this gives the end-user some time 
to get used to the device and evaluate it in practice. 
 Although error-reporting culture has increased in the past five years, the quality of 
these is still questioned. They are not seen as entirely reliable for monitoring device 
use history and repair. 
 Not every Trust has the same elements of an asset management system (e.g. library, 




The focus of Results II: Observations of Current Practice was to confirm initial 
observations and obtain a more formal understanding of current practice. However, 
during the discussion and through inductive analysis of the data, elements of the influence 
of purchasing practice on healthcare delivery were raised through the discussions. These 
discussions served as introductions to areas of potential risk both to the purchasing process 
itself, but with little allusions to the potential risk to the delivery of care. It is the third set 
of results in the next chapter that will now focus on case studies that exemplify some of 
these risks through different means. These case studies give concrete evidence of how such 
factors have contributed to poor healthcare delivery. Chapter 7 then discusses these factors 



















This section contains further case studies used to answer the main research question below, 
but with a discussion at the end of the chapter of how each case study demonstrated 
evidence to answer the research sub-questions:  
 







The three themes are illustrated through a series of examples, each contributing, in part, to 
each sub-question. This chapter first describes each of the case studies and the discussion 
at the end summarises the key learning points in context of the three answered sub-
questions.  
 
The studies include: 
 
1. Development of process maps of the purchasing practice at Trust A, building up to 
a workshop where risks in the process were identified. Insights and observations 
from both the process of developing the maps, as well as the identification of risks 
before and during the workshop, are shared. 
 
2. Three Case studies covering the standardisation of thermometers (Trust A), an 
evaluation of infusion pumps (Trust E) and the purchase of dialysis machines 
(Trust A) show a variety of challenges in purchasing decision-making.  
 
3. Three very different medical device purchasing process routes of Trust A are 
sketched out, with a discussion on the possible reasons for their variation. 




6.1  Overview of Challenges and Risks 
 
The factors addressed through the data beyond its basic aims are summarised in Table 21 
below. Similar to other chapters, Table 21 gives a summary of the factors addressed in this 
chapter, indicated in red.  
 
 
Table 20: Data gathered from Results III (Risks and Challenges in Current Practice) 




The research questions are addressed next in light of the three case studies, but also build 
on learning gained in the first set of results and Exploratory Studies. 
 
 
6.2  Identification of Process Risks 
 
This section describes the development of process maps to model the purchase of medical 
devices at Trust A. Process maps were not intended to be perfect descriptions of the 
process, but rather as tools to elicit insights from and engage with relevant stakeholders. 
As pointed out in the literature, a form of representation of the system is important for 
eliciting process risks (Jun 2007, Karsh & Alper 2005). The maps were then used to  lead 
to a risk workshop to identify current control measures and proposed control measures. 
Throughout this section, reference is made to Appendix III, which contains selected process 
maps to show the evolution of the diagrams.  
 
6.2.1  Process Map Development 
As can be seen in Figure AIII_1 in Appendix III, the first process map is a skeleton of the 
process introduced as a very rough draft. The diagram is repeated below in Figure 22 and 
is the first one, which was then populated by interviews with the participants themselves. 
Various iterations of the diagrams resulted in the rest of the pictures in Appendix III, but a 
description and a few examples are included here.  
 
 
AIII_1 to AIII_5: These diagrams show the process „as it is‟. Each diagram shows 
different levels of detail depending on the stakeholder interviewed, as each one shed 
light on the particular process section which was in their remit.  
 
AIII_6 to AIII_7: In follow-up interviews, respondents started to comment on how 
the process is „to be‟, from their perspectives. These comments were gathered, in 
part, in the initial interviews as well, but included only in these diagrams.  
 




AIII_8 to AIII_10: Through the analysis of the process „as is‟ combined with 
hypothetical „to be‟, and further refinement through participation at the MEC 
Procurement Subgroup meetings that these sets of diagrams were then created. The 
most developed version of the process maps is shown in Figure 23, copied from the 

















Figure 23: Developed version of process map (copy of AIII_8 in Appendix III) 
 
 
As pointed out earlier, no particular model is the exact depiction of the process, but these 
were the closest resemblance to the process as a whole that served the purpose of the 
discussion and initiated conversations on how to improve the process.  
 
In preparation for the risk workshop, it was felt by the participants in the map 
developments that a simplified version of the process would be more comprehensible for 
the required discussion. In order to provide this focus, a few modifications were made to 
include only the essential steps in the process and clump various process steps as 
occurrences in particular areas of the decision-making process. For instance, the „user 
identifies need‟ and its associated steps occur mainly at the ward, and these were depicted 
as the first grey-shaded area. The final version is AIII_9; this was the one used for the 
workshop.  








Figure 24: Process map used for risk workshop (copy of AIII_9 in Appendix III)    
 
 
Having completed a process map tool that could be used as a means to both generate 
discussion around the purchasing system, and elicit potential process risks, the process was 
also described in systems terms to help create the boundaries and focus of the particular 
system studied.  
 
Purchasing process as a System 
Given the substantial involvement with this particular group in Trust A, measures were 
taken to reduce potential bias that may have been developed through an ongoing 
interaction between the researcher and the interviewed stakeholders. To this end, the 




overall perspective and direction of the research process and the subject matter were to be 
re-addressed. In order realign the research process with the initial direction: the 





Table 21: Components of medical device purchasing system for Trust A 
 
 
The above system components were established both in discussion with participants and 
through analysis of the previous observations made during this study. Having established 
the system components, the boundaries for the study, and the anticipated inputs and 
outputs of the system, the participants at the workshops would have a more coherent 




understanding of the intention of the workshop. Table 21 was presented to the 
stakeholders invited to the workshop as a guideline for the upcoming discussion. 
Preparations for the risk workshop were then initiated.  
 
6.2.2  Evidence of Risk Prior to Workshop 
During the studies described in Results II, various observations were made that suggested 
the presence of risks in the process. Selected comments are listed in Table 22.  
 
Similarly, from the analyses of the observations and diary notes made during participation 
at these meetings; a set of recurring themes very similar to those brought up at the 
workshop were observed and even voiced by the very same stakeholders. A selected of 
these issues voiced or observed between December 2005 to September 2008 are listed 
below: 
 
 The remit of the MEC Procurement Subgroup needed to be revisited. The 
underlying knowledge is that they are responsible for purchasing under the Medical 
Equipment Committee (MEC) - but they only manages capital devices. 
 
 EBME feels they need more control of purchases. 
 
 Requisitioners/end-users still consider some medical devices as 'consumables' which 
does not give them true understanding of their use and risks. 
 
 Revenue devices are not centralised and could benefit from being as controlled as 
capitally funded devices as they are also medical devices with similar risks. 
 
 Development of the equipment catalogue is too much work - currently not 
supported by internal resources and tendering obstacles. 
 
 The web portal idea was supported from Jan 06, but took almost 2 years time to 
get going. 
 




 Bypassing control measures could be avoided if the nomenclature of devices in the 
software was improved.  
 
 No true audit of equipment exists. 
 
 Managing maintenance contracts seems an issue; and not all ward managers are 
aware of their existing contracts, even if they are potentially paying for a service 
they are not using. 
 
 
6.2.3  Preparation for Risk Workshop 
In addition to preparing the map of the process itself, some work was completed to ensure 
an accurate and thorough investigation could be achieved in the time available. The 
various risk assessment methods have been introduced in the literature review. In this 
study, however, a modification of these formal methods was necessary due to the existing 
methods used within the organisation and the time limitations available for this part of the 
study. On consultation with the risk manager at Trust A, it was felt that participants were 
more likely to respond accurately if they used a method familiar to them within the Trust. 
Additionally, this would also mean that the workshop would fall under their current 
governance structure and the subsequent control measures would be more likely to be 
reinforced and followed through.  
 
Challenges for planning risk workshop 
Following a meeting with the Risk department at Trust A, it was learned that the formal 
risk assessment methods even within the organisation are not always followed in practice.  
Risk assessment of the procurement process itself had never been explicitly considered. To 
add to the constraints, the team members were only available to meet for 2 hours.   
 






Table 22: Anecdotes alluding to failure modes in purchasing process 
 
  




Given the constraints required to truly justify the use of any formal risk assessment 
methods, no claim is made here to have adopted a method in its totality. The aim of this 
exercise was to simply arrive at some consensus as to where potential risks in the current 
practice exist. Furthermore, it was also noted that the hospital had already adopted its 
own „Risk Assessment‟ method for monitoring incidents, coordinated through the Risk 
Department as described earlier. All participants invited to the workshop would therefore 
already be familiar with this matrix and be comfortable with its use. Therefore, a 
compromise was reached in the method applied: elements of tradition risk analysis 
methods were adopted, but the exercise was conducted by a representative from the Risk 
Department in the hospital‟s own format.  
 
The participants at Trust A were already familiar with this matrix as it had been used in 
other service contexts, but never in relation to the purchasing of medical devices as a 
„service‟. Some preparation prior to the workshop was therefore required to familiarise the 
participants with the method and obtain individual responses to risk assessments. These 
steps are described after a description of the risk matrix tool used at Trust A.  
 
Risk Matrix Tool for Trust A 
The process of risk assessment at Trust A begins with mapping the service to be assessed. 
At the meeting/workshop, a selection of „what if‟ questions are used as prompts. A 
particular hazard is identified and its potential causes and consequences are assessed. The 
team assess the hazard‟s risk using their risk (available from the governance or risk 
department), and determine if further mitigation is required. Further mitigation should be 
considered wherever the risk is assessed as medium or high. Then, the team develop 
relevant recommendations to control the high/medium risk hazards, and re-assess the risk 
with these recommendations in place. If the risk is still high, further recommendations 
should be developed. If the team cannot identify any practical means of mitigating the risk, 
the risk should be escalated for acceptance in accordance with the organisation‟s risk 
management department. A review or follow-up is then recommended for the team to 
examine the new control measures.  
 
For the risk analysis itself, a selection of methods are suggested: failure modes and effects 
analysis (FMEA); healthcare failure modes and effects analysis (HFMEA); hazard analysis 
and critical control points; hazard and operability; barrier analysis and the development of 




risk controls; probabilistic risk assessment. This tool/matrix is used once a potential 
incident or hazard has been identified and hence relates to the assessment of that incident. 
The tool is shown in Table 23.  
 
This tool is used in the following steps:  
 
Step 1: Identify the likelihood of the incident occurring; choosing from Rare (1), 
Unlikely (2), Possible (3), Likely (4), Almost Certain (5).  
 
Step 2: Assign a consequence to the incident; in context of Table 23.  
 
Step 3: Assign a Risk Rating to each event by calculating “Likelihood x 
Consequence = Risk Rating”) and the results are mapped onto a matrix; which are 
shaded green, yellow and red to indicate low, medium and high risk.  
 
(Steps 4 and 5 involve setting new control measures and monitoring these, but 
these are not covered within this exercise).  
 
  






Table 23: Consequence/Impact to service descriptions as used in risk assessments at Trust A (taken 
from Trust’s internal documents) 
 
 





In order to maximise the knowledge gained during the workshop, a set of preliminary 
interviews were conducted with each stakeholder prior to the workshop. This allowed for 
some direction for the discussion and a chance to elicit individual participants‟ views 
without influence or bias from other members in the group. The following people were 
interviewed in these preliminary interviews (on average 30min each) to go through the 
whole process: 
 
Head of Clinical Engineering and Medical Physics 
Head of Clinical Engineering 
Deputy Director of Finance  
Head of Procurement 
 
The map used for these interviews was the simplified version shown in Figure 24 (AIII_11 
in Appendix), which includes both revenue and capital devices as it is a high-level view of 
the system. It is understood that some devices that may normally fall under a revenue 
category may still take a capital route of purchase and so only a „likely‟ distinction is made 
in the diagram.  
 
The system may be more complex than what is presented in the diagram, and other 
barriers may exist not shown on the diagram. These were deliberately omitted to prompt 
discussions further.  Another prompter used during the interviews was potential scenarios 
of failure modes of risks in the process. These had already been encountered in previous 
selected quotes included Results I and II and listed below: 
 
 Requisitioner inputs incorrect e-class code (purchase not identified as medical 
device and by-passes system) 
 Requisitioner assigns an „immediate purchase‟ to the order (device identified by 
EBME post-purchase only) 
 Device delivered directly to ward (by-passes acceptance testing) 
 Requisitioner makes purchase when no funding available 
 Budget holder/approver cycle causes major delays 
 




The potential incidents in the list above were then re-written as „Failure Modes‟ with 
associated consequence and likelihood. Any of the above was said be at least possible and, 
in some cases, occur frequently (Likelihood range from 3-5). Depending on the device 
purchased and its own associated risk, the consequences may include harm to individual, 
moderate to high impact to services caused by delays, and moderate financial 
consequences. The extent of the consequences is dependent on the rigour of the current 
control measures. This highlights the need to conduct a risk assessment on the process as a 
whole (to identify stop-holes in later processes) as well as an assessment of its sub-
components (to identify the specific stakeholders involved at sub-process level).  
 
In terms of consequences, those identified from the table as being most relevant, and most 
frequently elicited above are: 
 
Impact to service 
Potential financial losses 
Harm to patient (in extreme cases) 
 
Participants also offered possible causes for these failure modes. Any one failure mode can 
be traced back to a number of causes. An attempt to map these causes onto the failure 
modes above is diagrammed below, following indications given by the participants 
themselves and also insights gained from observations during studies in Results II.  The 
diagram also lists the consequence and likelihood of these risks as elicited from these first 
interviews: 
 
6.2.4  Workshop Results 
The decision to hold a workshop was supported by the Medical Equipment Committee to 
highlight the risks and control measures in the purchasing of medical devices. The results 
were as follows, shown in Table 24 with assigned control measures proposed during the 
workshop. It must be noted here that many of these risks had been observed in earlier 
studies with this Trust, including in the Exploratory Studies.  
 






Figure 25: Failure modes found in workshop linked to original causes 
 
 
Risk evidence results  
An analysis of all these observations, together with the results of the workshop, were then 
summarised below in Table 25 showing the connection between risks as identified in each 
stage of research process: preliminary interviews, to observations during meetings, to the 
workshop itself. These have been partitioned according to each process step (i.e. using 
AIII_11 in Appendix III).  
 
Some of these issues were addressed later in designing the framework. The recurring issues, 
and those that received consensus from the risk workshop were all included as necessary 
points to be aware of in purchasing decisions.  
 






Table 24: Failure modes and controls; results from risk workshop at Trust A
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Table 25: Summary of risks identified in purchasing process at Trust A 




Impact on Trust A practice 
The feedback from the workshop was overall positive and highlighted how the research 
process as well as the systems techniques acted together as catalysts to make 
improvements: 
 
This was good as I have now been in this Trust for ten years and some of these 
same issues kept coming up. Only now did we have the focus to address them. 
FIN.proc_A (Head of Procurement) 
 
I think the process map gave us the focus to concentrate on the issues in a more 
holistic sense.  
ENG.med_A (Head of Medical Physics and Clinical Engineering) 
 
 
Whether or not this particular method was the best tool for eliciting such risks and putting 
new control measures in place cannot be proved, and no comments were provided on 
alternative methods for having assessed the process. However, the raising awareness of 
these critical failure modes in the purchasing process raised by the research process was 
agreed upon.  The MEC Procurement Subgroup has subsequently included „Purchasing 
Process‟ as a regular item in the agenda for their monthly meetings.  
 
 
 6.3  Challenges in Purchasing Decision-making 
 
The challenges in making purchasing decisions are demonstrated through case examples, 
each pointing to particular issues discussed at the end of the chapter.  
 
6.3.1  EXAMPLE 1: Evaluation and Standardisation of Thermometers 
One of the recommended steps by stakeholders in previous chapters as an ideal route 
towards safe purchasing practice is to „standardise‟ on product models following a formal 
„evaluation‟ of their use. This case serves as one example of achieving such a step, and the 
rationale behind such an exercise. The example chosen is the standardisation of 




thermometers. During the time of this project, Trust A was in the process of conducting a 
trial for new thermometers to replace their existing set throughout the hospital. This 
section delineates the observations made during the trial along with the rationale for its 
inception.  
 
All the information gathered here is presented as that gathered by the Trust itself in putting 
this case forward. It therefore is a reflection of what this particular Trust, and the 
individuals involved in driving this standardisation process, have chosen to take into 
consideration. 
 
Rationale for the process  
The evaluation process was initiated by a member of the research division at EBME in 
Trust A. Having attended a meeting for thermometry he was exposed to new thermometer 
models available on the market. The conclusion from this meeting was that tympanic 
thermometers were not the best available on the market for their use, but one tympanic 
supplier had the market share at the time. Around 40 different models were available on 
the market, but the ones chosen for consideration were those recommended from this 
meeting. There were other reasons for conducting an evaluation internal to the Trust: 
 
Supplier-driven Reasons: The model used at the time was that by a tympanic supplier, 
referred to as T_1. There was no formal agreement with them for the management of 
thermometers within the Trust, but a „verbal agreement‟ (Trust A, personal 
communication) with the EBME department. This agreement required that this supplier 
would provide the Trust with the devices free of charge, or for a nominal figure of £5, 
along with a 3-year warranty with the device. It was the supplier that wanted to secure a 
3-year formal agreement on the basis of consumable purchase, due to the risks associated 
with minimal commitment. 
 
Internal user habits: A high number of Model T_1 thermometers were being stolen. 
 
Accuracy/Device usage: A model by another supplier had previously been used (referred to 
as T_3A), but these were considered “flimsy” and “kept breaking”. However, another 
model by this supplier (T_3B) was an improved version; the tip was made of metal and 
was smaller.  




Financial considerations: Usually, thermometer consumables are negotiated by NHS 
Logistics. The supplier for T_1 had indicated that they would provide the thermometer 
device free of charge, but the price for consumables was fixed.  
 
Background to thermometers and their clinical use 
Body temperature is recognised as a vital clinical sign and a keystone of nursing and 
medical practice and for keeping patient records (Trust A Clinical Engineering 2008). Core 
temperature for a normal range is between 36.8 ˚C to 37.9 ˚C, but invasive procedures are 
required to access these body sites.  Thermometers serve to access other sites for 
intermittent body temperature, such as the mouth, axilla, rectum, ear canal, and forehead. 
These sites do not always coincide with core temperature (offsets range from 0.55 ˚C to 
1.25˚C). Estimates of core temperature are therefore attained through the device‟s internal 
algorithm.  
 
Thermometers form an important part of the healthcare service. The following points 
highlight the importance of their correct choice, configuration and use: 
 
 Most wards have in their protocol to measure core temperature only, but only one 
of these models gives the core temperature. From experience, the team noted that 
nurses have not always shown awareness of the difference between these two 
measurements, and simply expected a „number‟ (e.g. 37.5 ˚C), which may or may 
not be a display following the device‟s internal algorithm.  
 
 Due to the existence of different models with internal algorithms, a robust 
standardisation policy of both thermometer and configuration of the algorithm is 
required. 
 
 The cost of overnight stay in ICU estimated in excess of £1000. A wrong 
temperature measurement could lead to an unnecessary overnight stay. Core 
temperature is a vital clinical measure in the discharge criteria.  
 
 Erroneous measurements due to „faulty‟ devices or configuration put extra strain 
on resources by triggering other wrong diagnosis and create potential anxiety to 
patients.  




The most common types of thermometers are: 
 
Electronic contact thermometers (metal covered thermistor probes placed on) 
Infrared tympanic thermometers (IRET) 
Other types include mercury in glass and chemical (phase change) thermometers 
 
At the time of the evaluation, Trust A predominantly used an IRET model (Model T_1 in 
this report), with approximately 400 devices used in the Trust (Trust A Clinical 
Engineering 2008). The objective of the study was to assess the quality of the new 
thermometers on the market compared to the existing one. This was done by testing the 
intra- and inter-operator variability and to validate accuracy, when using these four 
different models of thermometers: T_1, T_2, T_3A and T_3B. 
 
Methods used and factors considered 
The study was conducted in two parts: 
 
Part 1 protocol: inter and intra-operator operability: Twenty-one consecutive 
measurements on one hundred consenting adult subjects were carried out by two 
trained operators.  
 
Part 2: clinical variability: The clinical accuracy of the selected devices were 
compared to a reference standard - an invasive general purpose temperature probe 
 
Four different models from three suppliers were considered for evaluation at the Trust, and 
the technical evaluation team considered the following criteria: 
 
Anticipated total required throughout the Trust (between 100-700 units) 
Type of technology for measurement 
Consumables required 
Details of contract offered 
 
The responses from the participants were to focus on usability. Participants had to indicate 
their level of satisfaction according to the thermometer‟s following characteristics: 
 









Results of the evaluation 
The study concluded that: 
Intra-operator repeatability analysis and Inter-operator reproducibility analysis indicates 
acceptable mean differences for all devices (Trust A Clinical Engineering 2008). 
 
Based on this data, they concluded that T_2 is inappropriate for clinical use. Both IRTT 
models from the third supplier were also acceptable, however, when considering accuracy 
the T_3 should only be used in ear mode (T_3B) and not core mode (T_3A). Model T_1 
remains a clinically acceptable choice of thermometer for routine estimation of core body 
temperature (Trust A, personal communication).  
 
Two major concerns centred the criteria for evaluation: cost of the device (lifetime) and 
accuracy. The cost calculations included: covers, batteries, cleaning, repair cost, 
calibration, warranty, and response time which then helped them calculate: initial purchase 
cost, batteries/year, cleaning per year, covers/year, repairs/year, calibration. In the end, the 
chosen device was actually the most expensive one. The authors of the report also wrote 
the following: 
 
“This [study] indicated the importance of using a holistic approach when selecting 
a thermometer for the Trust, i.e. both financial and clinical issues should have a 
strong influence on the decision” (Trust A Clinical Engineering 2008).  
 
Key learning 
The learning main points from this study, relevant to this thesis, are listed below: 
 
Drivers for purchase: 
The motivations and drivers for standardising on this device were: 
Usability 




User habits (devices were stolen) 
Costs/consumables package 
Types of technology available 
Supplier/design changes 
 
Many of these issues resulted in standardised consistent measurement because of 
differences in readings between different makes of thermometer (algorithm and operator-
device dependent differences) 
 
The criteria used to evaluate products: 
Cost was a main consideration but was not above inter and intra operability and accuracy 
of the devices. The recommended device was actually the most expensive one. The 
preference of the staff was also considered strongly.  
 
The main stakeholders driving the process: 
Staff from EBME were the drivers of the evaluation process. It must be noted that Trust A 
has a branch dedicated to research in EBME. Publishing these results were also a 
motivating factor for conducting the evaluation. 
 
 
The case itself does show challenges in the process of conducting standardisation per se 
(such challenges are depicted in the infusion pump case study later), but it serves to 
highlight the importance of standardising on particular types of devices. According to the 
authors of this study, thermometers are characterised by their critical path in the patient 
pathway – a wrong reading can lead to unnecessary increased costs in overnight stays. The 
device is also characterised by its internal design complexity. Each model has its own 
correction software to provide the required reading, and while the different settings on the 
thermometers can be modified to suit a ward‟s needs, errors can still occur if the user is 
expecting a different number on display.  
 
 
6.3.2  EXAMPLE 2: Purchasing of Dialysis Machines 
A very different piece of equipment to thermometers is the dialysis machine, primarily used 
to provide a replacement for lost kidney function. The equipment is therefore far larger, 




with greater design complexity, and used mainly in one area of the hospital: a dedicated 
dialysis centre. The equipment works by removing waste from the body through diffusion 
and ultra filtration via a semi-permeable membrane. The two primary types of dialysis are 
peritoneal dialysis, where a sterile solution containing minerals and glucose is run through 
a tube into the body, haemodialysis, which is the subject of this case study. 
 
Rationale for the process 
In 2002 a protocol was written by the Head of Renal Technical services, outlining the need 
for a new haemodialysis machine supplier. The reason given was that their primary vendor 
(Supplier X) supplied reliable and adaptable machines, but their second vendor (Supplier 
Y) retains “serious design and component faults, which the manufacturer has been unable 
to rectify” (Trust A Reports 2001-9) 
 
At the time, the Trust was running 46 machines in five clinical areas: in one chronic care 
area, in three acute areas, and the community. Machines run for over 5000 hours per 
annum. The working life of a haemodialysis machine is 7 years. This document proposed 
therefore to replace the following (in decreasing order of priority): 
 
From supplier X 
4 machines purchased in 1990 in acute inventory  
8 machines purchased between 1988 and 1990 in community 
12 machines purchased between 1993 and 1995 in the dialysis centre 
 
From supplier Y 
9 machines purchased in 1997-8  
 
The proposal in this document was to have preliminary discussions by the dialysis 
department, including clinical, nursing and technical representation. The list of potential 
vendors and products were derived through consensus by a selection of nursing and 
technical specialists, who helped design machine specification and supervise machine 
evaluation. However, a series of documents were written up leading up to this final 
proposal. An analysis of these documents, which highlight how the requests were made, is 
described in this section, following some background to the criticality of dialysis care. 
 




Background to dialysis care 
Haemodialysis works by pumping the patient's blood through the blood compartment of a 
dialyser, exposing it to a semi-permeable membrane. The cleansed blood is then returned 
via the circuit back to the body. This allows the removal of several litres of excess fluid 
during a typical 3 to 5 hour treatment. Studies have demonstrated the clinical benefits of 
dialyzing 5 to 7 times a week, for 6 to 8 hours. In general, studies have shown that both 
increased treatment length and frequency are clinically beneficial.  
 
Events leading to purchase requests 
In order to progress with this proposal by the dialysis department, three key documents 
had previously been written: 
 
1997: report on dialysis centre written by Biomedical Equipment Manager 
2000: written by Head of Renal Technical services on “status and future 
requirements” 
2001: report on “factors affecting the purchase of haemodialysis machines” 
 
The following phrases, quoted from these reports, illustrate the challengers faced by the 
authors of the reports: 
 
“I have after some deliberation compiled a report, which seeks to detail the 
importance of operational time in the role of the haemodialysis machine. I have 
also considered the clinical risks and financial pressure involved in operating 
haemodialysis machines beyond their safe working lives… This report is derived 
from an assessment of the existing machine stock and from my 23 years renal 
experience”. (Trust A Reports 2001-9)  
 
The report clearly states reasons for the request and the specific characteristics of 
haemodialysis machines and serves to “clarify the reasons why haemodialysis machines 
cannot easily be compared to other types of Biomedical equipment”:  
 
“Substantial differences [exist] between haemodialysis machines and other 
biomedical equipment”, for instance computer-managed control, blood handling 




module and fluid management components – all indicative of the complexity inside 
the machine… 
 
…The role of the haemodialysis is unique; it is a chemical factory with the job of 
producing from raw components a clean (sometimes sterile), physiologically 
balanced solution comparable to blood…  
 
…It must function within tight tolerances, dictated by national and international 
standards. It must also be self-cleaning, programmable, reliable and safe. The main 
factors affecting its safety and reliability stem from the wear and stresses to 
components that derive from this „chemical factory‟ process.”(Trust A Reports 
2001-9) 
 
A detailed description of the operational, financial and clinical problems associated with 
haemodialysis machines is then given. In particular, as a way of differentiating this 
particular piece of equipment from others, emphasis is made on the reliability, safety and 
the ability to adapt to changing clinical goals.  
 
Finally, an outline of why the current stock of haemodialysis machines do not satisfy these 
goals and requirements for the treatment of dialysis patients, to end with a strong 
conclusion and recommendation that all twelve haemodialysis machines over 10 years old 
should be replaced as soon as is practically possible. They also call for the Trust‟s capital 
funding allocation to the dialysis centre should be reviewed in light of the technical and 
usage information provided in this document.  
 
The next stage in this process was to fill out a request to the Medical Equipment 
Committee, requesting £337,500 (2001). This particular form is comprehensive in that it 
asks all the questions that match the life-cycle of the device and take into account the 
financial considerations of newly purchased equipment as a whole. This standard form 
queries the intention of the requisition, i.e. if it is replacing, and/or increasing existing 
capacity, and the options for sharing the equipment with others. According to this 
document, the new purchases would bring no increase to staffing and user training as they 
were replacements, and consumables would fit within existing contract; and consequently 
no increase in revenue costs. However, the workload was anticipated to increase by 10% 
per annum. 




Such requests were made for five consecutive years (2003/4 to 2008/9) and were rejected 
every time for unknown reasons.  
 
Key learning 
Although most of the interpretation of the document can be very subjective; what is 
pointed out here is the existence of frustrations towards Board Level management. This 
may or may not be typical of other Trusts, but it echoes the dissatisfaction stated in the 
previous evidence gathered in this study. The case served to highlight the importance of 
multidisciplinary engagement and empowerment and acknowledgement of those 
responsible for purchasing and maintaining equipment, but this cannot overcome the 
hurdle of allocating the required funds to clinical and technical need.  
 
 
6.3.3  EXAMPLE 3: Evaluation of Infusion Pumps 
This case examines an example of an evaluation exercise conducted at Trust E for 
replacing and purchasing new Pain-Control-Analgesia (PCA) pumps. Though the 
documentation leading up the evaluation was obtained from the Trust‟s internal files, the 
data for the evaluation day itself and the interviews held subsequently form part of this 
research.  
 
Rationale for the process 
New pumps were to be distributed across all pain-control teams throughout the Trust. 
This was not the first evaluation of its kind as there had been a previously conducted 
evaluation (2007) to replace PCA pumps and starting to replace older volumetric pumps. 
The sum requested for total replacement £605k, but only £200k was made available, 
which was insufficient to replace all pumps. Therefore, to ensure standardisation, the Trust 
opted to replace the volumetric pumps where it was possible to realise significant 
reductions in consumable costs (Trust E Report 2008).  
 
This evaluation described here, held in 2008, did have full stakeholder engagement from 
the start. It was conducted in three stages: 
 




Stage 0: Selection of suppliers for participation of evaluation meeting 
Stage 1: „Show and tell‟ evaluation meeting 
Stage 2: Trial period 
 
Background to infusion devices 
Infusion devices are used throughout the hospital and are used to administer therapeutics, 
such as analgesics, antimicrobials, blood products, chemotherapy, nutrients and so forth. 
The whole infusion device or system consists of the infusion pump (device), the giving or 
syringe set (usually considered the „consumable‟), and the fluids administered 
(pharmaceuticals). Infusions can be continuous infusion consisting of small pulses of 
infusion, intermittent infusion with a "high" infusion rate, and patient-controlled infusion 
on-demand, usually with a pre-programmed ceiling to avoid intoxication. The rate is 
controlled by a pressure pad or button that can be activated by the patient, which is the 
case for the device considered here, patient-controlled analgesia (PCA).  
 
Details of evaluation project 
Standardisation of products for Scotland at the time of this project was also closely related 
to the new governmental policies on framework agreements. The procedure starts with 
National Procurement (equivalent to PASA for Scotland), who convene a working group 
to issue an EU tender and evaluate responses for a particular product type. A framework 
contract is then issued, covering products from two or more suppliers and including 
contract costs covering all of Scotland. 
 
For volumetric infusion devices, the framework agreement included products from 4 
suppliers. Hospitals who wish to order are required to carry out a mini tender exercise to 
select a preferred device from the 4 suppliers, which was the procedure adopted in this 
Trust. The Head of Clinical Engineering for Trust E had short listed 4 models/different 
suppliers and asked them to liaise with respective medical physics team at each site to 
arrange for bringing in a pump for evaluation by pain control team (before evaluation 
day). Each selected hospital in the Trust had different medical physics teams and pain 
control teams, and different existing models being used (3 adult and one children‟s 
teaching hospital). The experience of the stakeholders involved in this study were gathered 
for the purposes of this thesis and described next.  




Results of Stage 1: Show-and-tell day 
These comments were gathered as part of this research to elicit stakeholder perception on 
how the evaluation process was conducted and on standardisation in general.  
 
Many participants offered their opinion on the process of standardising itself, and the 
balance needed between absolute standardisation and the exigencies of  each ward.  
 
While I know some of my colleagues around Scotland disagree with me, I do not 
believe that standardisation necessarily means one model only. In particular, for 
volumetric pumps, over 4 major acute hospitals and a few smaller ones, we have 
argued that we should standardise on 2 or perhaps 3 models.  
ENG.snr_E 
 
Similarly, comments were made about the evaluation day itself. Participants were grateful 
that it occurred, but offered suggestions on improving it. There was also a suggestion that 
some suppliers might be more disadvantaged than others, noting that subjectivity cannot 
be removed from such an evaluation process.  
 
I'm just not 100% sure how useful that exercise is… The last representative… 
came to see us yesterday and my view of the pump changed completely from what I 
thought [previously] at the meeting, and now is one of the ones we'd like to try... 
The pump came across in the meeting quite badly [and it was the first time we saw 
it as it was not available before]. But the trainer was very good, the one who came 
to see us last Friday... quite confident and showed us how robust it was. 
CLIN.nurs_E1 
 
I just wish we had all the pumps before and the paperwork before it. It went ok.  
CLIN.nurs_E2 
 




The most comments offered were those around the involvement of stakeholders in the 
decision-making process and in the evaluation process. This was especially of nurses who 




may usually have felt out of the decision process in the past and welcomed this process as 
an opportunity to voice their opinion on device choice.  
 
I‟m glad we are involved in this; we have no influence in medical devices… but if 
we feel that our opinion counts, it is a more positive experience. So this evaluation 
has been good. I‟m not coming here thinking why am I involved... these products 
need to last for 5 years; it's not going to be replaced. So we need to move to a 
pump to give us with the reliability that we have had so far... 
CLIN.nurs_E1 
 
I think the right people were represented at evaluation… [it] was all done very well. 
CLIN.nurs_E3 
 
The right people were involved  
CLIN.nurs_E4 
 
However, it also surfaced that the communication of the reason for this exercise and the 
need for new pumps may not have been optimal;  
 
With this new pump there hasn‟t been a lot of guidance as to why we have changed 
over. The division was changing over so we were just told [to show up on the day]. 
TRAIN.clin_E 
 
After the show-tell evaluation day, the stakeholders taking part in the evaluation were sent 
a questionnaire to decide on which pumps would go through to stage 2. A set of questions 
for technical evaluation and one for clinical evaluation were included. The types of 
comments made on the pumps are described below: 
 
Pump1: It was a concern that the pump can start up in non-PCA mode, this new 
design concept (while potentially beneficial to the supplier and design), “may not 
be secure or robust enough”… “Awkward locking mechanism; separate parts will 
get lost”. 
 




Pump2: The pump, or perhaps supplier is “known to be very reliable”. They also 
noted that they offered an “excellent”, and the design is considered “simple, robust 
and secure”.  
 
Pump3: It was “not robust enough”, although apparently the company had voiced 
to be willing to develop the design. Other concerns were that it was “very portable, 
so may get lost or stolen”. They also mentioned that it is “awkward and fiddly to 
use”.  
 
Pump4: It was considered to be “well constructed” with a “clear display” and 
“good safety features”, although the “user interface could be sturdier” but there 
were concerns about the supply of consumables.  
 
Pump2 and Pump4 were selected for evaluation at all adult sites. The children‟s hospital 
opted to evaluate Pump3 due to “different operating requirements” but it was not ready 
for clinical evaluation.  
 
Results from Stage 2: Device Use Trial  
For Stage 2 of the evaluation process, a two-week trial of the pumps in the clinical areas 
took place, while technical assessments were conducted by Medical Physics staff at each 
site. During this stage, assessment criteria for the clinical staff were: 
 
General impression 
Controls and displays 
Training and manuals 
Functional/operational 
Patient safety aspects 
Patient‟s perception 
Free text, subjective comments 
 








Ease of maintenance 
Ease of cleaning 
Configuration ease of control 
Technical manuals 
Patient safety 
Anti-tamper and locking 
Technical training and support 
Availability of spare parts 
Subjective free text comments 
 
Both sets were given „equal weighting‟ in the overall evaluation.  
 
Final device selection 
The main concerns in the returned evaluations were related to size, age and after sales 
support. Clinical staff preferred Pump4, and technical staff preferred Pump2, though both 
pumps met clinical need. The results were presented in a comprehensive report shown with 
quantitative figures of the results of the evaluation forms.  
 
All stakeholders were invited again to a meeting to select the final pump. The document 
reflects a long discussion that was very comprehensive, and during which all results 
presented and all once again invited to submit a view. Neither model met needs of sick 
children but these would be evaluated in future. It was agreed that if the issues with 
Pump4 could be resolved, this would be purchased (issues about longer-term support 
provided by them). It was also agreed that pumps should be with medical physics before 
staff training began. 
 
Key learning 
This was a comprehensive evaluation process, which showed an open and transparent 
process, inclusive of the relevant stakeholders in the life-cycle of the device (training, 
maintenance and end-users). Good personal links were established with the suppliers and 
the sales representatives.  More involvement and openness on the rational for conducting 
the evaluation in the first place could have been communicated somewhere along the 
process.  




Part of the reason why the process worked as a cohesive whole is that there was mutual 
respect for the department driving the process (the individuals at the EBME unit). In turn, 
participation and engagement in the trial was welcomed.  
 
 
6.4  Discussion on Challenges and Risks 
 





The key learning points arising directly from these case examples are listed first, followed 
by further analysis on this learning, and its contributions to the research questions.  
 
6.4.1  Learning from Case Examples 
 
Example Case 1: Process Mapping and Risk Identification - Device purchasing practice 
has holistic consequences in the management of healthcare 
 
The example at Trust A highlighted the holistic consequences of device purchasing 
processes. Feedback from the participants was overall positive and highlighted how the 
research process as well as the systems techniques acted together as catalysts to make 
improvements to stakeholders which might otherwise have operated in silos. New control 
measures were assigned for the group to follow. In the short term, the process itself and its 
new control measures are now regularly assessed by the MEC Procurement Subgroup. 
Long-term improvements to care and efficient delivery of equipment to patient care are yet 
to be assessed.  
 




Example Case 2: Thermometers - Standardisation of device models is particularly useful 
for devices used throughout the hospital and of critical importance in avoiding usage 
errors. 
 
The case itself does not show challenges in the process of conducting standardisation per se 
(such challenges are depicted in the infusion pump case study later), but it serves to 
highlight the importance of standardising on particular types of devices. According to the 
authors of this study, thermometers are characterised by their critical path in the patient 
pathway – a wrong reading can lead to unnecessary increased costs in overnight stays. The 
device is also characterised by its internal design complexity. Each model has its own 
correction software to provide the required reading, and while the different settings on the 
thermometers can be modified to suit a ward‟s needs, errors can still occur if the user is 
expecting a different number on display.  
 
 
Example Case 3: Dialysis - Current practice in division of allocated funds for capital and 
revenue devices can create obstacles to fulfilling clinical and technical requirements.  
 
Although most of the interpretation of the document can be very subjective; what is 
pointed out here is the existence of frustrations towards Board Level management. This 
may or may not be typical of other Trusts, but it echoes with dissatisfaction stated in the 
previous studies. The case served to highlight the importance of multidisciplinary 
engagement and empowerment and acknowledgement of those responsible for purchasing 
and maintaining equipment, but this cannot overcome the hurdle of allocating the required 
funds to clinical and technical need.  
 
 
Example Case 4: PCA pumps evaluation - Multidisciplinary stakeholder engagement helps 
address all clinical, technical, and financial considerations for purchase, especially when 
conducting an evaluation of a new model on which to standardise. 
 
This was a comprehensive evaluation process, which showed an open and transparent 
process, inclusive of the relevant stakeholders in the life-cycle of the device (training, 
maintenance and end-users). Good personal links were established with the suppliers and 
the sales representatives. Part of the reason why the process worked as a cohesive whole is 




that there was mutual respect for the department driving the process (the individuals at the 
EBME unit). In turn, participation and engagement in the trial was welcomed.  
 
6.4.2  Risks and Challenges that impact Healthcare Service 
The key risks and challenges exemplified in these case examples are highlighted here, and 
linked back under general topics identified in both the literature and the results in the 
previous chapters.  As with previous chapters, the factors table (presented earlier in Table 
20 for this chapter) points out the main factors considered within this chapter. As 
identified in the risk workshop at Trust A, all failure modes and risks identified are 
initiated in the early steps in the purchasing process. In a more generic diagram of the 





Figure 26: Failures in the system highlighted in the first four steps in the process 
 
 
The risks in current practice, their variance from good practice, and the potential impact to 
healthcare services, are discussed in light of the factors in Table 7.  




Challenges relating to stakeholders 




Device knowledge & competence 
Process knowledge 
Stakeholder engagement 
Resources for decisions 
Drivers for decisions 
Culture and mindsets 
 
Both purchasing and operations management theory identified the important role that a 
purchasing manager plays in any supply chain, as they provide a vital link between the 
operation itself and its suppliers. This is especially applicable to medical device purchasing 
given the displacement between the end-user and the supplier. Although this study 
identified various stakeholders that also adopt the role of the purchaser (for instance, 
doctors and nurses who initiate a requisition), ultimately someone is responsible for 
managing that particular process. Sources specific to medical device purchasing identified 
the EBME representatives, or Clinical Engineers, as a key player in providing the link 
between clinical stakeholders and financial stakeholders. This study also confirmed this 
observation.  
 
However, among the healthcare community these stakeholders may not always be obvious. 
There is an inconsistency of interpretation of roles in medical device purchasing among 
different stakeholders. For instance, the 'end user' may also be the „purchaser‟. However, 
to some stakeholders, a „purchaser‟ means the administrative tasked assigned to the person 
making the order. To others, this is a collective term. It was also noted that stakeholder 
involvement is device-dependent. For instance, there is less of involvement of patients for 
infusion device purchase, but acknowledgement of necessary involvement of Nurses and 
EBME (more than Clinicians and Purchasing) for decision-making. Each device has its own 
characteristics that determine its criteria for choice, as well as stakeholder engagement.  
 
As pointed out in the risk workshop, in particular the types of failures that can occur in 
this process are delays in the service and, in some cases, harm to patient through these 




delays. The timing of the process itself need not take long in theory, but, in practice, there 
are plenty of anecdotes presented in both this chapter and the preceding ones to illustrate 
delays or mismanaged processes. While the consensus at the risk workshop was that 
controls are required early in the process to avoid failures later, these are not necessarily 
sufficient. A more holistic approach and proactive approach on behalf of all stakeholders 
involved, even those at the later stages in the process, are required. This requires adequate 
stakeholder engagement, and hence knowledge of the process for these stakeholders.  This 
is mainly because this is not always a linear cyclical process, despite it being diagrammed 
as such for explanatory purposes in this study. For instance, the very same requisitioner is 
the one that will end up using the device; and the trainer who later needs to impart 
usability skills on to the end-users could also have a say in the preferred model.  
 
Another layer of complexity is due to the varying stakeholder groups coming from 
different areas within the healthcare service, which are part of the process in theory, but 
not in practice. Given that purchasing stakeholder group are not clearly defined, even 
when a consensus is reached for who the end-user and purchaser is, their roles and 
responsibilities and capabilities understanding differs. In Figure 26, each process step can 
correspond to a different number of stakeholders belonging to a varying level of 
organisational hierarchy within the Trust. The engagement of these stakeholders is not 
always present. This was also depicted early in the Exploratory Studies but was shown in 
practice. The example of the evaluation project at Trust E is a clear example of how 
stakeholder satisfaction can be achieved with a more open and engaging, holistic 
purchasing approach. 
 
Another problem right at the front end of the process is the lack of a common 
understanding of „what is a medical device‟ and „the importance of a medical device 
purchase‟ among purchasing stakeholders, or appropriate device knowledge and 
competence. This is specially the case among the end-users, but can extend in some 
instances among the members observed in the „medical equipment sub-committee‟ and its 
subgroups. The evidence also suggests the lack of full process knowledge or awareness of 
capabilities of purchasing system and its control failures. A potential reason behind this is 
another main source of conflict particular in Trust A: lack of process ownership and 
„device‟ ownership. Certainly a more proactive device ownership by the end user could 
contribute to a more proactive approach to gain the knowledge, skills and language needed 
to voice their requirements to the rest of the stakeholders in the purchasing process. At the 




same time, any particular stakeholder group, at least not at Trust policy level, does not 
officially own the process itself. While in practice this has naturally come to the EBME 
department as the main holistic process knowledge owners, it has been shown that certain 
purchases have bypassed their controls. Furthermore, even if the culture already supports 
the role of EBME, problems can arise if this authority is not recognised at Board Level. 
This was the case for the dialysis purchase example, which presumably for financial 
obstacles, was not able to argue for this purchasing case despite showing clear clinical and 
technical, and even financial benefits for its requests.  
 
As identified in this study, the knowledge base for each of those considerations sits either 
in different departments within a hospital, or in different stakeholder groups. For instance, 
clinical input is mostly elicited at the start of the process (except for certain types of 
purchases that have a clinical lead practitioner). In line with good practice identified in the 
literature, as well as a direct consequence of the finding that a medical device requires 
input from different stakeholder knowledge bases, a clear requirement is also the 
collaboration and engagement required between them within both the process design or 
within the culture of the organization. The engagement of these stakeholders is currently 
not always present, and are indicative of the „silo‟ mentality alluded to in literature. This 
was also depicted early in the Exploratory Studies but was shown in practice. The example 
of the evaluation project at Trust E is a clear example of how stakeholder satisfaction can 
be achieved with a more open and engaging, holistic purchasing approach. 
 
Technical knowledge, in combination with clinical knowledge can also encompass device 
usability, but device use competence is not adequately monitored. Financial and 
purchasing process knowledge is also scattered. The awareness and use of national bodies 
and agencies varies among stakeholders. In general, PASA is known to anyone from 
Finance, Procurement and Engineering, but not really to those towards the front-end of 
device use. This includes names of the agencies themselves (such as Collaborative 
procurement Hubs, or Pre-Purchase Questionnaires). Finally, end-users are not always 
aware of the options available for replacement equipment (e.g. ward storage options, 
neighbouring wards loans, use of equipment library); nor of whom to turn to for advice on 
purchasing decisions, and their available budget for new purchases. 
 
According to these findings, what “purchasers” rank as important for making purchasing 
decisions relates mostly to the training and maintenance given by the supplier. Less value is 




given to the internal capacity of their workforce to comply with training and usability 
requirements. The expectations lie slightly more with the supplier and the original „design‟ 
of the device and its robustness.  
 
The study also identified the dispersed use of any national guidance among the 
stakeholders, whilst placing heavier reliance on internal policies, measures, and human 
resources to control the management of devices. Furthermore, any guidance set out from 
national agency specific to device evaluations (driven by PASA-related organisations) are 
mainly used by EBME/Clinical Engineering staff and remain mostly unfamiliar to front 
end-users.  
 
Furthermore, as pointed earlier in the literature, there are groupings along the supply chain 
created either by regulators, suppliers, the market, or by organizations such as PASA that 
differ in their classification criteria. By the time the device reaches the hospital and is added 
to the general catalogue of electronic purchases, there is little distinction between a medical 
device purchase and other purchases such as stationary. The controls appear later at the 
back-end of the process, where the authorisation of the requisition reaches EBME 
department. But, as seen in the studies, this does not always occur and purchases do 
bypass this control. If the end-user would be aware of such risks at the start, the risk could 
be reduced.  
 
Challenges relating to the Process 
Setting priorities for use of inventories, apply a degree of control to each item; and then 
investing in an information processing system that can cope with their particular set of 
inventory control circumstances, all form part of good practice in asset management. As 
was noted in the Exploratory Studies, a full audit of the current processes, or the 
equipment situation is virtually „impossible‟ given the changing environment and extension 
of equipment to community care. Most Trusts do not have a full, up-to-date, complete 
audit of their asset base, and the few Trusts examined in this study have two if not more 
different asset management databases. The implications of this are that when reviewing 
expenditure for both capital and revenue-funded equipment, these are not done in the 
context of current equipment distribution, since this information exists in different patches 
throughout the Trust. The purchasing process is therefore somewhat disassociated from 
the medical device asset management process. An example of this is the equipment library, 




which loans out devices to lessen the purchasing expenditure for each ward, but is itself 
under-funded to provide its service.  
 
At the highest level, everyone‟s goal is to support patient care with adequate equipment 
resources. This study provides evidence to show that other sub-goals, when not aligned to 
this ultimate goal, may lead to poor delivery of the goal.  
 
Another indication from good practice was the assessment of risk of the process of 
purchasing. As noted from the study at Trust A, risk assessments on services or processes 
were not new to the stakeholders involved, but were new to the context of a purchasing 
process. This may largely be due to the lack of „ownership‟ of any particular individual or 
stakeholder group of the purchasing process, which itself was indicated strongly during the 
workshop.  
 
One of the unnecessary divides in the process, which does affect purchasing and hence the 
delivery of care, is the allocation of funding on devices, which constitutes an added 
pressure for decision-making. When a device is identified as a capital or revenue 
expenditure a separate purchasing route is taken and, particularly in the case of more 
expensive capita equipment, the purchase risks further delays to the service due to its 
numerous approval procedures. It is not claimed that rigorous controls and protocols 
should not be in place for device purchases, but what could change is the prioritisation to 
such rigour. Certainly in Trust A, revenue purchases do not go through the same 
procedures simply due to their lower price. However, the risks identified here apply to any 
given medical device – be it an expensive or cheaper one. Attention to true clinical and/or 
service factors which could serve as better measure of the amount of rigour required per 
purchasing decision, and not the unit price. This would require an alignment of goals from 
the Finance unit to the Clinical and Technical units.  
 
Feedback structures may be in place but have received some criticism even by stakeholders 
in this study. Although error-reporting culture has increased in the past five years, the 
quality of these is still questioned. They are not seen as entirely reliable for monitoring 
device use history and repair. Also, many of the elements of asset management systems 
differ from Trust to Trust and these have to then be established according to the resources 
and priorities available to each organisation.  
 




When the purchasing process is placed in context of a more general device management 
process, further complexities that affect effective purchasing are evident. As was noted in 
the Exploratory Studies, a full inventory of the current processes, or the equipment 
situation is virtually „impossible‟ given the changing environment and extension of 
equipment to community care. Most Trusts do not have a full, up-to-date, complete audit 
of their asset base, and the few Trusts examined in this study have two if not more 
different asset management databases. The implications of this are that when reviewing 
expenditure for both capital and revenue-funded equipment, these are not done in the 
context of current equipment distribution, since this information exists in different patches 
throughout the Trust. The purchasing process is therefore somewhat disassociated from 
the medical device asset management process. An example of this is the equipment library, 
which loans out devices to lessen the purchasing expenditure for each ward, but is itself 
under-funded to provide its service.  
 
The practical complexities of the purchasing system are one of the reasons for the 
inefficiencies displayed in the purchasing process. Part of this complexity is the existence of 
multiple input reasons for entering the purchasing process pathway. This dynamic 
environment creates added pressures on the process. The early stage purchaser, or 
requisitioner, is also the end user, and while their drivers for purchasing may be clear, they 
may not necessarily have a holistic knowledge base of the process and may therefore 
bypass process controls. Such conflicts in policy and practice are also due to „lack of 
manpower‟, „time constraints‟, „misunderstanding of process‟, „disconnects in 
communication‟ – all terms collected from phrases used in observations at Trust A and 
contributing to further pressures. Many top-level management barriers affect ideal goals 
such as evaluation and standardisation, and from these few case studies, it can be seen that 
the motivations can sometimes by solely financial.  
 
Another device management factor that has surfaced from these case studies is the variety 
of devices managed by a hospital, and the different forms that this management takes due 
to the particular characteristics of devices. Even the three examples in these studies: 
thermometers, infusion devices, and dialysis machines, have particular characteristics, 
which determine what type of purchasing pathway they take. Taking Trust A as the 
context, these devices, although all potentially part of the same „medical device purchasing 
process‟ actually show different pathways in practice. Figure 27 shows the three different 




routes that are present in Trust A. The dialysis machine is treated as a capitally funded 





Figure 27: Different purchasing routes taken by devices 
 
 
Infusion pumps are mostly, though not entirely, purchased by the equipment library and 
then loaned out to wards (some wards will still buy their own). Thermometers are treated 
almost as consumables as they are purchased by EBME and then distributed to wards and 
replaced when needed. These distinctions have come about partly for historical reasons, 
but partly due to the particular exigencies of these devices. Any holistic purchasing system 
for medical devices should take such requirements into account. This is another argument 
for distinguishing devices from other purchases within a hospital – not only are they 
associated with particular risks, but their sheer diversity in both use and clinical criticality 
necessitates further distinction. 
 
 
6.5  Summary of Challenges and Risks 
These challenges and risks observed, relating to the factors considered, are summarised in 
Table 26. 
 





Table 26: Challenges observed in current practice relating back to the factors considered 
 
 
The next chapter brings the learning from the three results chapter into a general 
discussion of findings, as well, as a discussion on the potential improvements that can be 
made. This leads into the motivation for designing a framework that captures the issues 


















Having gathered evidence and presented elements of current practice in medical device 
purchasing (Research Sub-Question 1), as well as presented risks in current practice 
(Research Sub-Question 2), this next chapter focuses on areas of improvement (Research 
Sub-Question 3).  
 
The aim of this study was to answer the following research questions, of which those 
discussed further in this chapter are shaded in grey: 
 






The three sets of Results (I, II, and III) focussed on the earlier research questions in this 
„Research Questions box‟, as indicated in each respective chapter. The aim of this chapter 
is to focus on the potential for improvement. A discussion of current practice, with a 
comparison to good practice, not only provides evidence of suboptimal practices, but also 
highlights the need for improvement. The direction and strategy for such improvements 
form the basis of the motivation for developing a framework also introduced in this 
chapter). This framework is presented that captures the main findings in diagrammatic 
form and serves potential improvement purposes. 
 
 
7.1  Overview of Improvement Measures 
Guidance on possible improvements measures arose both from the literature and the 
stakeholders views themselves, both of which are described here.  
 
Research Sub-Questions
1. What is current practice in medical device purchasing?
Who are the stakeholders and what are their roles in purchasing?
What type of knowledge and competence do these stakeholders have?
What are the resources and drivers for purchasing decisions?
What other factors influence current practice?
2. (How) does current practice present risks to healthcare delivery services?
What challenges and risks are present in current practice?
How are the factors of current practice different from good practice?
How do these factors impact the healthcare service?
3. Where are areas for improvement on current practice?
How do the stakeholders themselves view improved practice?
How can factors in current practice be managed towards improvement?




7.1.1  Improvement Measures from Literature 
The literature pointed to established principles on improvement measures from 
management sciences to design process improvements. Unless a new design of purchasing 
in hospitals is adopted, what can be achieved within the current context is an improvement 
on current practice – tending towards what the literature identified as continuous 
improvement. As noted earlier, the healthcare literature refers repeatedly to the PDSA cycle 
as one such method. This suggests a rather retrospective approach to assessing the quality 
and risk in a process, which was evident even in the way the risk workshop was initiated 
and conducted at Trust A – the risks were highlighted after events occurred. It is therefore 
suggested that even the first phase – planning – is not executed with the associated risks 
involved. The literature warns of such bad practice in organisations that tend to „fire-fight‟ 
rather than plan for potential risks.  
 
According to Clarkson and Eckert, in order to create improvements, the organisation 
needs to take into account (Clarkson & Eckert 2005): Current-state goals; Stakeholder 
intentions; Contextual forces. Such approaches are particularly useful in this context, 
where the purchasing decision is made by stakeholders belonging to different teams with 
varying knowledge of the process and of the product being purchased.  These three 
considerations were incorporated into the design of the questionnaire used as the basis of 
the semi-structured interviews in the study, as well as taken into considerations in the 
design of the research questions, as explained in Chapter 3. To reiterate briefly, the 
current-state goals as well as stakeholder intentions were elicited through discussions on 
drivers and intentions and attitudes towards purchasing for safety, and the contextual 
forces formed the basis of many of the parameters on which the findings were clustered 
throughout the study (in the form of a „parameters‟ table populated in each chapter. This 
table is re-visited in this chapter, particularly in the discussion on which factors can be 
managed to improve on current practice.  
 
The following sections address these considerations for improvement centred around the 
research questions: on the stakeholders‟ own views on improved practice, and how factors 
currently present in current practice can be managed towards improvement.  
 
 




7.1.2  Stakeholders‟ Views on Improvement 
This data was collected as part of the semi-structured interviews held at all the Trusts, 
centred around the questions in the Questionnaire. Although a small part of the data 
collection, it served to highlight stakeholders‟ own views on where improvements could be 
made, and whether or not the „culture‟ of the NHS is ready for such improvements.  
 
Participants in the interviews were asked two sets of questions, as laid out in the 
Questionnaire in Appendix II on what would be most useful if new purchasing for safety 
measures were to be adopted.  The full list of options are available in Question 6 in 
Appendix II. These were also combined with any other data emerging from the interviews 
in other parts of the data collection.  
 
Consistent support was given for the following recommendations: 
 
 Introduce medical device coordinators 
 Keep stakeholder groups separate 
 Educate end-user or medical device purchasing 
 Flexibility according to device type 
 Board level support  
 National awareness / campaign  
 
Differing views were received for the following ideas: 
 
 Tick box approach to assess purchasing practice  
 Training on purchasing practice 
 Set Trust objectives 
 
 
Other examples of control measures, which were suggested by the stakeholders through 
the interviews, and relate closely to recommendations in the literature, include:  
 
 Standardise on device models to avoid errors from end-users 
 Conduct evaluations and trials of models before final purchase 
 Communication of requirements to supplier from consumable to drug to device 




 Audit device use and repair  
 Incorporate purchasing process into a more general asset management system (e.g. 
library, device trainer/coordinator) 
 
In general, the recommendations arising from the views of the stakeholders themselves 
focus more on the engagement and process within the organisation, or measures that 
empower the purchasers and end-users themselves. This leaves room for improvement on a 
local process level, which constitutes the main contribution of this thesis. 
Recommendations for local improvements are discussed next by a comparison to good 
practice, referring again to the theory in the literature, to then investigate its applicability 
to this context.  
 
 
7.2  Managing Current Factors towards Improvement 
 
The literature points towards good practice in purchasing, to efficient operations 
management and general context for improvements in patient safety. Instead of listing the 
main pointers given in each separate field of practice, elements of good practice from 
operations management and purchasing practice are linked to the device purchasing 
guidelines, and discussed in context of the findings gathered in this study. This is to ensure 
the discussion is centred around the context of medical device purchasing and healthcare 
practice, and not just a direct comparison of two fields of practice.  
 
7.2.1  Distinguishing features of Medical Device Purchasing Process 
From the literature it is already clear that medical device purchasing is a domain of its 
own, although it has parallels to purchasing in other safety-critical contexts. Elements of 
good practice can of course be adopted from other industries, but an understanding of the 
context of use for such purchases needs to be taken into consideration. The three key 











Figure 28: Three considerations particular to medical device purchasing 
 
 
The contextual forces identified in this study can relate to the influence factors found to 
influence the purchasing process. In this study, a set of influence factors on the purchasing 
process were identified: contextual forces or factors that affect current practice. These 
factors are considered in discussing potential recommendations in the next sections.  
 
7.2.2  General areas of Improvement 
Having presented a discussion on how some of these factors are contributing to risks and 
where improvements could be made at the end of the last chapter, a list of these 
recommendations are now included in Table 27: 
 






Table 27: Potential areas of improvement addressing challenges observed 
 
 
Although so far each factor has been clustered as those relating to „stakeholders‟ and the 
„process‟ of purchasing, it can be seen from the table that some of these challenges and 
recommendations overlap between these two groupings. In the next table, these 
recommendations have been re-written in more generic form and verse, with the 
assumption that each particular line and factor has implications on both the stakeholders 
and the process. The recommendations are now termed under new groupings: 
 
 Considerations to do with buying the „right‟ device at the time of individual 
purchase 
 Considerations to do with „rightly‟ managing the process of buying devices 
 





Table 28: Considerations for each purchase, and considerations for the purchasing process 
 
 
This terminology used relates back to Figure 8 (repeated here) which seeks “Purchasing 
Process User Needs”, requiring their own “Validation” to check if the overall process 
delivers the user needs, and also seeks “Purchasing Process Design input”, requiring its 
own “verification” to see if the process has the correct elements in its design. Extending 
these concepts, in brief: 
 
Validation asks the question: Are we buying the right device? 
Verification asks the question: Are we buying the device rightly? 
 
 







Figure 8 (repeated): Activities associated with purchasing process validation,  
adapted from (Alexander et al. 2001)  
 
 
To elaborate on this terminology further, the following table describes the types of 
questions that would be appropriate for these two validation and verification aspects of 
the purchasing process, in the context of medical device purchasing.  
 






Table 29: Samples questions for individual purchases (validation of purchase) and for elements of 
purchasing activity (verification of purchasing process) 
 
 
At the highest and most ambitious level of process improvement, these are offered as 
recommendations for improving on current practice. For the purposes of this study, further 
analysis was conducted to assess realistic improvements that could be made in the shorter 
term on current practice, given the insight obtained during the research process.  These 
recommendations, leading to the motivation and design of an overall framework are 
described next.  
 




7.2.3  Specific areas of Improvement 
While ideally all factors for improvements would be considered for improving on current 
practice, it is important to take into consideration the realistic scenarios encountered in 
current NHS context. The factors have been termed either variables or constraints for the 
purposes of short-term improvement.  
 
Constraints: Device Knowledge; Culture & Mindsets, Pressures on process; Drivers for 
decisions 
It is not claimed that these are not changeable over time, but are assumed to be current 
constraints going by the evidence that these factors are embedded into the system, and 
have been for a long while as observed in the studies. They are therefore factors that affect 
practice, positive or negatively, but are not addressed as recommendations in this project. 
For instance, it is not assumed that one can change people‟s different knowledge of device 
ergonomics, unless training for physicians and nurses and technicians changes over time. 
Cultures and habits are also difficult to change in one organisation but can happen over 
time. The complexity factors that add pressures on the process include the variety of 
equipment, the difficulty to track and audit equipment, and the variety of routes taken to 
make decisions about device purchases given the sheer diversity of devices purchased in 
any given hospital. 
 
Variables: Stakeholder definition and engagement; Process Knowledge; Requirements 
communication; Control measures; Resources for decisions 
What can be changed in the short-term is how stakeholders are engaged, especially given 
their varying backgrounds. Greater awareness of the process can be disseminated to all 
involved stakeholders; or measures can be found that can communicate requirements; and 
provide new control measures.  
 
Recommendations for improvements in this study focus solely on what is believed to be 
possible to change, in other words – improvements on current practice. The framework 
developed therefore assumes that the factors termed „constrains‟ act exactly as that – 
constraints on the process, but that the variables are changeable in the foreseeable future. 
This constitutes the motivation for the design of the framework.  
 
 




7.3  Framework Design 
This section includes a motivation for designing the framework and the method for its 
design. 
 
7.3.1  Motivation for Framework  
The theme throughout this thesis has been that a medical device involves clinical, financial 
and technical considerations. This is what distinguishes it from other purchases in a 
hospital. Through the observations made in current practice, reinforced by some of the 
case studies, areas of improvement were identified, as discussed in Section 7.2.3. These 
areas of improvement relate to support for making individual purchasing decisions as 
targeted to whoever is acting as a purchasing stakeholder (purchase decision validation), 
and to those designing and monitoring the purchasing processes as a whole (purchase 
process verification). Each of these, in turn, can be explained through sample questions 
relevant to these two perspectives. Finally, the factors considered within these two 
perspectives were classified into variables or constraints for the purposes of this study.  
 
The framework introduced in this section focuses on making improvements on what have 
been termed „variables‟.  Table 30 shows which variables in particular are addressed with 
the design of the framework:  
 






Table 30: Factors considered in design of the framework 
 
 
The framework therefore is designed with two intents: 
 
1. As a representation of the issues addressed at each stage of the life-cycle of the 
medical device in a hospital (intended mainly for end-users/original requisitioners) 
 
2. As a self-assessment tool for those with more holistic process knowledge for 
medical device purchasing (e.g. EBME or Procurement) to measure its own capacity 
for addressing all relevant issues in medical device purchasing decision-making. 
 
 
7.3.2  Designing the Framework 
The data used for the design of the framework came mainly from two sources: the process 
representation of device life-cycle (repeated in Figure 29 below) and the list of themes 
derived from coding the data from interviews. The process of coding and analysing these 
themes has been described in the coding section in Chapter 3 (Section 3.3.2), and its 
content is elaborated further here.  




As noted in Section 3.3.2, the issues were re-arranged to correspond to particular stages in 
the life-cycle of a medical device within a hospital. Put simply, for each theme it was asked, 
“Where in the life-cycle does this theme become relevant?”. As was seen in Figure 16, there 
were originally ten distinct sub-processes under which to cluster these themes. However, 
during this analysis, it became clear that some of the issues gathered certain issues were 
common to more than one process step. This led to a new format for clustering, which 






Figure 29: Clustering of process steps 
 
 
The final list of themes from the data clustered within these process steps and issues are 
shown in Figure 30.  
 






Figure 30: Considerations for device purchasing in various stages of device life-cycle 
 
 
Using the representation in Figure 29 as a baseline, and the data in Figure 30 as the 
content, different designs for the framework were explored, to test its appropriateness for 
its potential intended use. Various forms to represent these processes and main stages were 
explored, but the main versions are included in this thesis.  
 
 
7.4  Framework Design Versions 
 
The three main forms were designed to meet the following criteria: 
 
1. A basic flow chart of main stages in the cycle  
2. A comprehensive cyclical life-cycle with its main „issues‟ incorporated inside each 
stage 
3. A more simplistic model that represents main stage-gates, but still includes key 
issues relevant to each stage 
 
These three versions were designed and demonstrated back to previously interviewed 
stakeholders for feedback.  Their development stages are described in detail next.  




7.4.1  Version 1: Flow-chart 
The first version is a basic flow-chart, keeping in line with the process map style of 
diagramming used for most of the data capture at Trust A. The diagram addresses each 
stage in the life-cycle‟s key considerations in very simple form. This flow-chart is mainly 
aimed for general hospital-wide use, to show the differences in key considerations at each 
stage of the process. The list on the right is an added text for those with more holistic 
process knowledge, to keep track of what aspects of the process (from requirements to 





Figure 31: Framework Version 1: Flow chart 
 
 
The feedback from this version, though only shared with a few stakeholders from Trust A, 
was not overwhelmingly in favour nor against it. This figure was shown after the later 




cyclical versions, which resonated with the participants far more. However, it was agreed 
that the consistent and simple descriptions of each process stage were “useful” and 
“clear”.  The figure serves as a good starting point for dissemination of process 
information in a hospital.   
 
7.4.2  Version 2: Life-cycle wheel 
The second version is a comprehensive cyclical life-cycle with its main „issues‟ incorporated 
inside each stage. The conceptual design is based largely on Gough‟s (Gough 2004) wheel 
for the life-cycle of packaged products for consumers. This same design had been used for 
the design of medical devices for home-use (Gupta 2007). The advantage of this model is 
that it allows for a grading scale with regard to each issue. Users of the wheel would assess 
the extent to which their organisation or group considers each of these factors. This 
approach lends itself to the maturity and organisational matrix models discussed earlier, 
and already familiar in some healthcare settings. These factors or issues were therefore 
designed to fit around a „purchasing life-cycle wheel‟ as follows: 
 






Figure 32: Framework Version 2: Life-cycle wheel 
 
 
However, the use and format for this particular instance varies from the original concept. 
In Gough‟s case, each issue had a grading scale for the organisation to assess to what 
extent the designer took into account that particular issue in the design process for any 
given product. In the first version, although this potential use was described to the 
participants, it was also highlighted that the diagram could be used as it is, with no 
grading scale, depending on its intended audience.  




Although each issue is allocated a stage in the life-cycle, the types of stakeholders involved 
at each stage (and hence the ones that need to take into account those particular issues) 
will vary according to the Trust‟s organisational hierarchy. Secondly, while this represents 
one life-cycle process for „a purchase‟ (for either one device or a group of devices), it is 
understood that such cycles may be happening in parallel at any given time during the 
running of a hospital and its operation. Decisions about device purchases occur at ad-hoc 
times. Therefore, the issues within the wheel do not have any hierarchy. 
 
The feedback received for this version was mixed. Comments were requested on the 
accuracy of the wording and issues noted, usability, and adoption by end-users.  
 
On accuracy and completeness 
Very comprehensive! 
Point of Care practitioner 
 
You‟ve captured a lot of issues here! 
Head of EBME 
 
Potential suppliers should come later in need communicated area. 
EBME administrator 
 
I have no problem with the wording. 
Nurse 
 
On overall structure and usability 
Would be inaccurate to add stakeholders as engineering are involved throughout 




These comments were incorporated into the design of the next version.  
7.4.3  Version 3: Stage-gate diagram 
Following the feedback and further analysis, a third version was created based on the 
assumption that certain „stage-gates‟ were present in the cycle; starting from the definition 




of need right to the point where the need is fulfilled. The main concept for the stage-gate, 






Figure 33: Concept for stage-gate version of framework 
 
 
This concept shown in Figure 33 was used to design what became the preferred design, 
shown in Figure 34.  
 






Figure 34: Framework Version 3: Stage-gate Cycle 
 
This version also received some comments from respondents. It was mainly used to test the 
accuracy of the wording used in the main stages in the cycle of a medical device, in 
preparation for the next framework design.  
  
It took me a while to get what you are trying to communicate with the other 
diagram [Version 2], but this [Version 3] is much clearer…more simple… I agree 
with the 4 stages, yes, the arrows are in the right direction. This covers most of 
procurement activity for a device. 
EBME Research and Development 
 
You'd be hitting similar group of people with 1 and 3... 2 is just more detailed and 
not for everyone. We could understand it.  
Head of EBME 
 
This diagram is fine, nice and easy!  
Renal dialysis technical manager 





I think you don‟t just mean specify requirements, you mean specify and evaluate 
before you make a decision.  
Head of EBME 
 
 
The blue arrow in the diagram was highlighted as being a different process to the rest. On 
design, this was intended to stand out as this is the stage where the knowledge about the 
device increases, and hence the internal capacity of the organisation or „purchasing team‟ 
to start the new purchasing cycle increases with each new purchase. It was pointed out by 
some participants that the internal capacity of the organisation extends to the first stage: 
specify requirements, as well. Given the crucial role in requirements specification in 
affecting the next stages, and the differences in requirements that each specific device has, 
this is also a large learning area per purchase, and increasing in capacity to specify 
requirements increases the organisation‟s device purchasing performance. These ideas are 
incorporated in the final design introduced next.  
 
 
7.4.4  Applicability of Framework  
The final stage in testing this initial framework concept consisted of modifying the main 
concept model to test its applicability to various devices and to different scenarios. As a 
starting point, Version 3 was modified to include the factors/considerations in Version 2, 
as shown in Figure 35. 
 






Figure 35: Framework combination of Version 2 and 3 
 
 
This design combines Versions 2 and 3 closely, as it has stage-gates for the process but also 
includes some of those key issues that require consideration within those stage gates. These 
were presented to stakeholders for feedback, firstly by testing variations for different 
device purchase routes, and then discussing its potential for general use in different 
hospital scenarios and potential changes in structures.  
 
Framework variations for device 
Representatives from the initial group of stakeholders were chosen, and were asked to 
comment in particular on their own experiences in purchasing a particular type of medical 
device. The results of this feedback are described next: 




Thermometers: Commenting on the thermometer study conducted at Trust A (Case 
Example 1 in Chapter 6), the respondent commented how the technology behind 
thermometers is different to other devices given that most of the complexity is 
encased in the device. He also commented that they are “so cheap anyway and all 
the technology is inside, the manufacturer knows all that. The main cost goes into 
the consumables.” The device is not serviced in-house and sent back to supplier 
when faulty, and so the purchasing arrangements with the supplier do vary. It is 
also not a capital funded device and the funding is already allocated, so the 
procurement process in-house is different. Specifying requirements was very 
important in their process as they had to conduct a scientific study to see which one 
to use for their particular clinical needs. A consideration perhaps not captured in 
this diagram is a risk assessment on infection control, which is important for this 
type of device that is disseminated throughout the hospital and requires new 
consumables on each use. Finally, the culture of device ownership is important for 
a device like this one, which can “easily go missing because it is so small”.  
 
Renal dialysis equipment: The considerations for renal dialysis equipment do not 
vary much for the main framework design – most of the issues are considered in the 
purchase, or at least were considered by the respondent. The main difference was 
the use of other funds such as charitable sources, which is more characteristic of a 
device that is more expensive and specialised. Experiences are also shared across 
Trusts in other dialysis centres to find out which suppliers are recommended.  
 
Infusion pumps:  All of the considerations were perceived to be applicable to 
infusion device purchases. In addition, the respondent pointed out the importance 
of national evaluations (such as BIME) and also emphasised the importance of risk 
assessments with the introduction of a new device.  
 
These comments were incorporated into the model to observe consistencies and the 
potential for applicability of different device purchase scenarios. The working samples are 
presented in Figures 36a,b,c, which incorporate these various comments by either omitting 
phrases from the original list of issues or shows new additions in italics.  
 











Figure 36b: Framework modified and trailed for infusion pumps 
 






Figure 36c: Framework modified and traialled for renal dialysis machines 
 
 
Framework applicability/usability feedback 
Finally, the framework was discussed with stakeholders with more holistic process 
knowledge of the purchasing system. Two respondents were chosen from Trust A for this 
purpose: Head of EBME and the Deputy Finance Director, both of whom had been 










Figure 37: Framework: Final design 
 
 
The respondents offered comments on the general design of the framework in its final 
version, as shown in Figure 37, which takes in all the considerations put forth by the 
respondents: 
 
I prefer this format to the earlier version - I don't need to rotate myself vertically to 
read this one! The content is very similar though, so I remain happy with it.  I 
don't think it's meant to explain everything in one slide, but rather to provide an 
aide memoire of topics relating to each part of the process - which you can then 
expand on if required. This is something you would give to new people who tend 
to be in silos, but if they have a diagram that shows them other bits of the process 
of how we exercise control and how they fit into it... so if it‟s simple like this one, 
it‟s useful for that! 
Deputy Director of Finance 





The diagram tells me to ask myself why I want this piece of kit, it then takes me 
through why, what should be the requirements and specifications, what do I need 
to run it... then takes me how to do those things and how to fund it. So it‟s good. 
…I can see it also points out things that we perhaps don‟t do particularly well, like 
„time for adoption of new device‟... and „equipment tracking system‟. Skill base 
variations is not really applicable if you standardise on equipment. … interesting… 
The culture of device ownership is interesting too. There‟s lot of evidence to say 
that if you give individual wards their budget, they take more care of their 
equipment. 
Head of Clinical Engineering 
 
Finally, an interesting observation came from the distinction between the red and blue 
arrows. This was initially intended to represent processes that remain the same (blue) and 
processes that change according to the device purchased (red). However, it was pointed 
out that many changes are being undergone both in health policy as well as by the 
suppliers‟ equipment services. The new „Managed Equipment Services‟ provided by many 
mean that less servicing may have to be done in house, and the communication and 
relationship between suppliers and purchasers will become far more significant: 
 
The BLUE/RED divide is perhaps not so much related to individual devices, but 
with the changes in the NHS and supply chain management that occur. In a way, 
with Management Equipment Services offered by suppliers, they will do all the 
bottom bits, and we still have to get the top half right in terms of requirements 
specification. Specify and evaluate varies completely depending on device. Funding 
varies depending if its revenue/capital, mainly done on price... Install and train is 
the same processes regardless of device. Use and maintain also will be the same 
procedures but differs slightly for device and skill variations.  
Head of Clinical Engineering 
 
 
The key message in both these respondents is the importance of identifying, specifying and 
communicating requirements, regardless of the device purchased, the hospital‟s context, 
and the policies changing around the public and private sector.  
 




As a means of relating the framework back to the systems discussions in earlier chapters, 
Figure 38 demonstrates the integration of such a purchasing cycle as part of the wider 





Figure 38: Integration of framework into wider healthcare delivery system 
 
 
Given this wider context of the system, it can be inferred that the suggested framework is 
presented for use when the new purchase involves such a systems change. For instance, 
standard daily purchases that have already gone through processes of evaluation, 
standardisation and all the other factors considered within the framework, need not repeat 




the process suggested in the framework. The trigger for consideration of these issues is 
effectively the recognition of anticipated „systems change‟ with the new purchase.  
 
The most obvious and comprehensive way of deciding whether or not systems change is 
required is, of course, to actually go through the process itself and recognise no need for 
going through the checklist. However, in some situations this is an unnecessary task, 
especially in routine purchases or in cases where a purchase is required urgently. The most 
simple way of answering it, in context of Figure 38, would be to ask if healthcare delivery 
system changes would be required, in other words:  
 
“Would the healthcare management system require re-design with this new purchase?” 
 
A list of trigger questions that serve to give details to the above question would have to be 
drawn up by the organisation itself, but a sample is suggested here, some of which are 
reactive to previous events, and some of which are proactive: 
 
1. Previous incidents: Did the previous purchase cause an incident? (where an event 
has resulted in actual or potential harm to patients or practitioners) 
2. Hazard identification: Do service providers using this device have local concerns 
and themselves identified potential hazards with this device?  
3. Service re-design: Are changes planned to an existing service or system that 
surrounds this device use, or is there a new service planned which includes the use 
of this purchase?  
4. External directives: Are there new policies or mandates that concern devices that 
also necessitate system changes?  
 
 
This trigger is indicated in a modified version of the framework shown in Figure 39, to 
suggest that at any time during the „Use & Evaluate‟ section of the life-cycle of the device, 
such wider system questions are to be considered before the cycle is triggered once again 
for a new purchase. The „Use & Evaluate‟ also is intrinsically linked to Figure 5 presented 
earlier in Chapter 2. In addition to the suggested system changes may come from either the 
manufacture and supply process or the internal hospital processes, once again emphasising 
the intrinsic sharing of risk and responsibility throughout the device life cycle. 







Figure 39: Framework: Final design with system trigger 
 
 
7.5  Summary of Improvements and Framework 
The main messages in implementing improvements are presented in this chapter, with some 
consideration of factors that may be more challenging to resolve within a short period of 
time. Improvement on current practice is therefore suggested, rather than a total change in 
practice. The framework designed highlights these areas of improvement and issues for 
consideration during device purchasing processes. Three versions are shown aimed at 
stakeholders with different levels of knowledge and capacity in terms of purchasing 
devices. The feedback obtained reinforces the need for disseminating a holistic process 
















This chapter revisits all the main points derived from each chapter, followed by a summary 
of key learning and contributions of the thesis and recommendations for future research. 
 
 
8.1  Chapter Overviews 
 
Chapter 1: This first chapter provided an overview of the research and motivation for its 
undertaking. 
The key message at the start of this thesis was that the research topic presents a gap in the 
literature in terms of empirical evidence for assessing current practice in device purchasing. 
Small studies have been conducted but the systems approach suggested here is scarce. The 
motivation for this more holistic approach is due to the existence of various decision-
makers involved in making a purchase, and the potential for addressing an area that can 
mitigate the risks associated with medical device errors. The need for investigating 
purchasing in practice and gathering empirical evidence was also highlighted, rather than 
just collecting policy-level guidance or following national agencies.  
 




Chapter 2: This chapter reviews the current available literature in this field, drawing 
from different disciplines, and concludes that there is a gap to be filled in current 
knowledge.  
The literature related to this thesis falls under a variety of disciplines but serves different 
purposes, from pointing towards good practice in purchasing, to efficient operations 
management and general context for improvements in patient safety. Healthcare design 
and process improvement methods were also introduced. The importance of defining and 
engaging stakeholders, having adequate control measures, understanding the drivers and 
resources available to purchasing decisions, and a general knowledge of the process, were 
all identified as being crucial to good general purchasing practice. Highlighted as an extra 
dimension specific to the healthcare context, it was recognised that there are attitudes and 
cultures specific to the healthcare environment, risks particular to the healthcare service, 
and further factors that increase the complexity of medical device purchasing systems. 
Design and systems approaches provide one way of analysing such complexities.  
 
Chapter 3: The direction and evidence gathered in the previous chapter are used to arrive 
at research questions, followed by an approach and draw on a suitable methodology for 
the research.  
Encompassed within a general realist approach, this study adopts systems theory as a way 
of approaching the subject, choosing the purchasing process as the „system‟ and the 
delivery of care its „super-system‟. The methodology follows an inductive strategy to 
provide a description of current practice and, due to limitations of access to healthcare 
settings, does not claim to provide grounds for proving new theory in terms of purchasing 
and supply of devices in the NHS. The study does, however, provide an understanding of 
current practice, and an analysis of the possible factors influencing risks and challenges in 
current practice. The methods chosen take into account potential bias and the importance 
of a systematic approach within opportunistic sampling. Furthermore, in line with good 
design practice as the basis for its approach, the study provides another example of how 
design practice works in researching one particular healthcare setting or system.  
 
Chapters 4, 5, and 6: These three chapters constitute the main body of evidence 
supporting the arguments made in this study.  
The Exploratory Studies provide a broad understanding of current practice and allow the 
stakeholders to dream scenarios for improvements. The subsequent chapters then cover 
Observations in Current Practice through more rigorous research methods, followed by 




identifications of Risks and Challenges in Current practice through deeper studies at Trusts 
in the form of Case Examples. All findings are analysed by the end of Chapter 6 aimed to 
examine inefficiencies in current practice, and whether and how such practice can lead to 
risks in the healthcare service.  
 
Chapter 7: This chapter discusses improvements on current practice and introduces a 
framework to represent considerations pertinent to safe device purchasing. 
The factors influencing current practice are analysed to identify where immediate 
improvements could be made, and which factors constitute issues that would require long-
term or major structural changes to the organisations involved. The suggested framework 
serves to then bring out the main issues in current practice in diagrammatic form, with the 
aim of serving potential improvements as elicited within the findings. 
  
 
8.2  Key Findings and Contributions 
 
It is observed through this study that current practice in medical device purchasing in the 
NHS presents risks to the delivery of healthcare. This has been concluded by different sets 
of empirical evidence: namely, by comparing current practice to good practice in literature 
on purchasing; by presenting anecdotal evidence of inefficiencies in the process with an 
impact on the service; and by eliciting stakeholders‟ own views on current practice. The 
findings have then been synthesised into a framework to show the characteristics of a 
medical device purchasing process that effectively focuses attention on patient safety, in 
direct answer to the main research question that triggered the study. The other key 
findings are reiterated in accordance with the research sub-questions, all shown below: 
 







8.2.1  Current Practice in Medical Device Purchasing 
Key learning in current practice relating to stakeholders and processes are listed here.  
 
Stakeholders, Roles and Knowledge Base 
 A purchaser usually refers to the person who places the order, but in practice 
incorporates roles in Engineering (Maintenance), front line staff (User) and clinical 
governance (Training). 
 Involvement of stakeholders in decisions varies according to the type of device 
purchased.  
 There is an inconsistency of interpretation of roles in medical device purchasing 
among different stakeholders. For instance, the 'end user' may also be the 
Main Research Question
Research Sub-Questions
1. What is current practice in medical device purchasing?
Who are the stakeholders and what are their roles in purchasing?
What type of knowledge and competence do these stakeholders have?
What are the resources and drivers for purchasing decisions?
What other factors influence current practice?
2. (How) does current practice present risks to healthcare delivery services?
What challenges and risks are present in current practice?
How are the factors of current practice different from good practice?
How do these factors impact the healthcare service?
3. Where are areas for improvement on current practice?
How do the stakeholders themselves view improved practice?
How can factors in current practice be managed towards improvement?
What are the characteristics of a medical device purchasing process
 that effectively focus attention on patient safety?




„purchaser‟. However, to some stakeholders, a „purchaser‟ means the administrative 
tasked assigned to the person making the order. To others, this is a collective term. 
 True knowledge of equipment ergonomics, safety and design (beyond regulatory 
indicators, focus on quality vs. cost assessment) is scattered among stakeholders, 
and device use competence is not adequately monitored. 
 Clinical input divided from the rest of process, only at start (except for 
pharmaceutical products, where „risk department‟ is involved) 
 The awareness and use of national bodies and agencies varied among stakeholders. 
In general, PASA is known to anyone from Finance, Procurement and Engineering, 
but not really to those towards the front-end of device use. This includes names of 
the agencies themselves (such as Collaborative procurement Hubs, or Pre-Purchase 
Questionnaires) 
 End-users are not always aware of the options available for replacement equipment 
(e.g. ward storage options, neighbouring wards loans, use of equipment library); 
nor of who to turn to for advice on purchasing decisions, and their available 
budget for new purchases.  
 
Resources and Drivers for decisions 
 Each device has its own characteristics that determine its criteria for choice, as well 
as level of stakeholder engagement.  
 What “purchasers” rank as important for making purchasing decisions relates 
mostly to the training and maintenance given by the supplier. Less value is given to 
the internal capacity of their workforce to comply with training and usability 
requirements.  
 There is dispersed use of any national guidance among the stakeholders but heavier 
reliance on internal policies, measures, and human resources to control the 
management of devices. 
 Internally evaluated equipment or use of BIME recommendations help guide device 
choice, but this is mainly used by Engineering staff. 
 
Process factors 
 Adopting new devices through trials is preferred, as this gives the end-user some 
time to get used to the device and evaluate it in practice. 




 Although error-reporting culture has increased in the past five years, the quality of 
these is still questioned. They are not seen as entirely reliable for monitoring device 
use history and repair. 
 Not every Trust has the same elements of an asset management system (e.g. library, 
device trainer/coordinator), and the reasons are mostly „historical‟. 
 Clinical Engineering or EBME department plays an important role in monitoring 
device use and management, and hence can act as one body with holistic process 
knowledge, if adequate resources are provided. 
 
These observations on current practice were then analysed to identify challenges and risks 
in current practice.  
 
8.2.2  Challenges and Risks in Current Practice 
These challenges were summarised in Table 26 shown again here: 
  






Table 26 (repeated): Challenges observed in current practice relating back to the factors considered 
 
 
8.2.3  Synthesis and Recommendations 
Finally, the key findings and main issues pertaining to medical device purchasing and its 
relation to patient safety were synthesised. Key recommendations were established as 
relevant to different communities, as well as integrating these issues into a usable 
framework. The key recommendations address different stakeholder groups, and are 
summarised according to these groups: 
 





Given the divided stakeholder base for device purchasing, and yet its implications for all of 
healthcare delivery, the acknowledgement of purchasing as an important part of healthcare 
delivery needs to be addressed. Adopting continuous improvement measures, embedding a 
culture of safety, and monitoring purchasing practice, are all measures that can be 
implemented towards this goal. A starting point, however, as contributed in this thesis, is 
building a common knowledge base of purchasing procedures across the hospital for 
purchasers and end-users alike.  
 
Processes across directorates (collaborations within a Trust) 
The importance of interconnectedness and avoiding silo units has been highlighted in this 
study. Recommendations in this area include the linking of asset management systems, 
consideration for a shared equipment library, collaboration between departments for the 
purchase of devices which require a consumable/drug/device combination, and a 
continuous monitoring of training for device use competence.  
 
Considerations for individual purchasing decisions 
Individual purchasing decisions require three main considerations: the clinical, technical 
and financial aspects of the purchase. Given that the bodies of knowledge for such 
expertise sits in different departments, collaboration and communication is key for 
successful purchasing decisions, to then be able to take into account the exact device 
requirements, training requirements, adequate funding, and allocated resources for its 
servicing.  
 
Core central control 
Finally, given the variances in identifying a true process „owner‟ for device purchasing in 
current practice, taking such a step would also help towards improvement. The role of 
EBME has been identified in this study and in previous literature as an obvious link for 
clinical and technical issues, but this could be made clearer and engage management 
support for added resources. Continuous improvement, process risk analysis, and potential 
re-design of future purchasing systems would necessitate for this, or another similar, 
central body.  





These recommendations were listed in Table 28 and are repeated here: 
 
 




The framework, presented initially mainly for usability and applicability to different device 
purchases, presents the main considerations pertinent to medical device purchasing to 
focus on the wider implications of patient safety. The final design is shown in Figure 39, 
repeated here.  
 






Figure 39 (repeated): Framework: Final design with system trigger 
 
 
8.2.4  Additional Learning 
Taking into account the factors that denote good practice from theory, this study has also 
contributed potential reasons for such challenges in current practice. The main issues 
identified are: 
 
 Those mostly involved with devices on purchase not always involved in decision-
making (e.g. maintenance, skills training, end-users). 
 Purchasing process is disassociated from the medical device asset management 
process. 
 Purchasing stakeholder groups are not clearly defined. 




 There is a lack of a common understanding of what is a medical device among 
purchasing stakeholders. 
 
Additional learning has been gained on the decision-making processes in medical device 
purchasing and the factors that contribute to the general device management in hospitals. 
Studying such a process that cuts across the healthcare system has also provided a valuable 
source of insight into the internal workings of the NHS at local level. The following points, 
though not expected to be derived from the study, were also noted: 
 
 The value of individual „champions‟ needed for bringing about change in the NHS, 
as mentioned both by the participants and by observing such individuals during the 
study 
 Historical and organic patterns of behaviour, as viewed especially in the divides in 
training structures among end-users and device funding streams 
 The organic growth of the use of medical equipment libraries as a means to manage 
assets 
 The role of a „Medical device coordinator‟, which does not exist in every Trust but 
is very much valued by those who engage with such an individual 
 The clear divide between revenue and capital purchases from a finance point of 
view, which then inevitably creates a bias in controls on expensive purchases, 
which may or may not have weightier implications on safety or criticality 
 The divided approach to training in skills for clinicians and nurses (including for 
medical devices) 
 The clear divide in regulations and local purchasing structures for Pharmacy and 
pharmaceutical products, despite its close link to devices (e.g. infusion devices) 
 
Such issues provide extra challenges in the background, in addition to those found in this 
study. Any recommendations made do not claim to address these, as they are largely 
historical and relate to the context of our current healthcare service, which may continue 
to change in the next few years.  
 
 




8.3  Reflections on Research Process 
The research process itself has provided valuable insight into working with NHS 
organisations; some of these reflections are mentioned here.  
 
Access to the NHS 
The study would not have been possible without the relevant contacts made at the various 
NHS organisations. Working together with PASA in the Purchasing for Safety project was 
an invaluable source of access to different Trusts and forming links to a wider net of NHS 
stakeholders. Similarly, the collaboration established with Trusts A and E for the more in-
depth studies provided a richer source of data and opportunities for observance which 
would have been difficult to grasp in a removed survey or remote study of any other kind. 
In particular, the relationship established with Trust A was important as the stakeholders 
viewed this interaction as more than a simple audit, which most consultancies have 
conducted. The balance achieved by gaining the trust of the stakeholders and yet 
maintaining an external academic gaze on the research topic provided a research challenge 
but was invaluable for collecting the data.  
 
Engagement of participants 
During the PASA Purchasing for Safety project, the questionnaires were first sent out as a 
set of online or email surveys to all participants in their study. Out of the potential total of 
32 stakeholders, only 8 responded in this first round. A re-design of the questionnaire, and 
the combination of a telephone interview together with the emailed questionnaire 
increased these respondents to a total of 17 and allowed for more open-ended responses.  




Jun et al. have pointed out that a single diagram cannot effectively capture various aspects 
of complex healthcare delivery, which consists of various stakeholders, information and 
tasks (Jun et al. 2009). The need has been raised for better application of diagrammatic 
representations to the design of healthcare systems (Edwards 2005). This project has 
demonstrated one application of using diagrams in collecting data and tested responses 




from participants in healthcare settings. The value of this method was felt both by the 
researcher and those involved the process, but valuable lessons were learned of how to use 
such methods, and to what level of detail is required per interview, depending on their 
background.  
 
Limitations of the study 
The general approaches to increase the credibility of the findings, in terms of limitations of 
sampling, validity, dependability, confirmability, and generalisability, were discussed in 
Section 3.3.1.  While it can be seen that prolonged involvement with the research 
participants helped increase validity of the insights gained, it is also acknowledged that the 
researcher‟s presence within the setting may have had an effect on the process in itself. This 
is an unavoidable characteristic of similarly designed action-based research projects, where 
the separation of the researcher‟s involvement from the natural evolvement of the subject is 
not clearly defined. The validity of the data, is also stronger in Trust A given longer term 
involvement. In synthesising the findings, the concepts in the final framework were chosen 
on the merit that these issues were those voiced across the Trusts examined (A-E) to 
achieve at least some generalisability, but it is acknowledged that the culture of each 
organisation may still affect its uptake and relevance. Finally, it must also be mentioned 
that, given the iterative nature of the project, to repeat this study with the exact same 
methods may not be possible. It is also acknowledged that the findings of this study can 
only claim to show empirical evidence of current practice within the current political 
climate in the healthcare system in the particular Trusts examined at the time.  
 
Comments from participants 
Some comments were invited from participants in the research on the collaborations 
established and the methods employed. A few are quoted here,  
 
My feeling is entirely positive; we wouldn‟t have had these discussions around 
processes without you doing the work. It took a while to get to the stage we 
wanted to get to, but that is simply how long these things take. It's a piece that we 
wanted to do, and perhaps we would've done it much quicker, but we did not have 
the resources for that. It‟s a useful process – and it was interesting that to some 
extent this was partly using analysis to either prove or disprove people's 




preconceptions about what went on! To those that doubted that this was a 
complex process, they were proved right to some extent. At the same time it caused 
us to justify the process we do have in place and to test how that could be changed. 
All that was entirely positive. For the future, perhaps we'd have done it more 
quickly and project managed to do it.  
Deputy Director of Finance, Trust A 
 
The whole collaboration has been very useful. It also questions us to look at what 
we are doing and how we might be able to change our processes or practices as a 
result… and I think it has changed in the last 3 years. We're actually checking in 
terms of what is ordered in terms of medical devices. We still end up with things 
within the Trust where we don't know about them and it's not through any formal 
procurement process, they just seem to appear… That is something we need to look 
at in more detail. Have people been trained on it, has there been risk assessment, 
maintenance, why have these people brought it in the hospital? Does our process 
take too long? Do people want to go around our rules? It's questioning why people 
do what they do, and how can we change the process to bring them on board. 
Head of Clinical Engineering, Trust A 
 
You have done very valuable work in addressing – and clarifying - fundamental 
and important issues that impact directly on healthcare. 
Head of Clinical Engineering, Trust E 
 
 
8.4  Future Work 
 
While the changes in policy and the NHS were not looked at in detail, there are some, 
which may have an impact on current practice, and these would be worth examining in the 
future. PASA will announce its closure in the coming year (2010) and the regional hubs 
will have more autonomy on purchases. The impact this will have on local Trust practice 
will be interesting to examine, but various approaches could be taken for such an 
investigation.  As described in the research approach outlined in Figure 2, this study is 
primarily a descriptive study, for which the synthesis and framework in Chapter 7 provides 
the starting points for a prescriptive study. This section of future work, therefore, is 




categorised under two headings: a set of reflections on repeating a similar study under 
„Descriptive Work‟ and suggestions on building on this knowledge gained to implement 
„Prescriptive Work‟.  
 
While reading these two types of work, it is worth bearing in mind the previously stated 
challenges on presenting design research methods and approaches in a healthcare 
community, as introduced in Section 3.1 under „Research Challenges‟. As found in the 
literature, the support for approaches advocated in design research and systems theory is 
present, but what this means in practice still requires communication with the healthcare 
community. This certainly reflects the experience in this study and would have to be taken 
into account in any future work of this kind.  
 
Descriptive Work 
Although much of the study already shows the lack of adoption of current guidelines, the 
more in-depth analysis was limited to Trust A. It is this long-term involvement that truly 
brought out the insights gained and confirmed observations made elsewhere. The value of 
such a trusting relationship built with the participants at this Trust cannot be 
underestimated. If the study could be repeated, therefore, it would be recommended to 
conduct a similar project with other Trusts in the NHS. The approach would work best by 
taking a sample of Trusts investigated in parallel, perhaps by different researchers, over a 
similar period of time (1-2 years) and comparing findings at designated intervals.  
 
This study was focussed on a total of five Trusts. Quantitative studies in the form of a 
survey or statistics on equipment purchases, savings through standardisation, and so forth 
would also add value to the arguments made for investing in improving purchasing 
practice.  
 
While the intention of this study was to survey current practice and spend time analysing 
its implications, the basic overview provided here could serve as a starting ground to test 
out pilots of „better practice‟. This would also reinforce not just the value of the factors 
identified, but the value of making any improvements at all, before prescriptive work is 
conducted.  
 





The prescriptive approach involves taking the current learning, synthesis, and framework, 
and implementing its recommendations in a sample of Trusts. The study would be 
designed to test the usability of framework in effectively bringing focus on elements of 
purchasing practice, as well as improve its design and content.  
 
Design approaches have been advocated in this study, using the terminology common to 
design researchers. However, there may be elements of design activity that already occur 
both at policy and at local planning level. These were not investigated here, but if 
recommendations (or the framework) were to be adopted, the current service planning and 
implementation procedures would have to be taken into account.  
 
 
8.5  Summary of Contributions 
The main contributions of this study are: 
 
1. A picture of current practice in medical device purchasing in the NHS in terms of: 
a. People (their knowledge base, drivers for purchasing, culture) 
b. Process (perceptions of an ideal process, issues raised in current process, 
comparison to policy recommendations to actual practice) 
 
2. Evidence of the influence of purchasing practice on safe healthcare service delivery 
(through reflections of Results II reinforced by examples in Results III vignettes and 
results of the risk workshop), shown in: 
a. A series of „factors that influence purchasing processes‟. 
b. Analysis of how these factors can be managed to improve on current 
practice 
 
3. A framework that highlights the main issues pertinent to device decisions to ensure 
quality and safety in the process of purchasing, addressing: 
a. Information needed for end-users who may otherwise be isolated 
b. Considerations needed for developing whole process knowledge 
c. System triggers required for such considerations 





Donald Berwick of the Institute for Healthcare Improvement in the USA, argues that 
healthcare services need a change of system, noting that “every system is perfectly designed 
to achieve the results it achieves” (Berwick 1996). Do we currently have a procurement 
system that is designed to achieve patient safety? The findings in this study suggest that 
this is not the case in current practice. A survey conducted in 2004 suggested that there are 
even barriers to bringing modern thinking and design practice in the NHS as a whole. The 
report noted that “a direct consequence of this has been a significant incidence of 
avoidable risk and error” (Department of Health 2003). Part of the recommendations 
included a systems-based, user-led approach to improving services across the NHS. To 
achieve this, both the design of the products or services and the medical system (or 
healthcare system) in which these products are to operate, need to include patient safety in 
their design, planning and implementation. This concept is not new to the NHS nor to 
healthcare literature; understanding patient safety as a „systems‟ problem is therefore 
increasing, but what does this imply? Perhaps acknowledging that our procurement 
processes are an integral part of our healthcare delivery system, whether we are the 
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Appendix II   Questionnaire
Purchasing for Safety Awareness Audit         
         
         
1.  Roles in the purchasing process           
           
  Purchasing Obtaining terms of contract from supplier     
   Authorising or signing the PPQ for trust     
   Choosing which device to purchase      
   Placing the order with suppliers      
           
  Training Training for staff on device use      
   Trialling of new products       
           
  Coordination Coordination of medical device purchase and use    
   Strategic contract planning and monitoring     
           
  At ward level Purchasing pumps and devices      
   Purchasing of syringe sets or consumables       
   Purchasing pharmaceuticals       
   Signing off requisition form       
   Filling in a requisition form       
   Identifying that injectable medicine is missing from unit or ward   
   Identifying that pump or syringe drive is missing from unit or ward 
           
  
On device arrival 
Picking up the orders from goods in      
  Conducting acceptance tests on new devices    
   Entering devices into a maintenance/clinical engineering asset register 
   Entering devices into a financial asset register    
   Delivering injectable medicines or devices to the unit or ward requesting it 
   Monitoring pumps administering injectable medicines    
           
  
Involvement of others in purchasing process 
       
    
Most of the 
time Often Occasionally Never Unsure 
  Patients         
  Nurses         
  Clinicians         




         
  
Procurement 
               
Appendix II   Questionnaire
        
2. Resources to help make purchasing decision     
         
  An internal medical device policy or set of guidelines covering the purchasing process 
  Does it include       
   standardisation?      
   centralisation?      
   guidance on device replacement?    
         
  A defined list of approved infusion devices     
   with accompanying documentation?    
         
  An equipment library (or equivalent)      
  Internal register for recording errors      
  Controls Assurance Standards      
  
Medicines and Healthcare products Regulatory Agency (MHRA): Device Bulletin 98 (01) the 
Management of equipment in hospitals and the community 
  Bath institute of Medical Engineering (BIME) recommendations   
  NHS Purchasing and Supply Agency (PASA) Tendering documents  
  Collaborative Procurement Hubs recommendations/contracts    
  National Institute for Clinical Excellence (NICE) guidelines   
  MHRA Incident Reports for infusion devices     
  Royal College of Pharmacists guidelines for practice (for training purposes)  
  Royal College of Anaesthetists guidelines for practice (for training purposes)  
  Skills for Health guidelines for practice (for training purpose)   
        
  National device alerts      
  Pre-purchase Questionnaire (PPQ)      
  Other documentation for purchasing      
  Device specification that considers safety features of new devices to order  
  Medical Equipment (or Device) Committee     
  Medical Device Coordinator      
         
   Which of the above do you find most useful and why?  
                
 
Appendix II   Questionnaire
         
3. Managing stock and devices in your trust 
         
    
Most of the 
time Often Occasionally Never Unsure 
  
An audit of existing stock to establish infusion 
device sufficiency and utilisation is carried out        
  
There is a known trust board member or 
body responsible for medical device 
management.        
  
When training not given by company, our 
clinical skills training department has the 
skills necessary to train staff on new models        
  
Clinical engineering personnel are trained to 
make decisions on safety of devices and 
systems prior to commissioning of infusion 
devices?        
  
Competency based training for clinical staff 
within the trust is actively assessed        
  
For each new infusion model, relevant 
training is given (% per department?)        
  
Infusion devices are evaluated by clinical staff 
prior to purchase        
  
There is a structured evaluation process or 
form        
  
This process/form is shared with other 
manufacturers?        
   Trusts?        
   CPHs?        
           
   
  When making a purchasing decision, who do you interact with?    
    
Most of the 
time Often Occasionally Never Unsure 
  Patients         
  Nurses         
  Clinicians         
  Collaborative procurement hub        
  Clinical engineering         
  Procurement         
              
 
Appendix II   Questionnaire
4. Drivers affecting purchasing decisions         









  Unit cost of device         
  Maintenance costs of device        
  Safety features         
  History of errors with device within trust       
  Ease of use         
  What staff are used to on wards        
  CE marked         
  Working relationship with sales representative       
  Matching to existing consumables        
  
Matching to existing equipment in the 
ward/unit       
  Device in standardised list        
  Quality of device         
  Name or brand         
  Supplier image         
  Training services given by supplier        
  Maintenance services given by supplier       
  Maintenance expertise available in-house for device      
  Device history globally        
  Robustness         
  Reliability         
  Usability         
  After-sales support         
           
  
Of above, which is the most important and 
why?       
  Which is least important and why?        
                  
 
Appendix II   Questionnaire
         
5. Barriers and toolkits             
      
Strongly 
agree Agree Disagree 
Strongly 
disagree 
  There is little or no internal support for purchasing for safety     
  Implementing purchasing for safety practices would require significant cultural change 
  We lack the knowledge/tools for purchasing for safety      
  There is no time nor budget to support purchasing for safety     
  It is too difficult to think how we can purchase for safety     
  There are too many other problems and drivers to think about purchasing for safety   
  Purchasing for safety is an unachievable goal       
           
  Of above, which is the most significant and why?       
  Which is least important and why?             
         
6. What would be most useful?             
  A national awareness campaign        
  Board level trust support        
  Set practices as Trust objectives for the year       
  Attending conferences on purchasing for safety       
  Receiving an assessment form to tick that requirements for purchasing for safety are met 
  Training for yourself and colleagues on how to purchase for safety    
  Using collaborative procurement hubs in order to assess best practice    
  Better clinical training on use of equipment       
  Establishing new National Standards & Targets         
  Other?         
         
  Of above, which is the most helpful and why?       
  Which is least important and why?        
                  
         
Thank you for your time.       
         
Your Trust        
Your Job Title   CPH? Y N   
Your role description        
         
Length of service at trust/site       
Length of service in current role       
         
 Who would you suggest to speak to next?      
 

Appendix III Figure  AIII_1
User completes non-stock 
requisition
Manager/ budget holder 
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